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Katherine Lansu: Ligand Discovery and Functional Characterization of MRGPRX Family 
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(Under the direction of Bryan Roth) 
 
Orphan G protein coupled receptors (oGPCRs) have no known endogenous modulators 
and poorly understood function. As GPCRs make useful targets for modern pharmacotherapies, 
improving our understanding of oGPCR pharmacology and function could be beneficial for 
human health. The primate-exclusive family of Mas-related G protein-coupled receptors 
(MRGPRX) are four oGPCRs (MRGPRX1-4) with enriched expression in mast cells and sensory 
neurons of the dorsal root and trigeminal ganglia. The MRGPRX receptors are hypothesized to 
regulate itch, pain, inflammation, and other sensory modalities. To uncover the functions of these 
receptors, I sought to generate selective and potent small molecule modulators of MRGPRX2 
and MRGPRX4. I applied a combined in vitro and in silico approach to tackle this problem. I 
began by performing a high-throughput small molecule β-arrestin screen to identify novel 
chemical matter for MRGPRX2 and MRGPRX4. Using this method, I discovered several novel 
MRGPRX4 agonists and that MRGPRX2 is a novel Gαq-coupled opioid receptor activated by 
endogenous pro-dynorphin-derived peptides and exogenous opiates, such as morphine and 
codeine. Then, utilizing the active and inactive compounds from the small molecule screening, 
my collaborators generated computational homology models for MRGPRX2 and MRGPRX4 
based on the kappa opioid receptor (KOR). For MRGPRX2, they used the computational model 
to predict a pair of nanomolar selective probes to determine that agonism of this receptor leads to 
iv 
 
degranulation in a human mast cell line. For MRGPRX4, they used the homology model to 
predict essential binding pocket residues for agonist activity. I then synthesized several 
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micromolar potency probes for MRGPRX4. Lastly, using data from a collaborator’s genome-
wide association study, I characterized an MRGPRX4 coding variant to increase preference for 
menthol cigarette smoking in African Americans and identified menthol as a negative allosteric 
modulator of MRGPRX4. Altogether, these studies provide novel chemical matter for the 
pharmacologically dark receptors MRGPRX2 and MRGPRX4 and suggest that these receptors 
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1.1 BACKGROUND  
The human fascination with drugs and their ability to heal, alter mood, or induce injury 
goes back to early civilizations (Merlin, 2003). Identifying helpful or harmful plant preparations 
was based on personal experience and observations in animals, with little understanding of how 
these enigmatic substances exerted their actions (Crocq, 2007). Without an understanding of the 
mechanisms of drug action, there was little progress in improving pharmacotherapies. Today, 
pharmacologists use systematic molecular approaches to discover safer and more effective drugs 
for the treatment of disease, but the innate human curiosity for drugs and their actions remains as 
strong as ever. Fortunately, the ancient exploration of unique chemical compounds provided 
modern pharmacologists with an array of molecules that have catalyzed our understanding of the 
body at the molecular level.  
Despite the historical prevalence of drug use for medical, personal, and spiritual purposes, 
specific drug receptors were not identified until the mid-20
th
 century. It was only in the early 
1900s that John Langley and Paul Erlich postulated the existence of “receptive substances” 
(Ehrlich, 1908; Langley, 1905). During this time and leading up to the 1940s, pharmacologists 
outlined basic theories of drug action by mathematically analyzing drug effects on animal organ 
preparations. Without knowing the molecular identity of the receptors, Hill (Hill, 1910), Clark 
(Clark, 1937), Gaddum (Gaddum, 1937), Schild (Arunlakshana and Schild, 1959), and other 
pharmacologists used potent chemicals such as atropine and ergotamine to define drug theory 
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(reviewed in (Rang, 2006)). Early receptor theory focused on mathematically defining 
interactions between ligands and receptors analogous to enzyme kinetics and incorporating the 
law of mass action (Fig 1.1) (Arunlakshana and Schild, 1959; Stephenson, 1956). Further 
progress developing receptor theory was delayed because many prominent scientists considered 
the receptor concept to be an abstraction and remained skeptical about the existence of receptors 
in cells (Ahlquist, 1973).   
The ability for drugs and hormones to produce physiologic changes was well-known, but 
it wasn’t until the 1960s and 1970s that the molecular mechanisms of this began to be understood. 
Martin Rodbell and Albert G. Gilman used novel biochemical approaches to identify 
heterotrimeric guanine triphosphate (GTP)-binding proteins, or G proteins (Rodbell, 1980; Ross 
and Gilman, 1977; Ross et al., 1978), that mediated hormone-induced increases of intracellular 
cyclic adenosine monophosphate (cAMP). Using radioligand binding, Robert Lefkowitz and 
colleagues then discovered the existence of specific beta-adrenergic receptors that bound to 
Figure 1.1: Basic Principles of Receptor Pharmacology. Blue box: Various models of receptor activity 
including the law of mass action as a simple starting point, leading to the ternary and extended ternary complex 
models. Lower right: definitions of terms for models. Top right: Simulated dose response curve depicting 
various ligand types with corresponding labels. Gray line indicates constitutive activity (R*). Modified from 
(De Lean et al., 1980; Kenakin, 2004; Samama et al., 1993)) 
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norepinephrine and the adrenergic antagonist propanalol (Lefkowitz and Haber, 1971). The 
discovery that many molecules exerted their signaling actions via receptors and G proteins 
prompted an important change in receptor theory by Andre De Lean, who created the ternary 
complex model to explain the allosteric interaction between activated receptor and G protein 
leading to signal propagation (De Lean et al., 1980) (Figure 1.1). These G protein-interacting 
receptors were deemed G protein-coupled receptors or GPCRs.  
From there, Black and Leff generated an operational model of receptor activity (Black 
and Leff, 1983), which allowed pharmacologists to quantify a drug’s parameters from functional 
and physiological assays. This operational model expanded receptor theory by considering the 
propensity of an agonist to elicit a response and the receptor occupancy of the system, which 
better explained the non-linear effects observed on tissues with increasing doses of drug 
(Kenakin, 2004). Later, De Lean’s ternary model was expanded to the extended ternary complex 
model (Samama et al., 1993) (Figure 1.1) to include consideration of non-ligand dependent 
active GPCR state (R*), also called constitutive activity (reviewed further in (Wacker et al., 
2017). This model was extended again to the cubic ternary complex model to explain the 
coupling of non-signaling G proteins with inactive receptor states (Weiss et al., 1996). In total, 
the culmination of biochemical and theoretical expertise allowed the field to quantify how G 
proteins, receptors, and ligands functioned in concert with one another to produce cellular 
signaling. These advances ultimately stimulated the improvement of ligands and their 
pharmacologic parameters.  
To further discuss ligands and their actions at GPCRs, it is helpful to outline some basic 
pharmacological principles (for a detailed review, see (Kenakin, 2009a)). A ligand possesses 
affinity for a receptor of interest, which is a measurement of the strength of the ligand’s 
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molecular interaction with the receptor. The term potency refers to the amount of drug needed to 
produce a certain response and is usually provided as an EC50 value, referring to the 
concentration needed to produce a half-maximal response. On the other hand, efficacy is the 
ability for a ligand to produce a response in a system, which can be pluridimensional (Galandrin 
and Bouvier, 2006) and refer to several distinct outputs. Activating compounds, called agonists, 
can either be full agonists that produce the maximal response (Emax), or partial agonists that 
produce a sub-maximal response (Fig 1.1). Inverse agonists reduce efficacy compared to 
constitutive signaling and neutral antagonists inhibit the effects of agonists without altering basal 
(R*) activity (Fig 1.1). The variety of ligands and efficacies makes GPCRs complex signaling 
transducers capable of producing an array of signaling outputs.  
To add to this complexity, the completion of the human genome sequencing project in 
2003 revealed the existence of more than 800 GPCR genes, making it the largest category of 
membrane proteins in the genome (Fredriksson et al., 2003). About 400 of these receptors are 
odorant receptors, with the remaining non-olfactory receptors subdivided into five families: 
Rhodopsin (Class A), Secretin (Class B), Glutamate (Class C), Frizzled/Taste (Class F), and the 
Adhesion Family (Alexander et al., 2015). The substantial number and diversity of GPCRs 
expressed throughout the body, coupled with their relevance to signaling, make these receptors 
extremely successful drug targets. In fact, GPCRs are a staple target of modern medicines and 
make up the largest category of proteins targeted by FDA-approved drugs (30%) (Overington et 
al., 2006). In order to continue generating novel GPCR-targeting drugs, it is important to 
understand and apply the molecular mechanisms of GPCR-induced signal transduction, which 





1.2 GPCR SIGNALING AND FUNCTION 
GPCRs can be modulated by diverse chemotypes, including ions, hormones, plant 
alkaloids, and neurotransmitters (Allen and Roth, 2011). At the molecular level, GPCR agonists 
stabilize active receptor conformations leading to structural changes in the Gα subunit of the G 
protein and the exchange of guanine diphosphate (GDP) by GTP (Gilman, 1995; Rodbell, 1995). 
Active GTP-bound Gα subunits dissociate from the obligate dimer Gβγ and then each subunit 
binds separate downstream effectors to initiate intracellular signaling cascades (Preininger and 
Hamm, 2004)(Fig 1.2). Gα proteins come in four main subtypes defined by sequence and the 
intracellular signaling cascade they modulate: Gαs stimulates cAMP production at adenylyl 
cyclases (AC), Gαi/o inhibits cAMP production at ACs, Gαq/11 activates phospholipase C (PLC) 
to generate inositol phosphates and the release of intracellular calcium stores, and Gα12/13 
activates various cytoskeletal-related processes including actin polymerization (Buhl et al., 1995; 
Simon et al., 1991). Each GPCR canonically couples to a particular Gα subtype, although G 
protein “switching” may occur, creating the potential for a multiplicity of downstream effects for 
each GPCR (Milligan and Kostenis, 2006). Humans also express five distinct Gβ subunits and 12 
Gγ subunits that can interact in various combinations to create many potential signaling outputs 
(Hurowitz et al., 2000). Following GPCR activation and G protein dissociation, Gβγ directly 
modulates multiple effectors depending on the obligate dimer composition, including inward 
rectifying potassium (Kir) channels, PLC, ACs, and an array of kinases (Fig 1.2) (see (Khan et al., 
2013) for a comprehensive review). 
Active GPCR conformations recruit binding of G protein-coupled receptor kinases 
(GRKs) to phosphorylate the receptor and change its conformation, prompting the recruitment of 
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β-arrestin proteins (Lohse et al., 1990). β-arrestin binding initiates receptor internalization  via 
endocytosis in clathrin-coated pits (Lefkowitz, 1998). This important step in a GPCR’s lifespan 
is essential for downregulating a signal and allowing the cell to return to homeostasis (Fig 1.2). 
Internalization of the receptor results in endosomal degradation of the receptor or recycling back 
to the membrane (Koenig and Edwardson, 1994; von Zastrow and Kobilka, 1994). The 
regulation of internalization and membrane expression is essential for proper signaling kinetics 
and cellular function. Notably, β-arrestin binding can also initiate distinct, non-G protein-
dependent intracellular signaling (Luttrell et al., 1999).  
Not all ligands signal equally though the described effectors, however. Ligands that 
preferentially modulate one signaling pathway over another, in comparison to a reference ligand, 
have functional selectivity (Urban et al., 2007). Functionally selective ligands often have 
different cellular and physiological efficacy than balanced ligands, as each pathway downstream 
of a GPCR regulates a distinct functional effect. One way to quantify functionally selective 
ligand activity relies on utilizing the Black-Leff operational model and/or the calculation of 
relative activity (RA = log(Emax/EC50)) (Kenakin, 2009b). The rational design of functionally 
selective ligands is useful for basic scientists needing precise tool compounds and for drug 
discovery efforts aiming to reduce unwanted side effects. One such example of a potentially 
useful functionally selective agonist is PZM21, a G protein-biased opioid receptor ligand that 
displays reduced respiratory depression but maintains analgesic efficacy (Manglik et al., 2016).  
GPCRs function to recognize and transduce chemical stimuli into cellular signaling 
responses. The diversity of molecules, GPCRs, G proteins, effectors, and tissue expression 
profiles results in a seemingly infinite array of efficacies. Further, multitudes of receptors must 
translate the barrage of chemical information into a phenotypic response. In order to understand 
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and modulate this process, it is necessary to study receptors at the molecular, cellular, and 
physiological level. Thus far, there has been extensive progress in identifying receptors that 
mediate essential physiological roles, including the adrenergic, serotonin, and opioid receptors. 
Studies on these receptors provide a framework for dissecting GPCR structure, signaling, and 
function. 
 
1.3 –OPIOIDS AND OPIOID RECEPTORS   
Our understanding of GPCR action is limited by the availability of compounds to 
selectively modulate those receptors. Opioids, chemical compounds isolated from the opium 
poppy such as morphine and codeine, are some of the oldest drugs used by man and today 
include thousands of chemical analogs (Roth and Kroeze, 2015). This surplus of chemical matter 
makes it is no surprise that we understand the opioid receptors in great depth. Shortly after the 
radioligand binding experiments performed by Lefkowitz to identify the beta-adrenergic GPCRs 
(Lefkowitz and Haber, 1971), radiolabeled opioid antagonists were used to discover the presence 
of opioid receptors in the brain (Pert et al., 1973). By this time, there were already hundreds of 
synthetic opioids with similar scaffolds and varying chemical substituents that were selective for 
each receptor (Snyder and Pasternak, 2003), leading to the radioligand characterization of three 
separate opioid receptors by 1978 (Kosterlitz and Leslie, 1978; Lord et al., 1977). Today, there 
are four known receptors in this family of Class A GPCRs with ~70% sequence identity to one 
another: the µ-opioid (MOR), κ-opioid (KOR), δ-opioid (DOR), and the nociceptin/orphanin FQ 
peptide receptor (NOP). These receptors are expressed throughout the brain, spinal cord, afferent 
sensory nerves, and intestines (Ryall, 1989). Both exogenous opioids and endogenous opioid 
peptides modulate these receptors, which in turn mediate an array of psychological and 
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physiological effects including analgesia (Waldhoer et al., 2004), drug addiction/abuse (Kreek, 
1996), mood (Lutz and Kieffer, 2013), respiration (Shook et al., 1990), and gut motility (Kurz 
and Sessler, 2003).  
Determination of each opioid receptor’s physiological contributions and biochemical 
characteristics was made easier by the fact that many opiate analogs had already been used in 
numerous physiological and clinical experiments before the receptors and their cognate 
endogenous peptide agonists were identified (Pasternak and Pan, 2013). A further illustration of 
the necessity of opioid small molecules in facilitating research on the opioid receptors is the fact 
that NOP was not identified until 1994 (Mollereau et al., 1994). NOP has substantial differences 
in pharmacology when compared with the other three opioid receptors (Toll et al., 2016) and 
selective NOP modulators were only recently identified (Mustazza and Bastanzio, 2011). The 
Figure 1.3: Typical opioid ligand chemotypes. Structures of five common opioid scaffolds are shown, 
with the positions numbered in the 4,5α-epoxymorphinans for clarity. Example compounds are listed in 
italic below each class. Note that acyclic analgesics can have many other scaffolds.  
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available opioid molecules exposed several key pharmacological parameters that define opioid 
receptor pharmacology, which will be useful to understand in Chapter 3.  
The four main types of opioid chemical scaffolds are 4,5α-epoxymorphinans, morphinans, 
benzomorphans, phenyl-piperidines, and acyclic analgesics (Figure 1.3) (Pasternak and Pan, 
2013). Using these compounds, it was determined that each of the four opioid receptors bind to 
distinct ligands, but all are Gαi/o-coupled and reduce intracellular cAMP/neuronal transmission. 
Analogs of these scaffolds revealed that opioid receptors exhibit stereoselectivity, or a preference 
for certain optical isomers over others (Loh et al., 1974). Only the natural levorotary opioid 
enantiomers activate the opioid receptors (Pasternak and Pan, 2013; Sromek et al., 2014). 
Although the dextrorotary opioid enantiomers are inactive at the canonical opioid receptors, 
many retain physiological activity perhaps through alternate receptors including the anti-tussive 
dextromethorphan. Another pharmacological characteristic of the opioid receptors is that all four 
can be antagonized by naloxone, a 4,5α-epoxymorphinan with an N-allyl substitution (Mollereau 
et al., 1994; Waldhoer et al., 2004). Identification of naloxone and other antagonists 
demonstrated that, generally, extending the length of the nitrogen substituent in morphinans, 
benzomorphans, or 4,5α-epoxymorphinans transforms agonists into opioid antagonists (Lemke et 
al., 2013). This is true for the pan-opioid antagonist naloxone and the subtype-selective 
antagonists naltrindole, nalbufine, butorphanol, naltrexone, and β-furnaltrexamine, among others. 
These compounds were used for upwards of 40 years to characterize the physiologic and 
molecular efficacy of opioid receptors, and although recent progress has been made in generating 
novel chemotypes for opioid receptors (Manglik et al., 2016), much of how we understand the 
actions of these GPCRs is in the context of morphine-based scaffolds.  
In addition to opioid alkaloids and synthetic compounds, endogenous opioid peptides also 
10 
 
bind to all four opioid receptors. Identification of endogenous opioid peptides was determined 
using radioligand binding with selective, high affinity radioactive small molecule opiates 
(Hughes et al., 1975; Pasternak et al., 1975; Terenius and Wahlstrom, 1975). All of these opioid 
peptides are cleaved from four precursor peptides: pro-proopiomelanocortin (POMC), 
proenkephalin (PENK), prodynorphin (PDYN), or pronociceptin/orphanin FQ (PNOC) (Figure 
1.4) (Waldhoer et al., 2004). Generally, the peptides formed from these precursor peptides target 
the DOR, MOR, KOR, and NOP receptors, respectively, although the peptides lose opioid 
subtype specificity at higher concentrations. Of the 27 identified opioid peptides, all 27 (Fig 1.4) 
contain a critical N-terminal sequence Tyr-Gly-Gly-Phe-Met/Leu (YGGFM/L) that is required 
for opioid receptor binding except for the nociceptin peptide, which contains an N-terminal Phe 
(F) instead of a Tyr (Y) (Meunier et al., 1995). The processing and selectivity of these peptides 
depends on tissue expression, post-translational modifications, and presence of cleavage 
enzymes (Berezniuk and Fricker, 2011). For these reasons, there are still likely some unidentified 
Figure 1.4 Opioid peptides. Opioid peptide fragments derived from each of the four pro-peptide genes.  
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opioid peptide fragments and/or opioid peptides with unidentified functions that may contribute 
to undiscovered opioid functions.  
The determination of the inactive state crystal structures of all four opioid receptors 
(Fenalti et al., 2014; Granier et al., 2012; Manglik et al., 2012; Thompson et al., 2012; Wu et al., 
2012) revealed the molecular determinants of classical opioid ligand binding. These structures, 
as well as the active-state MOR (Huang et al., 2015a), exposed atomic detail of each opioid 
receptor’s unique orthosteric binding pocket and conserved structural features for which to 
compare other Class A GPCRs. All residues in this section and later which will be described 
according to the Ballesteros-Weinstein numbering system (Ballesteros et al., 1995). This format 
designates the amino acid first, followed by a number (1-7) indicating the transmembrane 
domain (TM), followed by a third number that refers to the position from the most conserved 
residue, which is always designated 50. For example, position D5.46 is an aspartate in TM5, 4 
residues from the most conserved residue Pro5.50.   
The inactive and active state opioid structures displayed all of the highly conserved 
GPCR residues (N1.50, D2.50, R3.50, 4.50, P5.50, P6.50 and P7.50), which make up critical 
activation microswitches throughout the GPCR that are altered upon ligand binding and 
important for initiating signaling, such as the PIF, CWxP, DRY, and NPxxY motifs (see Table 
1.1) (Nygaard et al., 2009; Vardy et al., 2013; Wacker et al., 2013). Additionally, the inactive 
state structure of the human DOR (Fenalti et al., 2014) demonstrated a conserved sodium ion 
binding site near D2.50, N3.35, and S3.39, providing crystallographic evidence of sodium’s 
allosteric effects on opioid ligand binding, which had first been proposed long before the 
determination of the opioid crystal structures (Pasternak and Snyder, 1975).  
The orthosteric binding pockets are comprised of residues located at the tops of TMs 3, 5, 
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6, and 7, with minor variations of residues between opioid receptors allowing for ligand 
specificity among subtypes (Shang and Filizola, 2015)(see Table 1.1). Further receptor 
differences can be observed in the KOR and NOP structures, which have ligand binding residues 
extending into a pocket defined by TM2, 3, and 7 (Thompson et al., 2012; Wu et al., 2012). The 
crystal structures also demonstrate the poorly conserved extracellular loop (EL) 3, located 
between TM 6 and TM7, which may act as a lid for the ligand or otherwise be involved in ligand 
binding and/or kinetic differences between the receptors (Filizola and Devi, 2013; Manglik et al., 
2012). One of the most important residues identified in the opioid crystal structures is the highly 
conserved D3.32, which forms an ionic interaction with the amine of morphinan and other 
classical opioid compounds in all four receptors.  
In addition to clarifying the molecular mechanisms of receptor activation, the opioid 
receptor crystal structures may promote the discovery of novel opioid small molecule 
chemotypes using structure-based drug design (SBDD) techniques. Novel chemotypes may have 
unique cellular and physiological signaling signatures and/or improved opioid receptor subtype 
specificity. As such, SBDD can lead to the development of more precise treatments of pain, 
addiction, affective disorders, or other pathologies. Thus far, SBDD approaches have been 
successful at the β2-adrenergic receptor (Kolb et al., 2009), KOR (Zheng et al., 2017), and with 
MOR, where a combined in vitro/in silico approach was used to identify a novel, G protein-
biased agonist with reduced side effects (Manglik et al., 2016). Opioid pharmacology research 
has entered a new era where the availability of good probes, high- resolution structures, and 
relevant animal models will continue to provide new information about the molecular and 






Interacting residues MOP DOP KOP NOP MOTIF MOLECULAR FUNCTION(S)
N/N/N/N 1.50 + + + + Coordination of water molecules (Fenalti et al., 2014); stabilizes other activation motifs
D/D/D/D 2.50 + + + + Coordination of sodium ion (Fenalti et al, 2014)
A/A/V/V 2.53 - - + - Ligand specificity (Wu et al 2012)
T/T/T/T 2.56 - - + - Coordination of water molecules (Wu et al)
Q/Q/Q/Q 2.60 - - + + Hydrogen bonding with ligand (Thompson et al., 2012)
N/K/V/D 2.63 - - + + Ligand specificity (Wu et al 2012; Thompson et al., 2012)
V/V/V/V 3.28 - - + + Hydrophobic interactions with ligands (Wu et al., 2012)
I/L/L/I 3.29 - - + + Hydrophobic interactions with ligands (Wu et al., 2012)
D/D/D/D 3.32 + + + + Salt bridge with amine-containing ligands (Manglik et al., 2012)
Y/Y/Y/Y 3.33 + + + + Coordination of water molecules (Vardy et al., 2013)
N/N/N/N 3.35 + + + + Coordination of sodium ion (Fenalti et al, 2014)
M/M/M/M 3.36 + + + + Hydrophobic interactions with ligands and coordination of water molecules (Thompson et al., 2012)
F/F/F/F 3.37 - - - + Coordination of water molecules (Vardy et al., 2013)
S/S/S/S 3.39 + + + + Coordination of sodium ion (Fenalti et al, 2014)
I/I/I/T 3.40 + + + - PIF Facilitates receptor activation (Vardy et al., 2013)
R/R/R/R 3.50 + + + + DRY Formation of "ionic lock" to stabilize inactive state  (Nygaard et al., 2009)
W/W/W/W 4.50 + + + + TM structural integrity (Manglik et al., 2002)
E/D/D/G 5.35 + - - - Ligand specificity  (Granier et al, 2012)
K/K/K/A 5.39 + + + - Coordination of water molecules (Wu et al, 2012); Ligand specificty (Thompson et al., 2012).
V/V/V/I 5.42 + + + + Form hydrophobic contacts with ligand (Wu et al., 2012)
A/A/A/S 5.46 - - - + Hydrogen bonding with ligand (Thompson et al., 2012)
P/P/P/P 5.50 + + + + PIF Facilitates receptor activation (Vardy et al., 2013)
F/F/F/F 6.44 + + + + PIF Facilitates receptor activation (Vardy et al., 2013)
W/W/W/W 6.48 + + + + CWxP "Rotamer toggle switch"; facilitates receptor activation (Nygaard et al., 2009)
P/P/P/P 6.50 + + + + CWxP "Rotamer toggle switch"; facilitates receptor activation  (Nygaard et al., 2009)
I/I/I/V 6.51 + + + + Form hydrophobic contacts with ligand (Manglik et al., 2012)
H/H/H/Q 6.52 + + + + Coordination of water molecules (Manglik et al., 2012); Ligand specificty (Thompson et al., 2012).
V/V/I/V 6.55 + + + + Form hydrophobic contacts with ligand (Manglik et al., 2012); ligand specificity (Wu et al 2012)
K/W/E/Q 6.58 + + - - Ligand specificity  (Vardy et al., 2013, Fenalti et al., 2014)
W/L/Y/L 7.35 + + + - Ligand specificity  (Manglik et al., 2012, Granier et al., 2012)
I/I/I/T 7.39 + + + + Hydrophobicity; Ligand specificty (Thompson et al., 2012).
G/G/G/G 7.42 - - + - May provide space and stabilize activation switch between 7.43 and 3.32 (Kolinksi et al., 2009)
Y/Y/Y/Y 7.43 + + + + Provides stabilizing hydrogen bonds (Manglik, et al., 2012 Thompson et al., 2012); involved in activation
P/P/P/P 7.50 + + + + NPxxY Facilitates receptor activation  (Nygaard et al., 2009)
W/W/W124/W (EL1) - - + - Hydrophobic contact with JDTic; ligand specificity (Wu et al., 2012)Table 1.1: Amino acids among opioid receptor structures. Light gray background: Residues within 4 Å of lig  indicated with a "+" or "-" if present. Dark blue font 
indicates identical residues at all four receptors; light blue font indicates identical residues in MOP, DOP, and KOP, but unique to NOP; red font labels divergent residues in 
all receptors; orange font indicates unique residues to either MOP, DOP, or KOP. Dark gray background: conserved residues that are involved in receptor function. Blue 
background: residues associated with sodium binding. Associated motifs are labeled; all proposed functions are summarized in right-hand column. (Modified from Filizola 








1.4 – ORPHAN GPCRs 
In contrast to the opioid and aminergic receptors that were characterized predominantly 
using ligand binding studies, as many as 120 of the 394 non-olfactory GPCRs have no known 
endogenous ligands or suitably selective probes (Fredriksson et al., 2003; Rask-Andersen et al., 
2014). As a result, these understudied or orphan GPCRs (oGPCRs) have mostly unknown 
function despite demonstration of their existence via genomic sequencing. Tissue expression 
profiling and phylogenetic analyses suggest many oGPCRs are highly conserved in sequence 
and/or tissue expression, while others may have species-specific pattern and expression. 
Uncovering these receptors’ functions can occur in two main ways: genetic studies or 
identification of novel oGPCR modulators. The identification of oGPCR putative function is 
especially relevant to generating innovative new drug targets, as GPCRs are highly druggable but 
only 10% of the 394 non-olfactory GPCRs are utilized as drug targets  (Wacker et al., 2017). 
Thus, oGPCR research expands the repertoire of targets that can be utilized for treating an array 
of diseases and may also identify the source of unwanted side effects for approved clinical drugs.  
While determining the phenotypic functions of oGPCRs can be accomplished using a 
variety of genetic approaches, the identification of selective ligands offers differences and 
advantages over genetic studies alone (Knight and Shokat, 2007). Genetic ablation studies (e.g. a 
knocked-out oGPCR of interest) are commonly employed to detect oGPCR-mediated behavioral 
and physiological phenotypes, however, not all receptor knockouts result in measureable 
phenotypic changes. Further limiting the utility of knock out studies is the lack of expression of 
some primate oGPCRs in rodents and poorly conserved tissue expression across species. In 
contrast, selective oGPCR ligands provide the opportunity to test both agonism and antagonism, 
which is a more physiologically relevant manipulation than gene knockout since GPCRs evolved 
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to transmit extracellular stimuli into a particular phenotype. Further, receptor knockout 
eliminates basal signaling that may be responsible for homeostasis of a particular phenotype. 
Selective oGPCRs modulators can also be utilized in a wide range of biochemical, in vitro, and 
in vivo studies that enrich our understanding of the receptor’s specific and multifaceted functions.  
The general approach for identifying novel oGPCR ligands centers on testing a library of 
potential ligands for receptor interactions in an over-expression system. One of the most 
important parameters in this experimental framework is the selection of the ligand library 
(Janzen, 2014). One option is a focused library of similar chemical scaffolds (Harris et al., 2011), 
such as a panel of known neurotransmitters tested at an orphan receptor with known brain 
expression; this approach was used to deorphanized the 5HT1A serotonin receptor  (Fargin et al., 
1988) and the D4dopamine receptor (Bunzow et al., 1988). Alternately, a more unbiased 
approach involves using ligand libraries containing heterogeneous chemotypes (Irwin, 2006), 
which can promote exploration of greater chemical space and improve the hit rate.  
Another vital parameter for oGPCR ligand screening is the selection of the assay system. 
Radioligand binding assays have been the standard for finding novel compounds for established 
receptors, but these assays are not suitable for many oGPCRs because there is almost no 
chemical matter to start with, including radioligands. Instead, cell-based functional assays have 
become the standard approach since there is no requirement for a high affinity radioligand or 
tracer. Functional assays rely on measuring downstream signaling and have the advantage of 
amplifying the signal to produce a higher signal-to-noise ratio (Thomsen et al., 2005). 
Determining which functional assay to use is non-trivial, as GPCR downstream signaling can 
occur through G proteins, arrestins, and/or other effectors (DeWire et al., 2007).  
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Standard G protein-based functional assays typically measure intracellular cAMP levels 
for Gαs and Gαi-coupled receptors, or intracellular calcium and/or inositol phosphate 
accumulation for Gαq/11-coupled receptors. These assays are easy to use and can be optimized for 
high-throughput application, however, most oGPCRs have unknown G protein coupling. To 
circumvent this issue, one can perform multiple G protein assays or switch to a modified Gαq-
coupled assay relying on chimeric G proteins or forced coupling. Chimeric G proteins are Gαi/o 
proteins engineered to have Gαq-coupled C-terminal amino acids, allowing Gαi/o-coupled 
receptors to signal through PLCβ and produce intracellular calcium release (Allen and Roth, 
2011). Similarly, forced coupling is the overexpression the promiscuous proteins Gα15 and Gα16, 
which couple to many receptors and stimulate PLCβ, in order to measure intracellular calcium 
release from receptors with unknown coupling. While forced and chimeric approaches can lead 
to the discovery of novel oGPCR agonists, there is the potential for these assays to have a high 
false positive rate or lead to inaccurate conclusions about a receptor’s role in native systems 
(Kostenis, 2001). If used, modified G protein assays should be validated in orthogonal assays 
that assess endogenous G protein read-out or other measures of activity.  
Arrestin recruitment-based assays may be more broadly applicable for oGPCR ligand 
discovery considering the G protein coupling is often unknown and arrestin recruitment is a more 
universal read-out for GPCR activation (Luttrell and Lefkowitz, 2002). Common arrestin 
recruitment assays rely on bioluminescence resonance energy transfer (BRET) or enzyme 
complementation (Zhang and Xie, 2012). Both of these techniques rely on the generation of 
either a bioluminescent or chemiluminescent signal following the interaction of a tagged receptor 
and tagged arrestin. These assays have been employed for high-throughput screening (HTS), but 
may be problematic for receptors that poorly recruit arrestin, such as the chemokine receptor 
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CXCR7, the α1A adrenergic receptor ADRA1A, and the angiotensin II receptor AGTR2 (Kroeze 
et al., 2015; Rajagopal et al., 2010). Any functional assay used for HTS (including arrestin-based 
assays) carries the risk of missing functionally selective compounds or antagonists (Kenakin, 
2013; Ngo et al., 2016). This caveat should not preclude the use of functional assays in HTS 
campaigns for oGPCRs, as false negatives are inherent to screening assays (Zhang et al., 1999) 
and any discovered and validated oGPCR chemical matter will be useful. 
Although less commonly used, small molecule screening platforms in the yeast 
Saccharomyces cerevisiae are also suitable for revealing oGPCR ligands. These versatile assays 
rely on the heterologous expression of a human GPCR gene in place of the singular S. cerevisiae 
GPCR Ste2 (Pausch, 1997); GPCR activation by a ligand prompts activation of a mitogen-
activated protein kinase (MAPK) cascade and transcription of a reporter gene that can be easily 
measured. This approach has been successfully used to find orphan receptor ligands (Huang et al., 
2015b), discover oGPCR Gα-coupling (Brown et al., 2003), and identify ligands for established 
GPCRs (Stewart et al., 2010).  
Since the identification of orphan GPCRs in the 1980s, many receptors have been “de-
orphanized” using one or several of the methods described above (Civelli et al., 2013). “De-
orphanized” receptors have validated endogenous ligand pairings; thus, a receptor may have 
several proposed small molecule agonists but still remain an oGPCR. Examples of successfully 
deorphanized receptors include the NOP opioid receptor, whose deorphanization in 1995 
prompted many studies that have since identified its role in modulation of analgesia, tolerance, 
and reward pathways (reviewed in (Toll et al., 2016)). The cannabinoid receptors (CB1 and CB2) 
(Matsuda et al., 1990; Munro et al., 1993), the ghrelin receptor (GHSR) (Kojima et al., 1999), 
and the orexin receptors (HCRTR1 and HCRTR2) (Sakurai et al., 1998) are three examples of 
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previously oGPCRs that have been identified to be therapeutically relevant to analgesia and 
appetite, obesity, and narcolepsy, respectively (Civelli et al., 2006). Importantly, despite this 
progress in finding ligand-receptor pairings, over 100 receptors remain categorized as oGPCRs 
(Davenport et al., 2013). Additionally, many proposed oGPCR-ligand pairings remain un-
validated following the first publication. To this end, the use of multiple assay platforms and 
techniques is extremely important to the deorphanization of these receptors.  
 
1.5 COMPUTATIONAL APPROACHES TO oGPCR PHARMACOLOGY 
The advent of computational, cheminformatic, and bioinformatic analyses catalyzed new 
approaches to receptor deorphanization such as virtual ligand screening (VLS)(Evers and Klebe, 
2004), molecular modeling (Eswar, 2007), and in silico ligand design (Besnard et al., 2012). The 
generation of freely available chemical/pharmacological databases and technological advances in 
GPCR crystallography of GPCRs propelled advances in these computational methods to make 
them exceptionally useful for pharmacological applications. For example, PubChem 
(https://pubchem.ncbi.nlm.nih.gov/), ChEMBL (https://www.ebi.ac.uk/chembl/), the Ki Database 
(https://kidbdev.med.unc.edu/databases/kidb.php), and ZINC15 (http://zinc15.docking.org/) are 
public databases containing chemical structures annotated with efficacy (and sometimes affinity) 
at various protein targets, including GPCRs, with chemicals, drugs, and drug-like molecules. 
These databases can be utilized to predict novel receptor interactions based on chemical structure 
similarity (Hert et al., 2008; Keiser et al., 2007; Mestres and Gregori-Puigjane, 2009) or as 
source databases for virtual docking and VLS (Huang et al., 2015b). 
High-resolution GPCR crystal structures provide an atomic map of the receptor, 
including the binding pocket, which gives insight into the molecular determinants of drug action. 
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Resolving GPCR structures has historically been a challenge (Jazayeri et al., 2015), but advances 
in lipidic cubic phase crystallography has enhanced success in this area, leading to the generation 
of tens of active and inactive-state GPCR structures from Classes A, B, C, and F. These 
structures afford a scaffold for understanding how GPCRs respond at the molecular level to a 
chemical stimulus. Leveraging these structures, newer in silico efforts aim to use the structural 
information to computationally predict novel ligand-receptor interactions and even design new 
therapeutics that exploit a particular molecular characteristic  (Carlsson et al., 2011; Cavasotto 
and Orry, 2007; de Graaf et al., 2011; Kolb et al., 2009).  
As most structures to date require a high affinity ligand to stabilize a receptor 
conformation, no orphan GPCR structures are available for performing structure-based in silico 
predictions. Homology models, computational models of oGPCRs based on receptors with 
known structure and similar sequence, have been employed in lieu of having an oGPCR crystal 
structure (Evers and Klebe, 2004). Homology models have a predicted 7TM and binding pocket 
structure that use commonly conserved structural motifs as anchor points. VLS campaigns can 
then be performed using databases of millions of chemical structures against the homology 
model of the receptor to predict novel oGPCR ligands (Huang et al., 2015b).   
 VLS is useful because it can probe a much wider array of chemically space than would be 
possible with in vitro testing using chemical libraries of actual molecules. Additionally, VLS and 
other computational methods can easily test molecules that are difficult to synthesize for activity 
without having to synthesize them, which is more cost-effective and prompts more high-risk 
chemical testing, leading potentially to new chemical scaffolds for targets. Computational 
pharmacology approaches should be used carefully and validated using in vitro or in vivo studies 
that validate the findings and improve the predictive power of future computational methods. 
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Although there has been great improvement over time using these approaches to accurately 
predict activity at oGPCRs, more work needs to be done to improve these models to increase the 
success rate and general utility.  
 
1.6 - MRG RECEPTORS 
 The Mas-Related GPCRs (MRGs) are a large family of Class A oGPCRs named for their 
sequence similarity to the MAS1 receptor, an oGPCR that was previously misattributed to be a 
proto-oncogene activated by angiotensin peptides (Bader et al., 2014). Approximately 25 Mrg 
genes exist in mice and can be categorized according to sequence homology as MrgprA, B, C, D, 
E, F, G, and H subfamilies (Bader et al., 2014; Liu et al., 2008). MrgA, B, and C subfamilies are 
found only in rodents and contain whole clades of genes (Solinski et al., 2014). In contrast, 
MrgD, E, F, G and H subfamilies contain a single gene and are expressed in primates, rodents, 
and several other vertebrates (Zylka et al., 2003). More interestingly, there is a primate-exclusive 
subfamily of MRGs referred to as MrgprX containing MRGPRX1, 2, 3, and 4 receptors 
(Burstein et al., 2006; Lembo et al., 2002).  
Mrg gene clusters group together on the same chromosomes; in mice this is on 
chromosome 7 and in humans on chromosome 11 (Dong et al., 2001; Liu et al., 2009; Zylka et 
al., 2003). The abundance of MRG genes in close proximity to one another is attributed to local 
gene duplication events that occurred a result of retrotransposons and non-homologous 
recombination near the Mrg loci (Zylka et al., 2003). Phylogenetic analyses suggest Mrg genes 
diverged recently in murine and primate evolution, with MrgX genes resulting from gene 
amplification and selection events following the primate-mouse divergence (Choi, 2003; Zylka et 
al., 2003). MRGRX receptors have approximately 50% sequence identity to the other MRG 
receptors but are not strictly orthologous with any rodent-specific MrgA, B, or C genes (Dong et 
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al., 2001). In fact, each MrgprX gene is more similar in sequence to one another than to any of 
the MrgprA, MrgprB, or MrgprC genes (Dong et al., 2001; Lembo et al., 2002). The lack of 
rodent orthologs has made studying the function of MRGPRX receptors via genetic methods 
difficult, although there have been attempts to define functionally orthologous rodent receptors 
(McNeil et al., 2015).  
Analysis of synonymous and nonsynonymous substitutions among the rodent and primate 
MRG genes demonstrates that most of the variation between genes arises in the extracellular 
domains and predicted binding pockets as a result of positive evolutionary selection (Choi, 2003). 
It follows that despite the myriad of duplicated MRG genes, MRG receptor diversity reflects 
adaptive evolution from species-specific pressures (Zylka et al., 2003). Thus, each MRG 
subfamily of receptors may be uniquely adapted for species-specific functions and ligands. In 
contradistinction, the opioid receptors do not show evidence of positive selection, suggesting that 
MRG receptors are distinctively adapted in the sensory system, where both MRG and opioid 
receptors are expressed (Choi, 2003).  
Almost all MRGs have enriched expression in small-diameter sensory neurons in the 
dorsal root ganglia (DRG) and trigeminal ganglia (TG) due to conservation of promoters and 
transcriptional regulatory elements among genes (Dong et al., 2001; Lembo et al., 2002; Zylka et 
al., 2003). The DRG and TG are clusters of thousands of bipolar neuronal cell bodies whose 
axonal projections are directed towards the spine and towards the body (Le Pichon and Chesler, 
2014). These ganglia act as the major receiving nodes for peripheral sensory stimuli and function 
to relay these messages to the central nervous system for processing (Figure 1.5). Generally 
speaking, DRG sensory neurons project to the skin and some peripheral tissues including the 
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intestines(van Diest et al., 2012), whereas TG sensory neurons innervate the head, eyes, cheeks, 
teeth and jaws (Haas et al., 2011; Zheng et al., 2014). 
The sensory nerves can contain small, medium, and large diameter neurons that convey 
different types of information (thermal, mechanical, and/or chemical). MRG subfamilies are 
found in distinct small diameter sensory neuron subpopulations in the DRG and TG, which 
further differs by species (Zylka et al., 2003 (Liu et al., 2008; Zylka et al., 2003). Small diameter 
nociceptive neurons can be peptidergic (expressing CGRP, Substance P, and TRPV1) or non-
peptidergic (marked by the presence of the canonical marker of dorsal root ganglion C fibers 
isolectin B4 (IB4) (Fang et al., 2006)); MRG receptors are predominately found in the non- 
peptidergic, IB4+ subtype (Figure 1.5) (Liu et al., 2008; Zylka et al., 2003; Zylka et al., 2005).  
Figure 1.5: MRG expression in DRG and TG neuronal subpopulations. Diagram depicting known 
MRG expression in the DRG and TG, with shades of red indicating non-peptidergic neuron subtypes. 
Relevant laminae of spinal cord are labeled (I-III).  
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Rodent Mrg-expressing neurons are further subdivided into those with co-expressed 
MRGPRA/B/C receptors or those having only MRGPRD receptors (Figure 1.5) (Bader et al., 
2014). The majority of MRG-expressing neurons studied in rodents innervate the skin and 
synapse onto laminae II of the spinal cord, which is predominantly involved in the processing of 
pain and temperature (Diaz and Morales, 2016; Zylka et al., 2005). It is also notable that mouse 
MRGPRC receptors were identified in vagal sensory afferent nerves, suggesting MRG receptors 
could mediate a separate, distinct array of sensory roles, including modulation of organs such as 
the lungs, heart, and intestines (Lee et al., 2008). If true in primates, MRGPRX receptors could 
mediate the health or sensation of vital internal organs, making these receptors particularly 
relevant to druggable physiology. 
 MRGPRX receptors are also found in IB4+ nociceptive neurons (Lembo et al., 2002), 
and while there appears to be conservation of MRGPRD neuronal C-type fibers between 
primates and rodents (Wooten et al., 2014), whether MRGPRX receptors have subtype-specific 
sensory neuron expression is unknown. Potential differences between rodent MRG and primate 
MRG neuronal subtype specificity make transgenic knock-in studies with MRGPRX receptors 
problematic. Further, these notable differences in neuronal subpopulation expression combined 
with the substantial genetic variance in binding pocket residues suggests each MRG may have 
distinct functions and pharmacology. To add to this complexity, there are not validated 
endogenous ligands or reliable chemical probes for most MRGs (see guidetopharmacology.org 
for an up-to-date list of proposed ligands or Bader et al., 2014). The reported ligands are 
frequently non-selective and have potency values in the high micromolar to low millimolar range, 
making selective pharmacologic experiments a challenge. Finding novel, selective MRG ligands 
is also alluring for pharmaceutical development, as their nociceptive neuronal expression 
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suggests potential roles in sensory, pain, or itch transduction.  
Studies in rodents support the notion that MRG receptors may be relevant to a variety of 
sensory pathologies. Knockout of MRGPRB4 in mice suggests this receptor mediates the 
sensation of light touching on hairy skin (Vrontou et al., 2013). Alternatively, similar knockout 
studies indicate mMRGPRA3 mediates chemical-induced itch via modulation of TRP channels 
in sensory neurons (Liu et al., 2009). In another study, mMRGPRC activation with the proposed 
MRGPRC-selective peptides BAM8-22 and γ-MSH 6-12 promoted not itch but pain-like 
behavior and allodynia in rodents (Grazzini et al., 2004; Ndong et al., 2009). In total, these 
studies demonstrate that MRGs play an integral role in detecting diverse stimuli and suggest the 
primate-exclusive MRGPRX receptors may also be vital for the sensation of innocuous and/or 
noxious stimuli. As knockout studies in primates are expensive and difficult, selective chemical 
probes for MRGPRX receptors would be useful tools for enabling pharmacologic manipulations 
in vitro and in vivo.  
Unfortunately, there are very few reported ligands for MRGPRX receptors. Since their 
initial discovery in 2001 (Dong et al., 2001; Lembo et al., 2002), a handful of ligands have been 
identified for MRGPRX1 and MRGPRX2 but none for MRGPRX3 or MRGPRX4. The first 
ligands identified were bovine adrenal medulla peptides BAM1-22 and BAM8-22 for 
MRGPRX1, which established that MRGPRX1 is Gαq-coupled (Lembo et al., 2002). Several 
other small molecule agonists activate MRGPRX1, including the low affinity agonist 
chloroquine (EC50 ≈ 300 µM) (Liu et al., 2009), several benzimidazole agonists (EC50 ≈ 300 nM) 
(Malik et al., 2009), and a positive allosteric modulator with unknown specificity for MRGPRX1 
that was demonstrated to inhibit spinal nociceptive transmission via Gαi-dependent pathways (Li 
et al., 2017).  
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Of the MRGPRX family, MRGPRX2 has the largest number of proposed peptide 
agonists, including the peptides Cortistatin-14 (Kamohara et al., 2005; Robas et al., 2003), 
PAMP-12 (Kamohara et al., 2005), and Substance P (Tatemoto et al., 2006), but whether any of 
these are true endogenous peptide(s) remains to be determined. To date, MRGPRX2 remains 
categorized as a Class A orphan receptor according to the IUPHAR classification (Alexander et 
al., 2015). There are also a number of proposed MRGPRX2 small molecule agonists including 
the delta opioid receptor agonist TAN-67 (Southern et al., 2013), complanadine A (Johnson and 
Siegel, 2014), compound 48/80 (McNeil et al., 2015), and numerous basic secretagogues 
(McNeil et al., 2015) but none have been demonstrated as selective.  
MRGPRX2 is the only MRGPRX receptor expressed in mast cells as well as sensory 
neurons (Kashem et al., 2011; Lembo et al., 2002; Subramanian et al., 2011a; Tatemoto et al., 
2006), and this characteristic has helped facilitate numerous studies of endogenous MRGPRX2 
function in human mast cell lines. Mast cells are the first responders to chemical signals of 
infection and allergy that will canonically release cytokines and inflammatory factors in response 
immunoglobulin E (IgE) antibodies cross-linking to IgE receptors in a process called 
degranulation (Metcalfe et al., 1997). GPCRs can modulate IgE-induced degranulation, initiate 
degranulation upon ligand binding, or abrogate degranulation depending on the receptor 
(Gaudenzio et al., 2016; Kuehn and Gilfillan, 2007). Several studies demonstrate MRGPRX2 
agonism promotes IgE-receptor independent degranulation, suggesting this receptor may be 
important for the primate immune system and the pathology of itch (Subramanian et al., 2011a; 
Tatemoto et al., 2006). Most of these studies, however, were performed using MRGPRX2 
agonists with unspecified selectivity and low potency, such as substance P (Tatemoto et al., 
2006), compound 48/80 (Kashem et al., 2011; McNeil et al., 2015), atracurium (McNeil et al., 
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2015), and LL-37 (Subramanian et al., 2011a). The generation of novel and selective MRGPRX2 
agonists would promote a more precise determination of the role of this receptor in mast cells 
and other tissues.  
Despite 15 years of MRG studies, nanomolar potency selective probes for each of the 
four MRGPRX receptors do not exist. For MRGPRX3 and MRGPRX4, there are no reported 
ligands (Davenport et al., 2013). Most information gathered about MRG receptors is the result of 
receptor knockout studies in rodents, which has resulted in valuable information for some MRGs 
but also fails to uncover the function of the primate-specific MRGPRXs. A lack of 
pharmacologic tools has limited our understanding of this family of receptors and the stimuli 
they transduce, which is especially relevant due to the diversity of binding pocket residues 
among these genes. It is clear that MRGs regulate a multiplicity of sensations in rodents, and one 
cannot help but wonder what sensation the MRGPRX receptors mediate in primates. Further, it is 
unclear whether MRGPRX receptors also define distinct neuronal subpopulations of sensory 
neurons or whether these receptors are uniquely adapted for primate sensory and/or immune 
function. Identification of endogenous ligands and ideal probes for the MRGPRX receptors (as 
defined by (Arrowsmith et al., 2015)) would enable a variety of in vivo, in vitro, and other 
biochemical studies that will uncover answers to some of these questions. 
The research contained in this dissertation aims to identify novel probes for the 
MRGPRX family of oGPCRs, specifically MRGPRX2 and MRGPRX4, and assess the putative 
functions of these receptors. First, I identified novel MRGPRX ligands using a β-arrestin 
screening platform. Then, combining further in vitro screening and in silico modeling/docking, I 
identified opioid agonists of MRGPRX2 and generated two MRGPRX2-selective probes. Using 
the identified opioid and selective chemical matter, I demonstrated that MRGRX2 functions to 
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mediate mast cell degranulation. Extending this approach to MRGPRX4, I identified new small 
molecule MRGPRX4 agonists including a pair of tool compounds. Lastly, I identified menthol as 
an allosteric modulator of MRGPRX4 from the results of a genome-wide-association study. The 
results of this work will shed more light on this interesting family of orphan receptors and the 




Figures 2.1, 2.2, 2.3, and 2.4 were modified from the originals, which were previously published in 
Nature Structural and Molecular Biology. The original citation is as follows: 
 
Kroeze, W.K., Sassano, M.F., Huang, X.P., Lansu, K., McCorvy, J.D., Giguere, P.M., Sciaky, N., and 
Roth, B.L. (2015). PRESTO-Tango as an open-source resource for interrogation of the druggable human 







CHAPTER 2: IDENTIFICATION OF INITIAL CHEMICAL MATTER FOR MRGPRX 
RECEPTORS VIA THE PRESTO-TANGO β-ARRESTIN SCREENING PLATFORM  
 
 
2.1 INTRODUCTION AND RATIONALE 
  Estimates suggest that 30% of the non-olfactory GPCRs are orphan and understudied 
(oGPCRs), meaning there are no known endogenous ligands and frequently no available 
chemical matter to interrogate their function (Fredriksson et al., 2003; Roth and Kroeze, 2015). 
High-throughput screening (HTS) of oGPCRs is a facile way to discover novel chemical matter 
for these understudied receptors (Civelli, 2005). Although many approaches have been devised 
to best achieve this task, recent progress in generating a β-arrestin screening platform called 
PRESTO-Tango allows for the measurement of multiple GPCRs across thousands of compounds 
(Kroeze et al., 2015). Arrestin-based approaches are more universal for assessing GPCR activity 
(Lefkowitz and Shenoy, 2005; Luttrell and Lefkowitz, 2002), as they do not rely on G protein 
coupling, making this format a good fit for oGPCRs with unknown G protein coupling. One such 
family of oGPCRs are the Mas-related G protein coupled receptor X family (MRGPRX). 
Chemical probes for these receptors would greatly improve progress in identifying their 
functions, as these primate-exclusive receptors are not readily testable in rodents (Lembo et al., 
2002; Zylka et al., 2003).  
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To identify chemical matter as a starting point for probe development for MRGPRX 
receptors, I utilized the PRESTO-Tango β-arrestin screening platform (Kroeze et al., 2015). 
Using this method, I screened 9 small molecule libraries containing 5,695 compounds for 
activity at each MRGPRX1, MRGPRX2, and MRGPRX4. This multiplexed screening campaign 
allowed me to compare MRGPRX activating compounds across this receptor family, and to other 
receptors screened by the Roth lab to determine possible promiscuous agonists and false 
positives. The initial traction gained in this screen was helpful in validating the utility of the 
PRESTO-Tango platform for oGPCR screening. 
In this chapter I will discuss detailed results of the screening performed at the MRGPRX1, 
MRGPRX2, and MRGPRX4 receptors, including major conclusions and identified chemical 




All transfections were done using the calcium phosphate method (Jordan et al., 1996). 
Chemical Compounds 
Library screening was performed using nine small molecule libraries: NCC-1 (NIH 
Clinical Collection), NCC-2 (NIH Clinical Collection), NIMH Library, Tocris, Prestwick, 
LOPAC, Selleck Chemical, Spectrum, and the Roth Lab Collection (in-house).  
Constructs 
The MRGPRX4-Tango codon-optimized plasmid was made as previously described 
(Kroeze et al., 2015), also see Fig 2.1a. The MRGPRX genes from these constructs (without the 
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modified tail) was subcloned into the FLP-IN inducible stable cell lines as per Invitrogen’s 
instructions using the FLP/IN construct. See Appendix 2 for all plasmid maps and sequences.  
PRESTO-Tango Assay Screening 
HTLA cells were maintained in DMEM (Corning) supplemented with 10% FBS, 2 
μg/mL puromycin and 100 μg/mL hygromycin B in a humidified atmosphere with 5% CO2 at 
37°C. Cells were seeded at 50% confluency and transfected with the MRGPRX4-Tango 
construct using the calcium phosphate method (Jordan et al., 1996). The following day, 
transfected cells were plated in poly-L-lysine-coated, glass-bottomed white 384-well plates 
(Greiner Bio-one) at a density of 20,000 cells/well. Twenty-four hours later, cells were treated 
with 10 μM concentrations of small molecules (in quadruplicate) diluted at 3X final 
concentration in drug buffer (1X HBSS containing 20 mM HEPES and 0.3% Bovine Serum 
Albumin, pH 7.4) and incubated for 18-24 hours. Following drug treatment, media was removed 
and Bright Glo (Promega) was added to each well (diluted 20-fold, 20 μL/well) and incubated 
for 15 minutes at room temperature. A TriLux luminescence counter was used to collect 
luminescence data, which were analyzed as relative luminescent units (RLU) using GraphPad 
Prism. Compounds with two-fold or greater increases in luminescence signal were considered 
“actives” and were subsequently assayed using concentration-response curves. More detail on 
the PRESTO-Tango assay can be found in (Kroeze et al., 2015).  
Intracellular Calcium Mobilization Assay 
I created a MRGPRX4-expressing tetracycline-inducible stable cell line containing the 
MRGPRX4 codon-optimized receptor sequence with an N-terminal FLAG tag using the FLP-
IN/T-REX Core Kit (Invitrogen). MRGPRX4 stable cells were cultured in DMEM containing 10% 
FBS, 100 µg/mL hygromycin B, and 15 µg/mL blasticidin. For the assay, cells were seeded onto 
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glass bottomed, poly-L-lysine coated, black 384 well plates at a density of 20,000 cells/well in 
medium containing 1% dialyzed FBS, 1 µg/mL tetracycline, 100 IU/mL penicillin, and 100 
µg/mL streptomycin and incubated 24 hours. After tetracycline induction, media was removed 
and cells were loaded for 1 hour with 20 µL/well of 1X FLIPR calcium dye (Molecular Devices) 
and 2.5 mM probenic acid in a humidified environment with 5% CO2 at 37°C. Then, baseline 
calcium levels were measured for 10 seconds, followed by drug addition of 10 µL of 3X 
concentrated drug in drug buffer (1X HBSS with 20 mM HEPES, pH 7.4) in 16 point 
concentration response curves from 0.003 nM to 10 μM. Fluorescence was measured for 200 
seconds and data were analyzed using GraphPad Prism. For double addition Schild competition 
experiments, potential antagonists were added 10 minutes before addition of agonist.  
Inositol Phosphate Hydrolysis: 
MRGPRX4 tetracycline-inducible cells were maintained in DMEM containing 10% FBS, 
100 µg/mL hygromycin B, and 15 µg/mL blasticidin. For the assay, cells were seeded into poly-
L-lysine coated, glass-bottom 96 well plates at a density of 50,000 cells/well in inositol-free 
DMEM (Caisson labs) containing 1 µCi/well of 
3
H-myo-inositol (Perkin Elmer), 1 µg/mL 
tetracycline, and 100 IU/mL penicillin and 100 µg/ml streptomycin and incubated 16-18 hours in 
a humidified environment at 37°C with 5% CO2. Following tetracycline induction and labeling, 
medium was removed and 200 µl/well of inositol-free DMEM (Caisson labs) was added per well. 
Then, 5X drug was added, diluted in drug buffer (1X HBSS with 20 mM HEPES and 0.3% 
bovine serum albumin, pH 7.4) in concentration response curves. Cells were incubated with drug 
for 1 hour in a humidified environment at 37°C with 5% CO2. At exactly 15 minutes before 
lysing, 10 µl/well of 26X concentrated LiCl (15 mM final concentration) was added. After drug 
and LiCl incubation, 40 µl/well of 50 mM formic acid was added and cells were incubated at 
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4°C overnight. The next day, 10 µl of lysate was transferred from each well into 96-well flexi-
plates (Perkin Elmer) and combined with 75 µl/well of 0.2 mg/well YSI RNA Binding Beads 
(Perkin Elmer). Lysate-bead mixture was incubated on a shaker at room temperature, protected 
from light, for 1 hour. Before reading on a TriLux beta counter, plates were centrifuged at 1000 x 
g for 2 minutes. CPM data were analyzed with GraphPad Prism.  
 
2.3 RESULTS 
2.3.1 Summary of screening results 
 To perform the PRESTO-Tango screen with the MRGPRX receptors, I used the “Tango-
ized” constructs. In brief, these constructs contain a receptor with an N-terminal HA-signal and 
FLAG-tag, followed by a modified C-terminal tail containing the vasopressin (V2) receptor tail 
to aid arrestin recruitment, a tobacco etch virus protease cut site, and a tetracycline transactivator 
protein (tTA) as previously reported by (Barnea et al., 2008) and (Kroeze et al., 2015) (see Fig 
2.1a). The constructs were transfected into HTLA cells expressing a luciferase reporter under 
control of a tTA promoter (see methods or (Kroeze et al., 2015)).  
Using these constructs, I screened 9 different small molecule libraries containing 9,218 
compounds (5,695 of which were unique) against each MRGPRX1, MRGPRX2, and MRGPRX4 
receptors (Fig 2.1a,b). To optimize the chemical space, the 9 libraries contained a mixture of 
FDA-approved drugs, lead-like compounds, tool compounds, and other various small molecules. 
I did not screen MRGPRX3, as we could not optimize the assay for optimal signal to noise for 
this receptor for unknown reasons. All compounds that activated the MRGPRX receptors above 
two-fold were considered to be potential actives and analyzed further with concentration 
response curves (Fig 2.1b). The total number of non-promiscuous active compounds and the hit 
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rate for each receptor from the number of unique compounds was as follows: 39 for MRGPRX1 
(0.68% hit rate), 81 for MRGPRX2 (1.4 % hit rate), and 54 for MRGPRX4 (0.95% hit rate) (Fig 
2.1c). Interestingly, the majority of the hits for each MRGPRX1, MRGPRX2, and MRGPRX4 
were unique to each receptor, with a minority of compounds shared amongst the MRGPRX 
receptors (Fig 2.1b-d). A list of which compounds were shared is provided in Figure 2.1d.  
 
2.3.2 NCC1 Library screen unveils novel MRGPRX actives in the GPCRome 
In the process of validating the PRESTO-Tango β-arrestin screening platform, Dr. Wes 
Kroeze compared the MRGPRX results of the first 446 small molecule screen (the NCC-1 
Figure 2.1: PRESTO-Tango screening at MRGPRX1, MRGPRX2, and MRGPRX4. A) Flow chart 
depicting Tango construct (modified from (Kroeze et al., 2015)) and experimental outline. B). XY Scatter 
plot showing all data points (averaged from quadruplicate wells) for the log2(Fold Change) activation at each 
MRGPRX1 (blue), MRGPRX2 (red), and MRGPRX4 (black). C). Bar graph showing the number of 
activating compounds (≥2 fold ) for each receptor, with red referring to unique compounds at each receptor 
among the three MRGPRX receptors and blue referring to shared active compounds. D). Table depicting a 
break down of the shared compounds from C. 
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library) with the results of 91 other GPCR targets tested in this library in PRESTO-Tango by 
other members of the lab. One of the most striking results from this screen was activity of 
nateglinide at MRGPRX4 (Fig 2.2a,b.). Nateglinide produced a 45-fold increase in luminescence 
over basal activity and did not activate the other 90 targets tested with this library (2.2a,b).  
To validate nateglinide’s activity at MRGPRX4, I performed 12-point concentration 
Figure 2.2: Discovery of unique MRGPRX4 nateglinide activity via parallel GPCRome screening of NCC1 
Library. Results of screening of the 446-compound NCC-1 library at 91 GPCR targets in the Tango assay and 
follow-up studies are shown. A) Heat map of the entire matrix (red, stimulation of luminescence over 
background). B) Close-up view of a section of the heat map in a, showing the activity of nateglinide at 
MRGPRX4. C) Concentration-response curve of nateglinide at MRGPRX4 in the Tango assay (n = 4). D) 
Concentration-response curve of nateglinide at MRGPRX4 by PI hydrolysis (n = 3) Data in concentration 
response curves are shown as mean ± s.e.m. of technical replicates. This figure was modified from the original, 
which can be found in the PRESTO-Tango resource paper (Kroeze et al., 2015) 
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response curves with MRGPRX4 and nateglinide in the PRESTO-Tango assay and found an 
averaged EC50 of 9.1 µM (Fig 2.2c). As the screening results suggested, nateglinide was also 
inactive at the other MRGPRX receptors (Fig 2.3a). From there, I generated a tetracycline 
inducible MRGPRX4 stable cell line and tested this receptor in three G protein assays to evaluate 
its canonical coupling (Fig 2.3b-c). Assessment of MRGPRX4 activity with Nateglinide in PI 
hydrolysis (Fig 2.2d) and GloSensor cAMP assays revealed that MRGPRX4 does not modulate 
Figure 2.3: Concentration-response curves of nateglinide in Gs and Gi assays in MRGPRX receptor-
expressing cells. A) Gs response to nateglinide in HEK293T cells expressing MRGPRX receptors, showing a Gs 
response only in cells expressing MRGPRX4 receptors at high concentrations of nateglinide. B) Comparison of 
the concentration-response curves in Gs assays of nateglinide and isoproterenol in MRGPRX4-expressing 
HEK293T cells. C) Concentration-response curve in Gi assay of nateglinide in MRGPRX4-expressing 
HEK293T cells. Data are expressed as mean ± SEM of triplicate or quadruplicate determinations, and curves 
were fitted using Graphpad Prism. This figure was modified from the original, which can be found in the 
PRESTO-Tango resource paper (Kroeze et al., 2015) 
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intracellular cAMP levels (Fig 2.6b,c) and instead promoted the hydrolysis of inositol 
phospholipids, indicating this receptors couples to Gαq (Fig 2.2d) and not Gαi or Gαs.   
To determine of other MRGPRX receptors might also couple to Gαq, I made 
tetracycline-inducible stable cell lines for MRGPRX1 and MRGPRX2 and tested them for 
activity with MRGPRX1 positive control peptide BAM8-22 (Lembo et al., 2002) and 
MRGPRX2 positive control SB 205, 607 (also known as TAN-67) (Southern et al., 2013) (Fig 
2.4). These experiments revealed that in HEKT cells MRGPRX1 and MRGPRX2, like 
Figure 2.4: Calcium mobilization responses in stable cell lines expressing MRGPRX receptors. (a,c,e) 
Concentration-response curves; data are expressed as mean ± SEM, and curves were fitted using Graphpad 
Prism. (b,d,f) Time course of responses, showing representative curves of experiments done in triplicate. (a, 
b) Responses of MRGPRX1-expressing cells to BAM8-22. (c,d) Responses of MRGPRX2-expressing cells 
to SB 205,607. (e,f) Responses of MRGPRX4-expressing cells to nateglinide. TRAP is an agonist for 
endogenous PAR1 and serves as an internal control for the calcium mobilization assay. This figure was 
modified from the original, which can be found in the PRESTO-Tango resource paper (Kroeze et al., 2015) 
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MRGPRX4, are Gαq-coupled receptors that promote intracellular calcium release, in line with 
previous reports from (Lembo et al., 2002) (Fig 2.4) 
 
2.3.3 A variety of ligands activate MRGPRX2  
The MRGPRX2 screening campaign revealed the largest number of active compounds 
compared to the MRGPRX receptors. Out of the 81 total activating compounds, there were 
several chemotypes that emerged to suggest common MRGPRX2 scaffolds. One of these 
chemotypes was histamine receptor 1 (H1R) antagonists (Fig 2.5).  From the initial screening, I 
tested four H1R antagonists clemastine, azelastine, cyclizine, and pizotifen in concentration 
Figure 2.5: MRGPRX2 activation by H1R antagonists. A) Concentration-response curves with H1R 
antagonists at MRGPRX2 in Tango; data are expressed as mean ± SEM of quadruplicate wells (n=1), and 
curves were fitted using Graphpad Prism. B) Chemical structures of compounds from A. C) Schild 
experiment to test histamine activity at MRGPRX2, with 3 or 30 μM histamine incubated with postitive 
control agonist TAN-67. Data are expressed as mean ± SEM of quadruplicate wells (n=1). 
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response curves in PRESTO-Tango to validate their screening activity and found all four had 
varying degrees of agonism at MRGPRX2 (Fig 2.5a,b).  
These data, coupled with MRGPRX2’s known expression in mast cells (Kashem et al., 
2011; Subramanian et al., 2011b), generated the hypothesis that the endogenous compound 
histamine might interact with MRGPRX2. To test this, I performed a Schild analysis experiment 
with 3 and 30 μM of histamine added to 12-point concentration response curves of positive 
control compound TAN-67 (Fig 2.5c). I found that histamine did not alter TAN-67 agonism or 
basal signaling and thus was neither an agonist or antagonist for MRGPRX2 (Fig 2.5c).  
The activity of the four H1R antagonists from the screening prompted me to compare all 
Figure 2.6: MRGPRX2 activation by H1R-interacting compounds. Graph depicting compounds 
annotated to interact with H1R from the original screening libraries and their activity at MRGPRX2 at 10 
μM in PRESTO-Tango. Data is expressed as log 2 of the fold change. Note that as not all libraries were 
annoted, this information is from a subset of the total number of compounds. 
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of the predicted H1R-interacting libraries from the original libraries to see if any structure 
activity relationship for MRGPRX2 and this scaffold was apparent. After graphing the fold-
change activity from the initial PRESTO-Tango screen at MRGPRX2 across all potential H1R-
directed compounds, I found that the length of the N-substituent appeared to correlate with 
agonism at MRGPRX2 (Fig 2.6). Future studies that parse out the full details of this SAR will be 
needed to confirm these assertions.   
At least four of the ligands identified from the PRESTO-Tango screen of MRGPRX2 
were opioid or opioid-like and these data will be discussed in detail in the following chapter.  
 
2.4 CONCLUSIONS 
 Here, I demonstrated the utility of the PRESTO-Tango screening assay (Kroeze et al., 
2015) for discovering chemical matter for the oGPCRs MRGPRX1, MRGPRX2, and 
MRGPRX4. After screening 5,695 unique compounds for activity at each receptor with nine 
chemically diverse libraries, I validated activating compounds in concentration response curves 
and orthologous assays. In total, the pooled screening data and analyses show that these receptors 
predominantly couple to Gαq and that there are substantial differences in MRGPRX 
pharmacology, as previously predicted by phylogenetic analyses (Choi and Lahn, 2003).  
 Of the MRGPRX receptors, I gained the most chemical traction with MRGPRX2 and 
MRGPRX4, which were activated by opioids, antihistamines, and the FDA-approved 
antidiabetic nateglinide. The Tango construct for MRGPRX3 did not produce a robust assay, and 
the screening actives for MRGPRX1 turned out to be either non-specific, not very potent, or 
were unable to be replicated. Future studies that could optimize these assays with changes to the 
DNA constructs or the diversity of the chemical libraries might improve screening results. 
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Alternately, as we and others have shown the MRGPRX receptors to be Gαq-coupled (Kamohara 
et al., 2005; Lembo et al., 2002), future studies looking for MRGPRX1 and MRGPRX3 
modulators could screen compounds in the intracellular calcium release assay. 
 Caveats of this study include the difficulty in determining antagonist compounds from the 
initial screen. Thus far, no antagonists for these receptors have been identified and future efforts 
could use this screen in “antagonist mode” or use the intracellular calcium assay to uncover 
novel antagonist scaffolds for MRGPRX receptors. These compounds would be useful as probes 
for biochemical and pharmacological assays and could potentially lead to the development of 
novel therapeutics.  
These data also provide a basis for further SAR studies that will occur in the next two 
chapters. For MRGPRX2, I pursued the opioid compounds from the initial screening instead of 
the antihistamine scaffold based on potency of the compounds in the concentration response 
studies. Future studies assessing further modifications to the antihistamine scaffold and 
functional implications of MRGPRX2 activation by antihistamines should be explored, since 
MRGPRX2 expression in mast cells (Kashem et al., 2011; McNeil et al., 2015; Subramanian et 
al., 2011b) poise it to be involved in inflammatory roles and potential regulatory feedback loops. 
For MRGPRX2 and MRGPRX4, this initial PRESTO-Tango screen promoted the development 
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3.1 INTRODUCTION AND RATIONALE  
 
G protein-coupled receptors (GPCRs) are seven transmembrane receptors that transduce 
extracellular signals into biological responses via heterotrimeric G-proteins and β-arrestins 
(Allen and Roth, 2011). GPCRs are involved in nearly every known biological system and, 
unsurprisingly, GPCR-targeting small molecules represent the largest target class for FDA-
approved drugs (Overington et al., 2006). Despite their therapeutic utility, only 10% of GPCRs 
function as therapeutic targets for FDA approved drugs (Overington et al., 2006), while ~120 of 
394 non-olfactory GPCRs represent “orphan receptors” or understudied GPCRs 
(“oGPCRs”(Huang et al., 2015b)) without useful probes and, frequently, without validated 
endogenous ligands (Fredriksson and Schioth, 2005; Rask-Andersen et al., 2014). The process of 
discovering specific and potent probes for oGPCRs yields useful research tools and can also 
illuminate previously unrealized drug interactions, potentially establishing new drug targets.  
To identify oGPCR ligands, we have developed and tested new physical and 
computational approaches for screening these receptors. The first physical method, dubbed 
“PRESTO-Tango,” involves high-throughput, massively parallel screening of potential  
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modulators (including small molecules, bioactive peptides, and other reagents) for their ability to 
stimulate β-arrestin recruitment at most non-olfactory receptors in the GPCRome (Kroeze et al., 
2015). The second orthogonal and complementary approach relies on the principle that over-
expressed G proteins facilitate a partially active state for most GPCRs enabling the discovery of 
both allosteric and orthosteric modulators for oGPCRs using engineered yeast (Huang et al., 
2015b) . Encouraged by the success of other structure-based drug design methods in GPCRs 
(Isberg et al., 2014; Mason et al., 2012; Ngo et al., 2016), our in silico approach leverages the 
physical screens to develop comparative structural models of the receptors, and then 
computationally screens a much wider chemical space—typically several million commercially 
available molecules—to find specific ligands for the oGPCRs.  
We apply this strategy to the Mas-related G protein-coupled receptor X2 (MRGPRX2) -- 
a primate-exclusive (Dong et al., 2001; Zylka et al., 2003) class A orphan GPCR expressed in 
mast cells and small diameter neurons in the dorsal root and trigeminal ganglia (Kamohara et al., 
2005; Lembo et al., 2002; Robas et al., 2003; Subramanian et al., 2013; Tatemoto et al., 2006). 
Several unrelated peptides are reported to activate MRGPRX2 including Cortistatin-14 (Robas et 
al., 2003), Substance P (Tatemoto et al., 2006), and PAMP(9-20) (Kamohara et al., 2005), 
whether any proposed peptides are endogenous MRGPRX2 agonists is unknown. MRGPRX2 
remains an oGPCR in part because no convincing rodent ortholog has been validated (see 
Discussion) and because MRGPRX2-selective nanomolar potency probes are unavailable. 
Although several selective agonists are reported for MRGPRX2 (Johnson and Siegel, 2014; 
Malik et al., 2009), the compounds are not easily obtained and have not been validated for 
specificity or potency. The identification of demonstrably selective, potent MRGPRX2 agonist 
probes represents an essential step toward illumination of its function in vitro and in vivo. 
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Here, we describe how an integrated approach combining our PRESTO –Tango method 
and our modeling and docking platforms led to the identification of MRGPRX2 agonists, 
including exogenous and endogenous opioids and a selective MRGPRX2 probe ZINC-3573. We 
confirmed ZINC-3573’s selectivity for MRGPRX2 via testing at 315 class A GPCRs using 
PRESTO-Tango, binding assays performed by the National Institute of Mental Health 
Psychoactive Drug Screening Program (NIMH-PDSP), and by testing the parent scaffold using a 
commercial (DiscoverX) kinome screen. Using ZINC-3573, we show MRGPRX2 activation 
induces intracellular calcium release and degranulation in a human mast cell line. We also 
demonstrate that MRGPRX2 represents a novel Gαq-coupled opioid-like receptor that could 
mediate some peripheral side effects of commonly prescribed opiate medications. This discovery 
of the specific MRGPRX2 agonist ZINC-3573, matched with an inactive enantiomer, provides 
the community with a pair of chemical probes by which the in vivo function of this fascinating 




HTLA cells were a gift from Dr. Richard Axel (Columbia University) and are maintained 
at low passage batches. FLP-IN/T-REX HEK-293-T cells were purchased from Invitrogen for 
ease of inducible stable cell line generation and were certified as HEK-T and mycoplasma-free 
by Invitrogen. FLP-IN/T-REX cells were made into inducible stable cell lines according to the 
manufacturer’s instruction. The LAD2 human mast cell line was obtained from cells’ original 
source lab of Dr. Arnold Kirshenbaum and Dr. Dean Metcalfe (Kirshenbaum et al., 2003) at the 
Laboratory of Infectious Diseases at the National Institutes of Health in Bethesda, MD and were 
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maintained as per the their instructions. No further characterization of HTLA or LAD2 cells was 
performed, as the cells came from the source labs 
 
Chemical Compounds 
The nine libraries used in screening were the NCC-1 (NIH Clinical Collection), NCC-2 
(NIH Clinical Collection), NIMH Library, Tocris, Prestwick, LOPAC, Selleck, Spectrum, and 




MRGPRX-Tango plasmids for MRGPRX1, MRGPRX2, or MRGPRX4 were made as 
was previously described (Kroeze et al., 2015) MRGPRX2 constructs were also “de-Tangoized” 
to form the WT-MRGPRX2 construct by inserting a STOP codon before the 3’ TEV site for 
transient transfection. MRGPRB2 insert was obtained from Dharmacon cDNA and subcloned 
into the PRESTO-Tango backbone. See Appendix 2 for all plasmid maps and sequences. 
 
PRESTO-Tango Assay Screening 
HTLA cells (HEK-T cells stably expressing a β-arrestin2-TEV fusion protein and a tTa-
dependent luciferase reporter) were maintained in DMEM (Corning) containing 10% FBS, 2 
μg/mL puromycin and 100 μg/mL hygromycin B in a humidified atmosphere at 37°C with 5% 
CO2. In brief, cells were plated to 50% confluency and transfected with a codon-optimized 
MRGPRX-Tango construct using the calcium phosphate method (Jordan et al., 1996) . The next 
day, transfected cells were transferred to glass-bottomed, poly-L-lysine-coated white 384-well 
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plates at a density of 20,000 cells/well. The following day, cells were treated with 10 μM 
concentrations of small molecules (in quadruplicate) diluted in drug buffer (1X HBSS with 20 
mM HEPES and 0.3% Bovine Serum Albumin, pH 7.4) and incubated for 18-24 hours. After 
drug incubation, medium was removed and 20 μL of Bright Glo (Promega) (diluted 20-fold) was 
added to each well and incubated 15 minutes at room temperature. Luminescence was measured 
on a TriLux luminescence counter and analyzed as relative luminescent units (RLU) using 
GraphPad Prism. Compounds that increased the luminescence signal by two fold or greater were 
considered “actives” and were analyzed further using concentration-response curves. More 
detailed discussion of the PRESTO-Tango assay can be found in (Kroeze et al., 2015). Total 
number of dose response replicates for each compound can be found in Appendix 2 Table 1.  
 
Intracellular Calcium Mobilization Assay 
We generated a MRGPRX2-expressing tetracycline-inducible stable cell line containing 
the MRGPRX2 codon-optimized receptor sequence with a N-terminal FLAG tag using the FLP-
IN/T-REX Core Kit (Invitrogen) following the manufacturer’s instructions. MRGPRX2 stable 
cells were maintained in DMEM containing 10% FBS, 100 µg/mL hygromycin B, and 15 µg/mL 
blasticidin. For the calcium mobilization assay, cells were plated into glass bottomed, poly-L-
lysine coated, black 384 well plates at a density of 20,000 cells/well in medium containing 1% 
dialyzed FBS, 1 µg/mL tetracycline, 100 IU/mL penicillin and 100 µg/ml streptomycin and 
incubated 24 hours. Following tetracycline induction, medium was removed and cells were 
loaded with 20 µl/well of 1X FLIPR Calcium dye (Molecular Devices) and 2.5 mM probenic 
acid, for 1 hour in a humidified environment at 37°C with 5% CO2. For mast cell calcium 
experiments, cells were seeded at a density of 50,000 cells/well in Tyrode’s buffer containing 1X 
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calcium dye and incubated for 1 hour before treatment and analysis. After dye loading, baseline 
was measured for 10 seconds before drug treatment, and then cells were treated with 10 µL of 3x 
concentrated drug in drug buffer (1X HBSS with 20 mM HEPES and 2.5 mM probenic acid, pH 
7.4) in 16 point concentration response curves from 10 μM to 0.003 nM. Fluorescence was 
measured for an additional 120 seconds and data was analyzed using GraphPad Prism. Total 
number of dose response replicates for each compound can be found in Appendix 2 Table 1. 
 
β-hexosaminidase Assay  
LAD2 cells were maintained in Stem-Pro34 medium (GIBCO) supplemented with 
StemPro34 Supplement (GIBCO), 2 mM L-Glutamine, 100 U/mL penicillin/streptomycin, and 
recombinant human stem cell factor (100 ng/ml) (Peprotech) as described in(Kirshenbaum et al., 
2003) . For the assay, adapted from (Staats et al., 2013) , cells were incubated in fresh medium 
for 18 hours prior to the experiment. If testing IgE activation, cells were also incubated with 
biotin-labeled IgE during this time. Then, cells were washed twice in Tyrode’s buffer (20 mM 
HEPES with 134 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5.5 mM glucose, and 0.3% 
bovine serum albumin, pH 7.4) and seeded at 10,000 cells per well of V-bottom clear 96 well 
plates in 90 μL of Tyrode’s buffer. Drugs were diluted at single concentrations or in 8-point 
concentration-response curves at a 10X working concentration in Tyrode’s buffer and 10 μL 
drug, or streptavidin for biotin-labeled IgE samples, and were added in triplicate to the 90 μL 
mast cell suspension. Drugs and cells were incubated for 30 minutes in a humidified incubator 
without CO2 at 37°C. After drug incubation, plates were centrifuged at 250g for 5 minutes and 
30 μl supernatant was added to new 96 well plates containing 10 μl of 10 µM 4-nitrophenyl N-
acetyl-β-D-glucosaminide (NAG) diluted in 0.1M Citrate Buffer (49.5% 0.1M citric acid and 
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50.5% 0.1M sodium citrate, pH 4.5). The remaining supernatant was discarded and cells were 
lysed by adding 100 μl of Tyrode’s buffer with 0.1% Triton-X-100 to the pellets and mixed. 
Thirty μL of lysate was added to 10 μL of 10 μM NAG. All plates were incubated for 90 minutes 
in a humidified incubator without CO2 at 37°C. Lastly, 100 μL of bicarbonate buffer (88 mM 
Na2CO3, 40 mM NaHCO3, pH 10) was added to stop the reaction, inducing a color change that 
was measured on an absorbance plate reader (BMG Labtech POLARstar Omega) at 405 nm. 
Results were analyzed by dividing the released fraction by the total fraction (released + lysed) 
and multiplying by 100 to get a percentage degranulation. To correct for spontaneous 
degranulation, average percent degranulation for vehicle-treated wells was subtracted from drug-
treated wells. Total number of dose response replicates for each compound is reflected in figures 
and figure legends. 
 
siRNA Knockdown and qPCR Analysis 
Using TransIT 20/20 transfection reagent (Mirus), 25 nM of each siRNA (Dharmacon # 
EQ-005666-00-0002, set of 4 distinct MRGPRX2 siRNAs) or the non-targeting siRNA control 
(Dharmacon # D-001910-10-05) was prepared in 250 µL of OPTI-MEM with 5 μL TransIT per 
reaction. After 30 minutes, the transfection mixture was added dropwise to 1.2 million mast 
cells/well of a 6-well plate and allowed to incubate 72 hours. After 72 hours, 200,000 cells were 
removed for use in the β-hexosaminidase assay and 1 million cells were assayed using qRT-PCR 
analysis with the High-Capacity cDNA Reverse Transcription Kit (Life Technologies) following 
the manufacturer’s instructions and TaqMan Universal Master Mix II with UNG (Life 
Technologies) and TaqMan Gene Expression Assay for MRGPRX2 (Life Technologies 




Significance calculations of siRNA experiments 
To assess significance, we used GraphPad Prism to perform a Two-way ANOVA and 
Sidak post-hoc with an alpha value of 0.05. Total number of replicates is reflected in figure 
legends and figures. 
 
Homology Modeling 
The alignment for the construction of the MRGPRX2 models was generated using 
PROMALS3D (Pei et al., 2008) , and homology models were built with MODELLER-9v8 
(Eswar, 2007) using the crystal structure of the κ-opioid receptor (PDB code 4DJH) as the 
template. The homology models were aligned against the entire MRGPRX and opioid receptor 
family. The alignment was manually edited to remove the amino and carboxy termini that 
extended past the template structure, to remove the engineered T4 lysozyme, and to create 
different alignments of the flexible and non-conserved second extracellular loop (EL2); the final 
resulting sequence alignment between the template opioid structure and the MRGPRX receptors 
is shown in Fig 3.10c. Three models were built from each of 180 elastic network models (ENMs), 
produced by the program 3K-ENM (Yang and Sharp, 2009), for a total of 540 models built 
during each iterative round of model refinement. Although EL2 is significantly shorter in 
MRGPRX2 than in other GPCRs, and it lacks the conserved disulfide bond between TM3 and 
EL2, an additional 540 models were also built forcing a putative disulfide between Cys168 in 






Models were ranked on the basis of prioritizing active opioids (dextromethorphan) over 
the rest of the inactive PRESTO-Tango library that was used in the β-arrestin screen, as well as 
over property-matched decoy small molecules. We further insisted that in its docked pose, 
dextromethorphan engaged in an ion pair between its charged nitrogen and an anionic side chain 
in MRGPRX2. The entire PRESTO-Tango library was docked to analogous 4DJH ligand 
binding site in the modeled MRGPRX2 receptors for several rounds of iterative binding site 
refinement. In each round, the top-ranked models were examined for a binding pose that made 
hydrophobic and electrostatic interactions with the receptor, including the key positive-negative 
charge coordination. Residues within 6 Å of the dextromethorphan pose were then minimized 
around the docked ligand with PLOP (Jacobson, 2002). The PRESTO-Tango library was then re-
docked into this optimized binding site for each model. This refinement continued for several 
cycles until the top-ranked models all converged to the same dextromethorphan pose, with the 
top-scoring model chosen as the final one. Structural models (PDB files) of MRGPRX2-
modelled complexes (with dextromethorphan and ZINC-9232) are shown in the Supplementary 
Data online with published manuscript. 
Virtual screens 
We used DOCK 3.6 to screen the ZINC database (http://zinc15.docking.org/). The 
flexible ligand sampling algorithm in DOCK 3.6 superimposes atoms of the docked molecule 
onto binding site matching spheres, which represent favorable positions for individual ligand 
atoms. Forty-five matching spheres were used, with each respectively starting from the previous 
refinement round’s best pose of dextromethorphan. The degree of ligand sampling is determined 
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by the bin size, bin size overlap, and distance tolerance, set at 0.4 Å, 0.1 Å and 1.5 Å, 
respectively, for both the matching spheres and the docked molecules. The complementarity of 
each ligand pose was scored as the sum of the receptor–ligand electrostatic and van der Waals’ 
interaction energies and corrected for context-dependent ligand desolvation using QNIFFT point-
charge Poisson-Boltzmann electrostatics models (Sharp, 1995). Partial charges from the united-
atom AMBER (Meng, 1992) force field were used for all receptor atoms; ligand charges and 
initial solvation energies were calculated using AMSOL (Chambers, 1996; Li, 1998) 
(http://comp.chem.umn.edu/amsol/). The best scoring conformation of each docked molecule 
was then subjected to 100 steps of rigid-body minimization. 
Selection of potential ligands for testing 
We docked the approximately 3.7 million commercially available molecules of the lead-
like subset of the ZINC database to the final MRGPRX2 models. The full hit list was 
automatically filtered to remove molecules that possess high internal energy, non-physical 
conformations, which are not well modeled by our scoring function. The reported rankings 
reflect this filtering. From the top 0.13% (~5,000 molecules) of the docked ranking list, 20 
compounds were chosen for testing, based on complementarity to the binding site and presence 




, mimicking those predicted for 
dextromethorphan.  
Chemistry General Procedures.  
 HPLC spectra for all compounds were acquired using an Agilent 1200 Series system with 
DAD detector. Chromatography was performed on a 2.1×150 mm Zorbax 300SB-C18 5 μm  
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column with water containing 0.1% formic acid as solvent A and acetonitrile containing 0.1% 
formic acid as solvent B at a flow rate of 0.4 mL/min. The gradient program was as follows: 1% 
B (0−1 min), 1−99% B (1−4 min), and 99% B (4−8 min). High-resolution mass spectra (HRMS) 
data were acquired in positive ion mode using an Agilent G1969A API-TOF with an electrospray 
ionization (ESI) source. Nuclear Magnetic Resonance (NMR) spectra were acquired on eith a 
Bruker DRX-600 spectrometer (600 MHz 
1
H, 150 MHz 
13
C). Chemical shifts are reported in 
ppm (δ). HPLC was used to establish the purity of target compounds. All final compounds had > 
95% purity using the HPLC methods described above. 
7-Chloro-5-phenylpyrazolo[1,5-a]pyrimidine. The title compound was synthesized 
according to a known literature procedure (Paruch et al., 2010). To a solution of 3-
aminopyrazole (2.0 g, 24 mmol) in acetic acid (15 mL) was added ethylbenzoylacetate (4.7 mL, 
27 mmol). The resulting reaction mixture was refluxed for 3 h before being cooled to rt and 
concentrated. The solid residue was diluted with EtOAc and filtered to afford 5-
phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one (4.19 g, 83%) as white solid. This intermediate (1.0 
g, 4.7 mmol) was dissolved in POCl3 (5.0 mL, 55 mmol). To the resulting solution was added 
pyridine (0.25 mL, 3.1 mmol) at rt. After being stirred for 3 days at rt, the reaction mixture was 
diluted with Et2O (50 mL) and filtered. The solid was rinsed with Et2O (2 x). The combined Et2O 
solution was cooled to 0 °C and treated with ice and water. The organic layer was washed with 
water (2 x) and brine (2 x). The organic layer was dried (Na2SO4) and concentrated to give the 
tittle compound (0.82 g, 76%) as pale yellow solid. 
1
H NMR (600 MHz, CDCl3) δ 8.23 (d, J = 
2.3 Hz, 1H), 8.12 – 8.04 (m, 2H), 7.58 – 7.48 (m, 3H), 7.45 (s, 1H), 6.84 (d, J = 2.3 Hz, 1H). 
13
C 
NMR (151 MHz, CDCl3) δ 156.2, 149.8, 146.1, 139.2, 136.5, 131.0, 129.2 (2C), 127.5 (2C), 
105.8, 98.8. HRMS (ESI-TOF) m/z: [M+H]
+




((R)-ZINC-3573). To a solution of 7-chloro-5-phenylpyrazolo[1,5-a]pyrimidine (0.069 g, 0.3 
mmol) in dioxane (2 mL) was added DIEA (0.19 mL, 0.6 mmol), followed by  (R)-(+)-3-
(dimethylamino)pyrrolidine (0.038 g, 0.33 mmol). The resulting solution was stirred for 16 h at 
rt before being concentrated and purified by silica gel column to provide the title compound 
(0.070 g, 76%). 
1
H NMR (600 MHz, CDCl3) δ 8.02 – 7.97 (m, 2H), 7.95 (d, J = 2.3 Hz, 1H), 
7.51 – 7.40 (m, 3H), 6.48 (d, J = 2.3 Hz, 1H), 6.12 (s, 1H), 4.30 (t, J = 8.8 Hz, 1H), 4.23 (t, J = 
9.8 Hz, 1H), 4.02 (q, J = 9.4 Hz, 1H), 3.83 (t, J = 9.5 Hz, 1H), 2.90 – 2.82 (m, 1H), 2.36 (s, 6H), 
2.29 – 2.21 (m, 1H), 2.01 – 1.91 (m, 1H). 
13
C NMR (151 MHz, CDCl3) δ 157.5, 151.8, 147.9, 
143.8, 139.2, 129.6, 128.7 (2C), 127.3 (2C), 94.9, 86.2, 65.2, 55.0, 50.1, 44.5 (2C), 30.1. HRMS 
(ESI-TOF) m/z: [M+H]
+
 calcd for C18H22N5, 308.1875; found: 308.1871. 
(S)-N,N-Dimethyl-1-(5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-3-amine 
((S)-ZINC-3573). The title compound (0.075 g, 81%) was prepared using the same synthetic 
procedure for the preparation of (R)-ZINC-3573 with (S)-(+)-3-(dimethylamino)pyrrolidine 
(0.038 g, 0.33 mmol). 
1
H NMR (600 MHz, CDCl3) δ 8.05 – 7.97 (m, 2H), 7.95 (d, J = 2.3 Hz, 
1H), 7.52 – 7.39 (m, 3H), 6.48 (d, J = 2.3 Hz, 1H), 6.12 (s, 1H), 4.30 (t, J = 8.8 Hz, 1H), 4.23 (t, 
J = 9.8 Hz, 1H), 4.02 (q, J = 9.3 Hz, 1H), 3.83 (t, J = 9.5 Hz, 1H), 2.91 – 2.81 (m, 1H), 2.36 (s, 
6H), 2.30 – 2.21 (m, 1H), 2.02 – 1.91 (m, 1H). 
13
C NMR (151 MHz, CDCl3) δ 157.5, 151.8, 
147.9, 143.8, 139.2, 129.6, 128.7 (2C), 127.3 (2C), 94.9, 86.2, 65.2, 55.0, 50.1, 44.5 (2C), 30.1. 
HRMS (ESI-TOF) m/z: [M+H]
+






Table 3.1: Validation of previously published MRGPRX2 agonists in PRESTO-Tango and 
FLIPR intracellular calcium release. pEC50s given with +/- SEM; Compounds with pEC50s 
over 4.5 are annotated as < 4.5 and NT = Not Tested because compounds are not commercially 
available or available via contact through source paper. Number of replicates of experiments in 
each assay, performed in triplicate, are shown beside each pEC50.  
3.3 RESULTS  
3.3.1 Identification of MRGPRX2 agonists 
We initially attempted to replicate prior reports of potential MRGPRX2 agonists to 
determine if any might prove suitable as leads for probe development. Unfortunately, we could 
not replicate the activities of most reported MRGPRX2 agonists when tested at the highest 
concentrations possible for our assays (Fig 3.1, Table 3.1). Thus, of the many putative 
MRGPRX2-activating peptides and peptide-like compounds, we could replicate activities only 
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Figure 3.1: Validation of MRGPRX2 and MRGPRB2 Agonists. (a–d) Average concentration–response 
curves in the Fluorescent imaging plate reader (FLIPR) intracellular calcium release assay (n = 3 
experiments in triplicate wells) in MRGPRX2-inducible cells, designated +X2 or –X2 for the presence or 
absence of tetracycline-induced receptor expression, for previously published MRGPRX2 agonists. The y 
axis shows the fold change of calcium release over the basal receptor signaling. (e) Concentration–response 
curves in FLIPR intracellular calcium release assay for stable cell lines expressing either human MRGPRX2 
(solid lines) or the proposed mouse ortholog MRGPRB2 (dotted lines) with X2-activating peptides 
cortistatin-14 and substance P and small-molecule agonist TAN-67. Y axis is fold-change calcium release 
over basal (n = 3 in quadruplicate) (f) Concentration–response curves for cortistatin-14, substance P, and 
small-molecule agonist TAN-67 with MRGPRX2-Tango (solid lines) and MRGPRB2-Tango (dotted lines) 
in the PRESTO-Tango arrestin recruitment assay (n = 3 in triplicate). The y axis shows the fold change 
response over basal luminescent signal. RLU, relative luminescent units. All error bars represent s.e.m. 
 for substance P, cortistatin-14 and PAMP (9-20) (Fig 3.1a,b).  Mastoparan, octreotide, leuprolide, 
and kallidin were inactive or only marginally so (e.g. Gαq EC50 = 11.5 µM for kallidin) at human 
MRGPRX2 (Fig 3.1c, Table 3.1).The putative MRGPRX2 agonist mastoparan (McNeil et al., 
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2015) was active in cells with and without MRGPRX2 expression suggesting non-specific 
activity (Fig 3.1d, Table 3.1).  
Of the more than one dozen non-peptide compounds reported to activate MRGPRX2, we 
could only replicate four (TAN-67 (Southern et al., 2013), compound 48/80 (McNeil et al., 2015), 
cetrorelix (McNeil et al., 2015) and the proposed selective agonist complanadine A (Johnson and 
Siegel, 2014)) and even these had low potencies or have other known receptor targets (Fig 3.1c,d, 
Table 3.1). Notably, we could not validate several recently reported secretagogue agonists for 
MRGPRX2 including the THIQ motif-containing octreotide, rocuronium, ciprofloxacin, 
atracurium, moxifloxacin, and levofloxacin (McNeil et al., 2015) even when tested up to 100 μM 
(Fig 3.1c,d, Table 3.1). Likewise, although the proposed nanomolar MRGPRX2-selective agonist 
complanadine A (Johnson and Siegel, 2014) was active in our assays, we measured a Gαq EC50 of 
18 µM and could not obtain a β-arrestin EC50 due to apparent cytotoxicity above 1 µM using 
PRESTO-Tango, a luciferase reporter-based β-arrestin screening platform (Kroeze et al., 2015) 
(Fig 3.1c,d, see Table 3.1 for a full list of validated compounds).  
As MRGPRX2 is expressed only in primates, finding a rodent analog would enable the 
use of genetic techniques to probe for the receptor’s functional roles, with the caveat that GPCRs 
may often be knocked down without incurring phenotypes that recapitulate their roles in 
pharmacology. The suggested MRGPRX2 rodent ortholog MRGPRB2 (McNeil et al., 2015) only 
shares 52% sequence identity with MRGPRX2 (Fig 3.2a) and we could not substantiate any 
proposed shared ligands except for Cortistatin-14, which had high micromolar activity at 
MRGPRB2 (Fig 3.1e, f; Fig 3.2b). Thus, although there have been prior studies of MRGPRX2 
and/or MRGPRB2’s pharmacology, many remain insufficiently robust for facile replication; and 
no independent studies have emerged that replicate these prior findings. Accordingly, we chose 
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Figure 3.2: MRGPRB2 does not share ligands with MRGPRX2. A) Sequence alignment of MRGPRX2 
(top) with MRGPRB2 (bottom), blue highlights conserved residues. B-C) Average concentration response 
curves in PRESTO-Tango for MRGPRB2 (n=2, triplicate) using ligands for MRGPRX2 or MRGPRB2 
positive control ligands Cortistatin-14, PAMP-12, Compound 48/80, and Substance P reported in [23] in 
PRESTO-Tango and in FLIPR (D-F) using the MRGPRB2 stable cell line and 100 µM ATP as a positive 
control, n=3 in triplicate. G) Depicts B2 stable cell line without TET for compounds observed in F), n=1 in 
triplicate. All error bars represent s.e.m. 
an unbiased approach to identify reliable MRGPRX2 probes. We recently proposed parallel 
screening strategies (Huang et al., 2015b; Kroeze et al., 2015) using small libraries of drugs and 
drug-like compounds as fruitful initial approaches to discover active compounds at oGPCRs 
(Kroeze et al., 2015). Here we screened 5,695 unique compounds for agonist activity at three 
members of the MRGPRX family (MRGPRX1, MRGPRX2, and MRGPRX4) using the 
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Figure 3.3: PRESTO-Tango Screening of MRGPRX2 reveals new agonists. (a) Venn diagram depicting 
pooled PRESTO-Tango screening actives for MRGPRX1, MRGPRX2, and MRGPRX4 for all hits with 
greater than two-fold activation over basal (known false positives and duplicates excluded). (b,c) Average 
concentration–response curves (n = 3 in triplicate wells for all, except ADL5859, for which n = 1) for the 
five compounds from the screening show low micromolar activation of MRGPRX2. (d) Concentration–
response curve for previously published MRGPRX2 peptide agonists at the MRGPRX2-Tango construct. y 
axes are shown as percent of TAN-67 activity. All error bars represent s.e.m. 
PRESTO-Tango platform. Our strategy was to screen against three MRGPRX family receptors 
in parallel to find active compounds with selectivity within the family.   
The screening revealed MRGPRX1 had the fewest number of actives (39), followed by 
MRGPRX4 (54), and MRGPRX2 (81) (Fig 3.3a). We were most interested in compounds 
showing selective MRGPRX2 agonism without apparent activity at other MRGPRX receptors. 
Among the 67 compounds that activated MRGPRX2, and neither MRGPRX1 nor MRGPRX4, 
were five opioid-related ligands ADL-5859, sinomenine, dextromethorphan, dextromethorphan’s 
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metabolite dextrorphan, and the previously reported MRGPRX2 ligand TAN-67 (Southern et al., 
2013), a delta opioid receptor agonist.  
Confirmatory concentration response curves using the PRESTO-Tango platform 
indicated the five opioid-like compounds had low micromolar potency (Fig 3.3b, c). To confirm 
the MRGPRX2-Tango construct performed similarly to the unmodified wild-type (WT) receptor, 
we tested previously reported MRGPRX2 agonists TAN-67 (Southern et al., 2013), cortistatin-14 
(Robas et al., 2003), substance P (Tatemoto et al., 2006), and compound 48/80 (McNeil et al., 
2015) and found all activated the MRGPRX2-Tango receptor at similar reported potencies for 
Gαq assays at the WT receptor (Fig 3.3d).  
Figure 3.4: Validation of MRGPRX2 opioid ligand activation. A tetracycline-inducible HEK-T cell line was 
created for MRGPRX2 WT inducible expression to test opioid and opioid-like ligands from PRESTO-Tango screen. 
A, B) Average concentration response curves in the intracellular calcium release assay with dextromethorphan, 
dextrorphan, and TAN67 (n=3, triplicate) in tetracycline-induced (a) and non-induced (b) cells. Error bars depict 
SEM.  
 
To confirm MRGPRX2 Gαq-mediated functional activity of agonists, we used a 
tetracycline-inducible WT MRGPRX2 stable HEK-T cell line to test for intracellular calcium 
release. Dextromethorphan, dextrorphan, sinomenine, and TAN-67 promoted intracellular 
calcium release when MRGPRX2 expression was induced by tetracycline (1 µg/ml; Fig 3.4a) but 





3.3.2 Preference for dextro-enantiomers and N-methyl scaffolds  
As several dextrorotatory opiate ligands activated MRGPRX2, we initially investigated 
ligand stereochemistry, aware that classical opioid receptors prefer levorotary morphinans and 
benzomorphans (Sromek et al., 2014). We assayed levorphanol and levallorphan, enantiomers of 
the screening hits dextrorphan and dextromethorphan, respectively, for activity at MRGPRX2 in 
β-arrestin recruitment and calcium mobilization assays. Levorphanol was approximately ten-fold 
less potent at MRGPRX2 than dextrorphan and levallorphan was completely inactive up to 100 
µM (Fig 3.5a). Likewise the dextrorotary morphinan sinomenine had comparable potency to 
dextrorphan and dextromethorphan at MRGPRX2 (Appendix 2 Table 1), more potent than 
sinomenine’s purported activity at the opioid receptors (Wang et al., 2008) (Fig 3.6). MRGPRX2 
also preferred dextrorotary benzomorphan compounds, as (-)-cis-normetazocine was ten-fold less 
potent compared to (+)-cis-normetazocine (Fig 3.5b, Appendix 2 Table 1).  
 
Figure 3.5: MRGPRX2 is activated by many opioid scaffolds. (a–d) Average concentration–response curves (n = 
3 in triplicate) for structurally related compounds, morphinans (a), benzomorphans (b), morphine and analogs (c), 
and codeine and analogs (d), in an intracellular calcium release assay in which the y axis is fold-change calcium 
release over baseline. Error bars represent s.e.m. (e) Summary of major findings in structure–activity relationships 
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for opioid scaffolds at MRGPRX2, including size of N-substituent, stereochemistry of chiral centers, and bulk on the 
3-position of the morphinan. 
To determine if other opioids activated MRGPRX2 with similar stereochemical 
preferences, we tested a panel of 11 morphine and codeine analogues for activity in PRESTO-
Tango and calcium mobilization assays, including the most common metabolites of morphine 
and codeine. Both (+)- and (-)-morphine enantiomers activated MRGPRX2 with comparable 
potency in PRESTO-Tango and calcium assays, as did (+)- and (-)-codeine and thebaine (Fig 
3.5c,d, Appendix 2 Table 1). For the metabolites, we observed differential effects of substitutions 
on C-3 and C-6 positions in the morphine scaffold, as replacement of morphine’s 3-hydroxy with 
a 3-methoxy (e.g. codeine and thebaine) had little effect on affinity or efficacy at MRGPRX2 
whereas replacement of the morphine’s 3-hydroxy with gluconuride to yield morphine-3β-
gluconuride eliminated MRGPRX2 agonist activity (Fig 3.5c,d, Appendix 2 Table 1). In the C-6 
Figure 3.6: Sinomenine activity at MOR, KOR, and DOR. A-C) Sinomenine activity (red) in the Glo Sensor 
assay for Gαi activity in comparison to other known potent opioid receptor agonists. Average n=3 in triplicate 
for all shown, error bars represent SEM. D-F) Competitive binding data for sinomenine (red) versus other potent 
opioid receptor ligands, average of two trials each in duplicate. 
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position, gluconuride or acetyl modifications to morphine and codeine all retained agonist 
activity, albeit with loss in potency compared to (-)-morphine and (-)-codeine, respectively (Fig 
3.5c,d, Appendix 2, Table 1). These preliminary opioid structure-activity relationships (SARs) 
demonstrate that larger modifications on C-6 are more tolerated than on C-3.  
We then explored the effect of substituents on the cationic nitrogen in the morphinans on 
MRGPRX2 activation. N-methyl substituted scaffolds, as in codeine, morphine, and metazocine, 
conferred receptor agonism while the N-unsubstituted norcodeine was inactive up to 100 µM 
(Fig 3.5b-d, Appendix 2 Table 1). Morphinans and benzomorphans with substituents larger than 
N-methyl, such as the N-allyl of levallorphan and N-allyl-normetazocine, and the N-cyclopropyl 
of naltrexone and cyclazocine, were inactive at MRGPRX2 (Fig 3.5a,b, Appendix 2 Table 1). 
The inactive morphinans and benzomorphans showed no antagonist activity against MRGPRX2, 
suggesting a tight SAR around substitution of this position. 
As mentioned, TAN-67 is a δ-opioid receptor agonist known to activate MRGPRX2 
(Southern et al., 2013). The active enantiomer at the δ-opioid receptor is (-)-TAN-67 whereas 
Figure 3.7: MRGPRX2 prefers dextroratory enantiomers including (+)-TAN-67. A) Concentration 
response in PRESTO-Tango for (+/-)-TAN-67 versus the purified enantiomer (+)-TAN-67. Y axis is percent 
of (+/-)-TAN-67, average n=3 in triplicate. B) Concentration response curves in FLIPR for (+/-)-TAN-67 
versus the purified enantiomer (+)-TAN-67, (average of n=3 in triplicate). Y axis is fold change intracellular 




(+)-TAN-67 displays pro-nociceptive activity in vivo through an unidentified receptor (Nagase et 
al., 2001) . We tested (+)-TAN-67 for MRGPRX2 activity in PRESTO-Tango and calcium 
mobilization assays and found (+)-TAN-67 was more potent than racemic (+/-)-TAN-67 (Gαq 
EC50 = 290 nM vs 740 nM) (Fig 3.7), demonstrating that MRGPRX2 prefers dextro-enantiomers 
at most chemical scaffolds with some exceptions. Neither (-)- nor (+)-naloxone antagonized (+/-
)-TAN-67 agonist activity (Fig 3.8a, b) and no other canonical opioid antagonists, including 
naltrindole, naltrexone, and β-chlornaltrexamine, inhibited (+/-)-TAN-67 activity. (Fig 3.8c-e). 
These SARs suggests that MRGPRX2, despite its distant sequence relationship to the four classic 
opioid receptors (transmembrane region sequence identity no greater than 26%), is an opioid-
responding oGPCR with important differences in ligand recognition patterns.  
  
Figure 3.8: MRGPRX2 is not antagonized by traditional opioid antagonists. A-D) Representative concentration 
response curves in the PRESTO-Tango assay using (-)- and (+)-Naloxone, β-chlornaltrexamine (BCNAL), Naltrindole 
(NTD), or Naltrexone (NTX), bottom right.  N=3 in triplicate for (+)- or (-)- naloxone experiments, n=1 in triplicate for 
BCNAL, NTD, NTX in TANGO. Error bars represent s.e.m.  
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3.3.3 Prodynorphin-derived peptides activate MRGPRX2 
A key question is whether MRGPRX2 is also activated by endogenous opioid ligands. 
Accordingly, we tested a panel of 20 endogenous opioid peptides for activity in PRESTO-Tango 
and intracellular calcium assays. MRGPRX2 was preferentially activated by prodynorphin-
derived peptides (Fig 3.9a, b) and only minimally activated, if at all, by other opioid peptides 
(Fig 3.9c,d). The full length dynorphin A (1-17) and several truncated prodynorphin peptides 
activated MRGPRX2 (Fig 3.9a). C terminal amino acid truncation of dynorphin peptides reduced 
agonist potency until dynorphin A (1-7) and dynorphin A (1-6) fragments, which were 
completely inactive (Fig 3.9a, Fig 3.10a).  
To determine if the C terminal portion of dynorphin A was sufficient for MRGPRX2 
activation, we assayed dynorphin A (13-17) and dynorphin A (6-17) and found that dynorphin A 
(6-17) retained minimal activity (EC50 = 39.6 µM) and dynorphin A (13-17) was inactive (Fig 
3.9b), suggesting both the N terminal YGGF motif and C terminal cationic tail are important for 
MRGPRX2 activation (Fig 3.10a). Dynorphin B (1-13) and α- and β-neoendorphin also activated 
MRGPRX2, with dynorphin B and α-neoendorphin having almost identical µM potency (Fig 
3.9b). Intriguingly, EC50 values for the dynorphin peptides were right-shifted in the PRESTO-
Tango assay, indicating perhaps modest G protein bias, similar to observations made for 
dynorphin peptides at the κ-opioid receptor (White et al., 2014).   
To determine whether more closely related receptors might share peptide ligands with 
MRGPRX2, we used the GPCRdb (gpcrdb.org) to identify class A receptors with greater than or 
equal to 30% sequence similarity to MRGPRX2 in the class A binding pocket (Fig 3.10b). We 
identified 14 receptors, 11 of which had established probes (10 ligands total). 3 receptors were 
oGPCRs with no known ligands. We tested the 10 established ligands for activity and found only 
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one ligand, somatostatin-14, activated MRGPRX2 (Supplementary Fig 3.10b,d; EC50 = 380 nM). 
This is consistent with previous reports that somatostatin-14, somatostatin-28, and Cortistatin-14 
are MRGPRX2 agonists (Robas et al., 2003; Southern et al., 2013). Interestingly, the canonical 
opioid receptors and somatostatin receptors are closely related in binding site-sequence space, 
                    
but not in small molecule-chemical space (Lin et al., 2013). Our data, along with previously 
proposed peptide ligands, suggest that although MRGPRX2 can be activated by many peptide 
ligands, this cannot be predicted from sequence similarity alone. 
 
 
Figure 3.9: MRGPRX2 is preferentially activated by prodynorphin-derived peptides. (a,b) Average 
concentration response curves (in triplicate wells; n = 3 for all except Dyn A fragments below 7 amino acids in 
length and α-neoendorphin for which n = 2 ; see Supplementary Table 2) for pro-dynorphin-derived peptides 
in MRGPRX2 Tet-On cells, in which the y axis is fold-change calcium release over baseline. Error bars 
represent s.e.m. (c,d) Average concentration–response curves (in triplicate wells; n = 3 for all except nociceptin 
and BAM(8–22) for which n = 2 and β-endorphin and BAM-22 for which n =1 ; see Supplementary Table 2) 
depicting nonprodynorphin-derived peptides with minimal activity compared to dynorphins in A and B. Error 
bars represent s.e.m. 
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Figure 3.10: Peptide agonism at MRGPRX2 and comparison among related receptors. A) Table 
showing peptide sequence alignment and Gα functional EC50 values in nM for MRGPRX2 and κ-OR for 
reference. MRGPRX2 values were measured in FLIPR intracellular calcium assay whereas κ-OR values 
were determined using the Glo sensor assay. κ-OR values are average of n=3, MRGPRX2 values are average 
of n=2 or 3 (see Supplementary Table 2 for details). B.) Results of sequence similarity search in GPCRdb for 
all class A receptors based on the class A binding pocket. Note the green highlights the only ligand active at 
MRGPRX2. C) Sequence alignment for all four members of MRGPRX family receptors aligned with κ-
opioid receptor (OPRK1) and nociceptin opioid receptor (OPRX1). Dark blue illustrates full identity residues 
and light blue indicates similar residues. D) Dose response curve, average of 2 trials, in FLIPR calcium assay 
for somatostatin at MRGPRX2 in MRGPRX2-expressing cells (left) and cells without MRGPRX2 (right). 
E.) Heat map matrix showing percentage sequence similarity (left) or sequence identity (right) for the entire 
sequences of the four opioid receptors and somatostatin 4 receptor in comparison to MRGPRX2. Red 
indicates lower percentage and green indicates higher percentage of similarity or identity. Modified from 
GPCRdb. F) Heat map matrix showing percentage sequence similarity (left) or sequence identity (right) for 
the Class A binding pocket residues only between the four opioid receptors and somatostatin 4 receptor in 
comparison to MRGPRX2. Red indicates lower percentage and green indicates higher percentage of 





MRGPRX2 is an opioid-like oGPCR that responds to endogenous pro-dynorphin-derived 
opioid peptides, binds to many well-known synthetic opioid agonists, but which differs from 
classic opioid receptors in its unique preference for dextro-morphinans, dextro-benzomorphans  
and its inability to be antagonized by potent and classic opioid receptor antagonists. Although 
none of these compounds are suitable as a selective probe or tool, the chemical matter identified 
was useful to launch an in silico campaign to identify novel chemotypes active at MRPGRX2. 
3.3.4 Structure-based docking predicts MRGPRX2-selective ligands 
We next turned to our computational approach using a 1000-fold larger compound library 
than that used in the physical screen—the over 3.7 million commercially available “lead-like” 
Figure 3.11: In silico MRGPRX2 homology modeling predicts a selective agonist. Workflow depicting 
MRGPRX2 homology model construction (top left) followed by identification of a putative binding site (top 
middle) that was confirmed by testing the mutations E164Q and D184N (top right, average dose response, n = 
3 in triplicate, shown with dextromethorphan (DXM). Then, ~3.7 million molecules were docked to predict 
the agonist ZINC-9232 (bottom left). Further iteration and testing revealed the tool and selective compounds 
(S)- and (R)-ZINC-3573 (bottom middle and right). Docking pose of selective compound is supported with 
mutation experiments in PRESTO-Tango (bottom right, average dose–response curve, average of n = 4 in 
triplicate). Error bars on graphs shown is representative of s.e.m. 
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molecules then in the ZINC database (Irwin and Shoichet, 2005). Our strategy was to calculate 
many 3D MRGPRX2 models, select those few that recapitulated the ligand recognition patterns 
we observed experimentally, and use these to template a final model to screen the full, larger 
compound library for novel molecules unrelated to opioid ligands but selective for MRGPRX2. 
The general approach for modeling and docking has been recently described (Huang et al., 
2015b), and we summarize it here (see Methods for more details). We first sought GPCRs of 
known structure with MRGPRX2 sequence similarity; intriguingly, this led to the κ-opioid 
receptor, which only shares 23.3% sequence identity in the transmembrane regions with 
MRGPRX2. We calculated an initial MRGPRX2 structure using Modeller (Eswar, 2007) and 
expanded on this using elastic network modeling to increase the amount of sampled backbone 
conformations (Yang and Sharp, 2009). From the initial model, we calculated 360 further 
structures using the Elastic Network Modeling program ENM; half of these had an extracellular 
disulfide bond imposed and half did not. Each of these was expanded three-fold with Modeller 
(i.e., using the ENM models as templates for Modeller). Overall, 1,080 models were calculated.   
We docked the 5,695 unique compounds from physical screening against all 1080 models 
(i.e., over 6 million compound-receptor docking calculations, and over 10
12
 individual 
configurations of the library molecules in the receptor). We looked for models that best enriched 
the discovered opioid agonists over the vast number of inactive decoy molecules. The top-
enriching models were inspected visually for binding poses that captured sensible ion-pairing 
interactions with the conserved aminergic group of the opioid agonists. This prioritized a model 
that had a background-corrected logAUC for enrichment (Mysinger and Shoichet, 2010; 
Mysinger et al., 2012) of 8.42—which happened to be the top-enriching model (this is not 




Figure 3.12: Mutations support in silico model of opioid ligand binding. Average concentration response 
curves in PRESTO-Tango depicting the effect of D184 mutations and E164 mutations on opioid ligand activity 
where A) is (-)-morphine, B) is (+)-morphine, C) is dextromethorphan and D) is Dynorphin A (1-13). Y axis 
depicts fold change over basal signal, average n=2 in triplicate. Error bars represent SEM.  E). Graph showing 
23 different rotamers of Asp184 (blue circles) and 27 different rotamers of Glu164 (orange squares) versus 
dextromethorphan RMSD in Å (Y axis). X axis is amino acid rotamer RMSD in Å. 
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(Carlsson et al., 2011), though usually the model chosen is among the best enriching models). 
Residues within 6 Å of the dextromethorphan pose were minimized around the docked ligand 
with PLOP (Jacobson et al., 2002), and the 5,695 molecules re-docked. Two rounds of docking 
and PLOP-based refinement led to the final modeled receptor conformation, which predicts the 




(Fig 3.11, showing 
dextromethorphan). The exact rotamer state of these residues allowed some flexibility; i.e., 
several different rotamers of the Asp/Glu led to productive placement of the known agonists (Fig 





. E164Q and D184N substitutions retained steric 
properties of the WT residues but removed their negative charges and both resulted in a loss of 
activity for dextromethorphan, (-)-morphine, and related opioids in the PRESTO-Tango assay 
(Fig 3.11, Fig 3.12a). We then tested the importance of the length of the acidic residue via 
E164D and D184E mutations and observed that E164D increased the Emax and reduced the 
potency of both dextrorphan and morphine (Fig 3.12a,c) while D184E ablated activity of all 
opioids tested (Fig 3.11, Fig 3.12a-d). The substitutions support the importance of the proposed 





are necessary for MRGPRX2 opioid activation.  
As an aside, dynorphin A (1-13) activity was lost with the D184N but not the E164Q 
mutation, suggesting only one of these residues is required for the opioid peptide interaction (Fig 
3.12d). We modeled the putative MRGPRX2-dynorphin binding site by overlaying the 
MRGPRX2 homology model with the previously published κ-opioid receptor docked with 
dynorphin A (1-13) (O'Connor et al., 2015). The N-terminal Tyr1 of dynorphin A (1-13) is 
accommodated within a negatively charged aromatic pocket, whereas Arg7 and Phe4 appear to 
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Figure 3.13: Modeling the MRGPRX2/Dynorphin Binding Site. A) Overlay of MRGPRX2 model (cyan) 
and KOR (brown) with dynorphin (1-13) (DYN, orange) docked based on NMR experiments. Dashed lines 
between DYN and MRGPRX2 show negatively charged residues pairing with positively charged DYN side 
chains. The charged N- and C-termini are very flexible, with the Tyr1 side chain occupying the sodium 
allosteric site near Asp
2.50
; the N-terminus is thought to partially interact with Asp
3.32
, the main ligand 
recognition site in opioid and aminergic receptors (in MRGPRX2, it is a Met). B) Surface representation 
shows the Tyr1 side chain is accommodated in an aromatic pocket in MRGPRX2. C) The positive charge and 
aromatic ring of dextromethorphan (green) and ZINC-3573 (magenta) overlap with the positive charge and 
aromatic ring of Arg7 and Phe4, interacting with Asp184 and Phe. D) Left: Overlay of all 5 KOR-docked 
DYN models in MRGPRX2 show the flexibility of N- and C-termini; Right: Arg7 side chains of each DYN 
model show a positioning preference for Asp184 over Glu184, supporting the mutagenesis studies. E) 
Positive (blue) and negative (red) electrostatic solvent-accessible surfaces of MRGPRX2 (top) and KOR 
(bottom). The large exposed negative surface allows for cross-recognition of DYN-like peptides containing 









shows a clear preference for charged interactions between dynorphin A 
and Asp184
5.36




With experimental support for the MRGPRX2 comparative model, we proceeded to 
virtually screen the ZINC library for new ligands. Over 3.7 million commercially available 
molecules were docked, each in an average of 926 orientations and 558 conformations; overall 
1.9 trillion docked complexes were sampled and scored (for details, see Methods). We selected, 
purchased, and assayed 20 compounds from the 0.13% of top-ranked compounds for activity at 
MRGPRX2. As there is little scoring difference among the top-ranked molecules, we chose 
molecules following our usual strategy (Irwin and Shoichet, 2016) and prioritized those with 
diverse, non-opioid chemotypes. We deprioritized molecules with apparently high internal 
energies, which the docking scoring function does not well account for(Irwin and Shoichet, 





similar to the modeled opioids. Of the 20 ZINC compounds tested, one, ZINC-72469232 (1, here 
on referred to as ZINC-9232), had substantial activity below 10 M in PRESTO-Tango and 
Figure 3.14: MRGPRX2 is preferentially activated by R-ZINC-3573. A) PRESTO-Tango average 
concentration response curve (n=4, triplicate) showing arrestin recruitment with (R) or (S)-ZINC-3573 
(EC50 of R enantiomer = 760 nM); B) Average concentration response curve in FLIPR calcium assay (n=5, 




calcium release assays (Fig 3.11). To improve potency, 22 analogs of ZINC-9232 topologically 
similar to the lead were obtained and tested. Of these 22, 7 were active, with the most potent 
ZINC-72453573 (2, from here on referred to as ZINC-3573) having sub micromolar potency 





using E164Q and D184N mutations and found that 
both eliminated ZINC-3573 agonism at MRGPRX2 (Fig 3.11), consistent with the modeling.  
 
3.3.5 ZINC-3573 as a chemical probe for MRGPRX2 
To confirm MRGPRX2 selectivity, we tested ZINC-9232 and ZINC-3573 activity at 315 
other human GPCRs using our PRESTO-Tango GPCRome assay. ZINC-9232 and ZINC-3573 
showed minimal agonist efficacy at receptors other than MRGPRX2 at 10 μM (Fig 3.15 a,b). 
ZINC-9232 was also screened against a panel of 97 representative human kinases using the 
DiscoverX KINOMEscan diversity panel; only three kinases were modestly inhibited, with IC50 
values between 20-30 µM (Appendix 1 Figure 1).      
These results encouraged us to synthesize both enantiomers of the more potent ZINC-
3573, originally supplied as a racemic mixture, in an effort to create a pair of differentially active 
molecules that could jointly be used as a chemical probe pair (Appendix 2 Scheme 1). The R-
isomer (3) retained an EC50 of 740 nM in PRESTO-Tango and a similar EC50 value of 1 µM in 
the calcium mobilization assay (Fig 3.14). The S-isomer (4) had little activity below 
concentrations of 100 µM (Fig 3.14). The separate activity of the enantiomers makes them 
highly attractive probes, as one can distinguish MRGPRX2 activity (owing to the R-isomer) from 
general, non-specific activity owing to the scaffold and its physical properties (due to either 
isomer). Each enantiomer was further tested using the PRESTO-Tango GPCRome screening 
73 
 
platform (Fig 3.15c,d), which indicated 21 receptors may be activated at 2-fold or higher by (R)- 
and (S)-ZINC-3573; however, subsequent concentration-response studies showed that no other 
receptor was significantly activated by either compound (Appendix 2 Figure 1). 
 
3.3.6 MRGPRX2 agonists induce degranulation in human mast cells 
MRGPRX2 has been implicated in IgE-independent inflammatory responses in mast cells 
using peptide ligands and other non-specific agonists (McNeil et al., 2015; Subramanian et al., 
2013; Tatemoto et al., 2006), prompting us to investigate whether MRGPRX2-selective agonists 
induce degranulation and mobilize intracellular calcium in the LAD2 human mast cell line. 
ZINC-9232 and ZINC-3573 induced intracellular calcium release and degranulation in LAD2 
mast cells at comparable potencies to assays performed in MRGPRX2-expressing HEK-T cells 
Figure 3.15: MRGPRX2 selective agonist confirmation.  A-D) PRESTO-Tango GPCR-ome screening 
results for 315 GPCRs against 10 µM of either A) ZINC-9232, B) (R,S)-ZINC-3573, C) (R)-ZINC-3573, or 
D) (S)-ZINC-3573 where X axis is individual GPCR and Y axis is fold change over baseline for each GPCR. 
MRGPRX2 is highlighted on each graph. All hits over two-fold activation were followed up in PRESTO-
Tango concentration response curves in Appendix 2 Fig 1. 
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(Fig 3.16a,b). For the stereochemical pair, only (R)-ZINC-3573 promoted degranulation in 
LAD2 mast cells (Fig 3.16b), consistent with the HEK-T in vitro activity. As expected, 
MRGPRX2 siRNA significantly reduced (R/S)-ZINC-3573-induced degranulation (Fig 3.16c, 
p=0.01). 
We then considered whether the opioid ligands might activate endogenously expressed 
MRGPRX2 to induce degranulation in mast cells. This is important, in part, because of the well-
known but enigmatic ‘histamine flush’ associated with many opioids, which is not due to 
engagement of classical opioid receptors. We found (+/-)-TAN-67, (+)-morphine, (-)-morphine 
and dynorphin A (1-13) produced robust intracellular calcium release in the mast cells while the 
structurally similar κ-opioid receptor agonist (-)-cyclazocine, which does not activate 
MRGPRX2, did not (Fig 3.16d). Correspondingly, structurally unrelated agonists for the κ, δ, 
and μ opioid receptors (Salvinorin A, BW373U86 and DAMGO, respectively) were inactive (Fig 
3.16e). To determine whether MRGPRX2-activating opioids induce degranulation, we first 
tested 10 μM (+/-)-TAN-67 in the presence or absence of biotin-labeled IgE antibodies and 
found that with or without IgE-biotin antibody activation via streptavidin, the MRGPRX2-ligand 
(+/-)-TAN-67 produced 70% degranulation, indicating MRGPRX2-mediated degranulation is 
IgE-independent (Fig 3.16f). MRGPRX2 agonists (+/-)-TAN-67, (+)-morphine, (-)-morphine, 
and dynorphin A (1-13) all promoted degranulation in LAD2 cells (Fig 3.16g) while the classical 
opioid agonists salvinorin A, BW373U86 and DAMGO did not (Fig 3.16h). 10 µM naloxone 
pretreatment did not influence the EC50 or Emax values of MRGPRX2 opioid agonists (Fig 
3.17a,b), whereas MRGPRX2 siRNA significantly attenuated (+/-)-TAN-67, dynorphin A (1-13), 
and (-)-morphine-induced degranulation (Fig 3.16c, Fig 3.17c,d). These data suggest MRGPRX2, 




                            
Figure 3.16: MRGPRX2 mediates intracellular calcium release and degranulation in the LAD2 human mast 
cell line. (a) Average concentration response for MRGPRX2-selective agonists ZINC-9232 and ZINC-3573 in the 
calcium mobilization assay in LAD2 mast cells (n = 3 in triplicate). (b) Average concentration response (n = 3 in 
triplicate) for MRGPRX2 probes ZINC-3573 (R) and ZINC-3573 (S) in the β-hexosaminidase degranulation assay 
in LAD2 cells. (c). Bar graph depicting fold change percent degranulation (baseline is average DMSO of all plates) 
induced by EC80 concentration of drug following 25 nM MRGPRX2 siRNA transfection. NT, non-targeting pool; 
siRNA 2 + 3, MRGPRX2 siRNA pool. Statistics were calculated using two-way ANOVA with a Sidak post hoc test 
(P < 0.05 = *; P = 0.031, 0.031, 0.033, and 0.017 for TAN, dynorphin A (Dyn A), morphine, and ZINC-3573, 
respectively). n = 3 for all except ZINC-3573, for which n = 2. All replicates in triplicate wells. (d) Concentration–
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response curves for MRGPRX2-activating opioid ligands and the structurally related, κ-opioid receptor ligand (−)-
cyclazocine in the calcium mobilization assay (n = 3 in triplicate). (e) Average concentration response in 
intracellular calcium release with MRGPRX2-activating (+/−)-TAN-67 and canonical opioid receptor ligands 
DADLE, DAMGO, salvinorin A, and BW373U86 (n = 3 in triplicate). (f) Bar graph depicting baseline normalized 
percent degranulation induced for each 10 μM (+/−)-TAN-67, DMSO, and calcium ionophore ionomycin (IONO) in 
the presence of absence of biotin-labeled IgE antibodies. (streptavidin in all wells, average of n = 2 in triplicate.) (g) 
Average concentration–response curves for MRGPRX2-activating opiates (n = 3 in triplicate) in the β-
hexosaminidase degranulation assay. (h) Degranulation concentration response with canonical opioid receptor 
agonists and MRGPRX2-activating (+/−)-TAN-67, (n = 3 in triplicate). All error bars demonstrate s.e.m. 
 
3.4 CONCLUSIONS 
Our MRGPRX2 results underscore two major findings. First, the oGPCR MRGPRX2 
responds to opioid drugs and endogenous pro-dynorphin peptides at potentially physiologically 
relevant concentrations and mediates opioid-induced degranulation in a human mast cell line. 
Although this receptor is not in the opioid receptor family by sequence similarity, its agonism by 
opioid drugs and peptides qualifies it as an atypical opioid receptor that responds to morphinan-
based opioids and transmitters. A second key result is the structure-based discovery of the 
selective, sub-micromolar MRGPRX2 agonist (R)-ZINC-3573. This agonist promotes 
degranulation in mast cells, has no measurable agonism at over 315 other GPCRs, and the parent 
scaffold has little activity against 97 representative kinases. The inactive enantiomer (S)-ZINC-
3573 and the active (R)-ZINC3573 are an effective and internally controlled probe-pair for 
investigating the biology of this intriguing primate-exclusive receptor. The probes will be made 
available to the community from Sigma-Aldrich (#SML1699 and #SML1700). 
SAR results show MRGPRX2 is distinct from the canonical opioid receptors. MRGPRX2 
prefers dextro-enantiomers and N-methyl substituted opioid scaffolds whereas opioid receptors 
prefer levo-enantiomer opioids (Jacquet et al., 1977; Sromek et al., 2014) and tolerate a wider 
array of N-substituents. In further contradistinction to the canonical opioid receptors, MRGPRX2 
is Gαq- rather than Gαi-coupled. Thus, MRGPRX2 may be classified as an atypical opioid 
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recognizing receptor, arguably more an example of convergent evolution within the GPCR 
family than the divergent evolution that relates the four canonical opioid receptors.  
MRGPRX2 activation by opiates may be relevant physiologically and therapeutically. 
We found MRGPRX2, not the canonical opioid receptors, mediates morphine and dynorphin A 
(1-13)-induced mast cell degranulation. Morphine and structurally similar analgesics induce mast 
cell histamine release (Baldo and Pham, 2012; Rosow et al., 1982) in humans, resulting in  
Figure 3.17: X2-activating opiates are not antagonized by naloxone in LAD2 cells, siRNA knockdown 
data. A) Representative concentration response curve depicting X2-activating opioids in LAD2 mast cells in the 
presence of 10 uM (-)-Naloxone as measured by intracellular calcium release. Y axis is fold change calcium 
release over baseline, n=1 in triplicate, error bars depict SEM for triplicate wells. B) Average concentration 
response curve depicting X2-activating opioids in LAD2 mast cells in the presence of 10 uM (-)-Naloxone as 
measured by Beta-hexosaminidase release. Values shown are normalized by subtracting baseline degranulation, 
average of n=3 in triplicate. C) Representative quantitative real time PCR data for MRGPRX2 knockdown in the 
presence of 25 nM of each siRNA (n=1). SiRNAs 2 and 3 were combined for use in knockdown experiments 
along with the non-targeting pool control (NT). D). Average quantification of knockdown, as measured by 
relative quantification (RQ) method to housekeeping gene GAPDH, for combination siRNA treatment vs non-
target control, (n=3).  
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pruritus (Kumar and Singh, 2013), vasodilation, and hypotension that is poorly reversed by 
naloxone (Baldo and Pham, 2012; Hutchinson et al., 2011); these effects are not seen for opioid 
analgesics lacking MRGPRX2 activity, such as fentanyl (Rosow et al., 1982). MRGPRX2 may 
also be involved in the efficacy of sinomenine, which is used to treat rheumatoid arthritis due to 
its histamine-releasing properties (Yamasaki, 1976) . Dextromethorphan’s potency at 
MRGPRX2 is also greater or equal to reported Ki values for μ, κ, δ, NMDA, and σ2 receptors 
(Sromek et al., 2014), suggesting MRGPRX2 could contribute to dextromethorphan’s side effect 
profile which includes itch at high doses (Zajac et al., 2013). Definitive studies in non-human 
primates are needed to address these hypotheses.  
The micromolar potency of pro-dynorphin peptides at MRGPRX2 suggests in vivo 
receptor activation might require close proximity to high local concentrations of dynorphin. 
Local synaptic concentrations of neuropeptides can reach millimolar range (Scimemi and Beato, 
2009)  and dynorphin is expressed in MRGPRX2-expressing regions (Podvin et al., 2016; 
Rojewska et al., 2014; Sweetnam et al., 1982). At such concentrations, dynorphin could activate 
synaptic GPCRs or those expressed in mast cells, which can localize to nerve terminals 
(Bienenstock et al., 1991). Thus, it is conceivable that MRGPRX2 is exposed to activating 
concentrations of dynorphin in vivo.  
Structural modeling enabled the discovery of a new scaffold, represented by ZINC-9232 
and ZINC-3573, unrelated to classical opioids topologically and structurally. The unusual 
specificity of ZINC-3573 against essentially the entire GPCRome and the relevant kinome, and 
the availability of an inactive enantiomer makes this molecule a uniquely useful MRGPRX2 
probe. Methodologically, we previously used the combination of an initial physical compound 
screen followed by a much larger docking screen to discover probes for oGPCRs (Huang et al., 
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2015b). Identification of ZINC-3573 by a similar approach against a wholly different receptor 
family suggests this approach has broad utility in structure-based drug design.    
The modelled MRGPRX2 provided intriguing insights to this receptor’s unique opioid 
pharmacology. MRGPRX2 shares no more than 26% sequence identity with the μ-, κ-, δ- or 
nociceptin-opioid receptors, and its modeled orthosteric binding differs from that of the 
canonical opioid receptors. The cationic nitrogen of the morphinans is recognized by an aspartate 
in the opioid receptors, located in transmembrane (TM) helix 3, position 3.32. The residue for 
cationic nitrogen recognition in MRPRX2 appears instead to be in TM5, Asp184
5.36
 (see Fig. 
3.8c). Many other recognition residues do not overlap in sequence or structural placement. 




of the MRGPRX2 putative 
binding site is closed off from ligand contacts in the classical opioid binding site by Tyr
3.33
 – this 
is a smaller Thr110 in MRGPRX2. These seeming mismatches reflect that different receptor 
environments can recognize related ligand chemistry and the capacity for ligands to interact with 
receptors from different evolutionary families (Barelier et al., 2015; Lin et al., 2013) and 
different G protein coupling.  
Certain caveats merit airing. We have not determined the structure of MRGPRX2 in 
complex with any of the ligands discussed here, and the modeling that we have used to interpret 
activity and to predict new molecules—however successfully—must remain tentative. Until the 
opioid actions at this receptor can be probed in vivo, so, too, must the physiological implications. 
We note that a prior study also suggested that MRGPRX2 is a novel “morphine receptor,” that 
mediates some of morphine’s analgesic activity (Akuzawa, 2007).  Whereas this report certainly 
shares some similarity with our observations, we find, in contrast, that MRGPRX2 is more 
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potently activated by (+)-, rather than (-)-, morphine, suggesting MRGRPX2 is unlikely to confer 
analgesia, as (+)-morphine is devoid of such activity (Jacquet et al., 1977; Wu et al., 2007).   
MRGPRX2 is a novel Gαq-coupled opioid-like receptor activated by endogenous 
prodynorphin-derived peptides and opioid compounds, including FDA-approved drugs and their 
metabolites. The discovery of selective and relatively potent MRGPRX2 agonist (R)-ZINC-3573 
and its inactive (S)-isomer provides researchers with a chemical probe pair to specifically 
modulate this receptor, illuminating its role in pathological reactions such as itch and potentially 









CHAPTER 4: DEVELOPMENT OF PROBES FOR MRGPRX4 
 
4.1 INTRODUCTION AND RATIONALE 
 The MRGPRX4 receptor is an understudied, primate-exclusive oGPCR expressed in the 
dorsal root and trigeminal ganglia (Davenport et al., 2013; Dong et al., 2001; Lembo et al., 2002). 
To date, there are no known rodent orthologues of the human MRGPRX4 that would enable 
genetic or behavioral studies assessing this receptor’s putative functions. Studies of other MRG 
receptors, combined with MRGPRX4’s tissue expression profile, suggest this receptor may be 
important for sensation of itch, pain, or other sensory stimuli (Solinski et al., 2014). Thus, small 
molecule probes for this receptor might enable new studies that directly test the function of this 
receptor in sensory physiology, which may have relevance to human health.  
Despite progress in identifying small molecule and/or peptide ligands for other human 
MRGPRX receptors (e.g. MRGPRX1, MRGPRX2)(Johnson and Siegel, 2014; Lansu et al., 2017; 
Li et al., 2017; Liu et al., 2009), the only known modulator of MRGPRX4 is nateglinide 
(Starlix®)(Kroeze et al., 2015). Identified in the Roth lab using the PRESTO-Tango small 
molecule screening platform, nateglinide is an FDA-approved anti-diabetic drug and a 
micromolar potency agonist for MRGPRX4. Nateglinide was selective for MRGPRX4 among 91 
total GPCR targets tested, suggesting MRGPRX4 selectivity among GPCRs (Kroeze et al, 2015). 
This compound is not a selective MRGPRX4 agonist, however, as its anti-diabetic activity is 
attributed to blockade of potassium channels in pancreatic β-cells (Akiyoshi et al., 1995; Fujitani 
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and Yada, 1994). It remains to be seen whether MRGPRX4 mediates any nateglinide’s clinical 
effects.  
  In order to identify small molecule probes for MRGPRX4 that would be useful for the 
scientific community, I first screened 5,695 unique small molecules for activity at MRGPRX4 
using the PRESTO-Tango system (Kroeze et al., 2015). After identifying several novel agonists 
for this receptor, I then generated chemical analogs and tested them for activity and selectivity. 
Using these data, my collaborator Joel Karpiak generated an in silico homology model of the 
MRGPRX4 to visualize a putative binding pocket, which I validated with mutagenesis 
experiments. Here, I demonstrate several novel non-selective small molecule MRGPRX4 
agonists, initial SAR, and propose two micromolar potency agonists as tool compounds that can 
be used for future studies of this receptor. Lastly, based on genome-wide association studies 
performed by collaborators at the National Institutes of Health, I characterized a coding variant 
N245S in MRGPRX4 that is associated with increased preference for menthol cigarettes in 




HTLA cells (a HEK-T stable cell line expressing a β-arrestin2-TEV fusion protein and a 
tTa-dependent luciferase reporter) was a gift from Dr. Richard Axel and were maintained at low 
passage. FLP-IN/T-REX HEK-293-T cells (Invitrogen, Cat# R78007) were obtained from 
Invitrogen in order to make the inducible stable cell line. Stable cell lines were generated from 





Library screening was performed using nine small molecule libraries: NCC-1 (NIH 
Clinical Collection), NCC-2 (NIH Clinical Collection), NIMH Library, Tocris, Prestwick, 
LOPAC, Selleck Chemical, Spectrum, and the Roth Lab Collection (in-house). For follow-up 
studies, nateglinide was purchased separately from Tocris (#4231). Repaglinide (#R9028) and 
mitiglinide (#SML0234) were purchased from Sigma Aldrich . 
 
Constructs 
The MRGPRX4-Tango codon-optimized plasmid was made as previously described 
(Kroeze et al., 2015). The MRGPRX4 gene from this construct (without the modified tail) was 
subcloned into the FLP-IN inducible stable cell lines as per Invitrogen’s instructions using the 
FLP/IN construct. MRGPRX4-R86M, MRGPRXR-R95M, MRGPRX4-N245S, MRGPRX4-
T43T, and MRGPRX4-T43T+N245S Tango constructs were generated using PrimeStarMAX 
(Takara) as per the manufacturer’s instructions. Mutations were confirmed by Sanger sequencing 
using primers V2tail forward, CMV forward BGHR, and TEV tail reverse primers. See 
Appendix 2 for all plasmid maps and sequences.  
 
PRESTO-Tango Assay Screening 
HTLA cells were maintained in DMEM (Corning) supplemented with 10% FBS, 2 
μg/mL puromycin and 100 μg/mL hygromycin B in a humidified atmosphere with 5% CO2 at 
37°C. Cells were seeded at 50% confluency and transfected with the MRGPRX4-Tango 
construct using the calcium phosphate method (Jordan et al., 1996). The following day, 
transfected cells were plated in poly-L-lysine-coated, glass-bottomed white 384-well plates 
84 
 
(Greiner Bio-one) at a density of 20,000 cells/well. Twenty-four hours later, cells were treated 
with 10 μM concentrations of small molecules (in quadruplicate) diluted at 3X final 
concentration in drug buffer (1X HBSS containing 20 mM HEPES and 0.3% Bovine Serum 
Albumin, pH 7.4) and incubated for 18-24 hours. Following drug treatment, media was removed 
and Bright Glo (Promega) was added to each well (diluted 20-fold, 20 μL/well) and incubated 
for 15 minutes at room temperature. A TriLux luminescence counter was used to collect 
luminescence data, which were analyzed as relative luminescent units (RLU) using GraphPad 
Prism. Compounds with two-fold or greater increases in luminescence signal were considered 
“actives” and were subsequently assayed using concentration-response curves. More detail on 
the PRESTO-Tango assay can be found in (Kroeze et al., 2015).  
 
Intracellular Calcium Mobilization Assay 
I created a MRGPRX4-expressing tetracycline-inducible stable cell line containing the 
MRGPRX4 codon-optimized receptor sequence with an N-terminal FLAG tag using the FLP-
IN/T-REX Core Kit (Invitrogen). MRGPRX4 stable cells were cultured in DMEM containing 10% 
FBS, 100 µg/mL hygromycin B, and 15 µg/mL blasticidin. For the assay, cells were seeded onto 
glass bottomed, poly-L-lysine coated, black 384 well plates at a density of 20,000 cells/well in 
medium containing 1% dialyzed FBS, 1 µg/mL tetracycline, 100 IU/mL penicillin, and 100 
µg/mL streptomycin and incubated 24 hours. After tetracycline induction, media was removed 
and cells were loaded for 1 hour with 20 µL/well of 1X FLIPR calcium dye (Molecular Devices) 
and 2.5 mM probenic acid in a humidified environment with 5% CO2 at 37°C. Then, baseline 
calcium levels were measured for 10 seconds, followed by drug addition of 10 µL of 3X 
concentrated drug in drug buffer (1X HBSS with 20 mM HEPES, pH 7.4) in 16 point 
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concentration response curves from 0.003 nM to 10 μM. Fluorescence was measured for 200 
seconds and data were analyzed using GraphPad Prism. For double addition Schild competition 
experiments, potential antagonists were added 10 minutes before addition of agonist.  
 
Whole Cell ELISA:   
To compare expression of the FLAG-tagged MRGPRX4 receptor and the MRGPRX4 
mutant N245S, I performed immunohistochemistry on cells plated in 384-well plates as 
described in (Sato et al., 2016). Briefly, transfected cells or stably expressing MRGPRX4 cells 
were seeded at a density of 10,000 cells/well in poly-lysine-coated 384 well plates. After 16-18 
hours, cells were fixed with 20 ul/well of 4% paraformaldehyde solution for 10 minutes at room 
temperature. Cells were then washed twice with 40 ul/well of phosphate-buffered saline (PBS), 
pH 7.4. Cells were then blocked with 5% normal goat serum in PBS for 30 minutes at room 
temperature. After removing blocking solution, 20 ul/well of anti-FLAG–horseradish 
peroxidase–conjugated antibody (Sigma-Aldrich, diluted 1/10,000) was added and incubated at 
room temperature for 1 hour. Following antibody incubation, cells were washed 2x with 80 
ul/well of PBS. Then, 20 ul/well of SuperSignal Enzyme-Linked Immunosorbent Assay Pico 
Substrate (Sigma-Aldrich) was added and the resulting luminescence was measured using a 
MicroBeta Trilux luminescence counter. Data was analyzed using GraphPad Prism, replicates 
were averaged by taking fold change compared to WT receptor expression. Each experiment was 
performed with 64 wells per receptor. 
  
Inositol Phosphate Hydrolysis: 
MRGPRX4 tetracycline-inducible cells were maintained in DMEM containing 10% FBS, 
100 µg/mL hygromycin B, and 15 µg/mL blasticidin. For the assay, cells were seeded into poly-
86 
 
L-lysine coated, glass-bottom 96 well plates at a density of 50,000 cells/well in inositol-free 
DMEM (Caisson labs) containing 1 µCi/well of 
3
H-myo-inositol (Perkin Elmer), 1 µg/mL 
tetracycline, and 100 IU/mL penicillin and 100 µg/ml streptomycin and incubated 16-18 hours in 
a humidified environment at 37°C with 5% CO2. Following tetracycline induction and labeling, 
medium was removed and 200 µl/well of inositol-free DMEM (Caisson labs) was added per well. 
Then, 25 µl of 10X concentrated (-)-menthol diluted in drug buffer (1X HBSS with 20 mM 
HEPES and 0.3% bovine serum albumin, pH 7.4) was added followed by 25 µl of 10X 
concentrated Nateglinide in concentration response curve. Cells were incubated with drug for 1 
hour in a humidified environment at 37°C with 5% CO2. At exactly 15 minutes before lysing, 10 
µl/well of 26X concentrated LiCl (15 mM final concentration) was added. After drug and LiCl 
incubation, 40 µl/well of 50 mM formic acid was added and cells were incubated at 4°C 
overnight. The next day, 10 µl of lysate was transferred from each well into 96-well flexi-plates 
(Perkin Elmer) and combined with 75 µl/well of 0.2 mg/well YSI RNA Binding Beads (Perkin 
Elmer). Lysate-bead mixture was incubated on a shaker at room temperature, protected from 
light, for 1 hour. Before reading on a TriLux beta counter, plates were centrifuged at 1000 x g for 
2 minutes. CPM data were analyzed with GraphPad Prism. Normalized data (fold change over 
basal) were averaged to analyze replicates. 
Homology Modeling 
These models were generated by Joel Karpiak in the same fashion as those of the 
MRGPRX2; for further details please see (Lansu et al., 2017). In brief, the alignment for 
generating the MRGPRX4 models was performed in PROMALS3D (Pei et al., 2008) and 
homology models were constructed with MODELLER-9v8 (Eswar, 2007) using the crystal 
structure of the κ-opioid receptor (PDB code 4DJH) as a template. The initial alignment included 
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the entire MRGPRX and opioid receptor family. The alignment was manually edited to remove 
the N- and C- termini, which extended past the template KOR structure, and the engineered T4 
lysozyme. He also created alternate alignments of the flexible and non-conserved second 
extracellular loop (EL2). Three models were built from each of 180 elastic network models 
(ENMs) generated by the 3K-ENM program (Yang and Sharp, 2009) for a total of 540 models 
for each iterative cycle of model refinement. 
 
Model evaluation 
Models were ranked by Joel Karpiak to prioritize active compounds such as nateglinide 
over the rest of the inactive PRESTO-Tango β-arrestin screening compounds. The entire 
PRESTO-Tango library was docked to equivalent 4DJH ligand binding site in the modeled 
MRGPRX4 receptors for several cycles of iterative binding site refinement. In each round, the 
top-ranked models were examined for a binding pose that made hydrophobic and electrostatic 
interactions with the receptor, including the key positive-negative charge coordination. Then, 
residues within 6 Å of the nateglinide pose were minimized around the docked ligand with PLOP 
(Jacobson, 2002). The PRESTO-Tango library was then re-docked into this optimized binding 
site for each model. This refinement continued for several cycles until the top-ranked models all 
converged to the same nateglinide pose, with the top-scoring model chosen as the final one. 
 
 
Chemistry General Procedures 
N-Cycloheptanecarbonyl-D-phenylalanine (D-KL1) 
To a vial containing a solution of D-phenylalanine methyl ester (215.7 mg, 1.0 mmol) 
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and cycloheptane carboxylic acid (177.8 mg, 1.3 mmol) in 5.0 mL of CH2Cl2 was added Et3N 
(0.30 mL, 2.3 mmol), followed by propylphosphonic anhydride (0.80 mL, 800 mg). The 
resulting reaction mixture was stirred on ice for 2 h and then was washed 2X with a mixture of 
water (4.0 mL) and 1 N NaOH (0.50 mL), discarding the aqueous washes each time. The washed 
organic layer was then extracted 5X with a mixture of water (4.0 mL) and 1 N HCl (0.50 mL) to 
remove any unreacted amino acid. The resulting solution was washed 1X with saturated brine, 
dried overnight at 4° C over Na2SO4, then filtered and concentrated by rotary evaporation to 
afford 302 mg (99.5%). The resulting oil was hydrolyzed by stirring with MeOH (3.0 mL) and 2 
N NaOH (1.2 mL) at 50°C for 5 h. The pH was adjusted to 2-3, and the mixture was 
concentrated by rotary evaporation.  The resulting solid was crystallized from MeOH-H2O to 
give a white solid; 70 mg (23%); mp 109-110°C.  
 
N-Cycloheptanecarbonyl-L-phenylalanine (L-KL1) 
The title compound was prepared following the same conditions as for N-
cycloheptanecarbonyl-D-phenylalanine, except using L-phenylalanine methyl ester (215.7 mg, 
1.0 mmol). The resulting white solid weighed 80 mg (26%); mp 102-104°C.  
 
(R) and (S)-N-1,2,3,4-tetrahydronapthalene-2-carbonyl-D-phenylalanine 
The title compounds were prepared following the method employed for N-
cycloheptanecarbonyl-D-phenylalanine, except using 1,2,3,4-tetrahydro-2-napthoic acid (220.3 
mg, 1.3 mmol). In order to separate the diastereoisomers following hydrolysis, the oil was 
separated by centrifugal thin layer chromatography (Chromatatron, Harrison Research) using a 2 
mm silica gel rotor, eluting first with CH2Cl2, then 10% MeOH in CH2Cl2 for the first product 
89 
 
fraction, and 12% MeOH in CH2Cl2 to obtain the second product fraction. The mixtures were 
concentrated and crystallized spontaneously to give white crystalline solids (100 mg, 125 mg, 
31%, 38%. mp >280°C for each). Because this chromatron rotor had been used previously under 
an ammonia atmosphere, it was discovered that the plate had retained sufficient ammonia to 
convert the eluting products into their ammonium salts. Two products were produced, KL2a or 
2b (also called F2 and F3) to refer to the fraction number from purification on the chromatatron. 




Following the same general procedure as before D-phenylalanine methyl ester (107.9 mg, 
0.5 mmol) and 4-phenylcyclohexane carboxylic acid (100 mg, 0.50 mmol) were converted into 
the title compound to produce a white solid (100 mg, 57%); mp 163-165°C.  
 
(4-Hydroxycyclohexane-1-carbonyl)-D-phenylalanine (D-KL5) 
The title compound was prepared following the same synthetic method as 
cycloheptanecarbonyl-D-phenylalanine, except using 4-hydroxycyclohexane acid (180.0 mg, 1.3 
mmol). (42 mg, 15%) 
 
Genome-wide association study 
Dr. Denis Drayna and colleagues at the National Institutes of Health performed the 
genome-wide association study. Briefly, whole exome sequencing was performed on a subset 
(N=389) of 561 self-identified smokers from the Dallas Heart Study (DHS) and the Dallas 
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Biobank (Victor et al., 2004) and aligned to a human reference genome (GRCh37) to identify 
variants using the Genome Analysis Toolkit (McKenna et al., 2010). Dr. Drayna and colleagues 
genotyped Illumina Infinium HumanExome BeadChip v12.1 data from the DHS and Dallas 
Biobank to call genetic markers and variants. To determine if variants identified in the Dallas 
cohort were present in other populations, Sanger sequencing was performed on DNA samples 
from the saliva of 718 smokers in a second cohort (the Shroeder population; enrolled in the DC 
Tobacco Quitline (DCQL) (Kirchner et al., 2013)). To determine exome-wide associations, 
ancestry of the Dallas cohorts was inferred using principle component analysis (Price et al., 
2006). Exome-wide association analysis was performed with the PLINK v1.90p program (Chang 
et al., 2015) and tested for significance using a likelihood-ratio test (Xing et al., 2012) in R 
(www.r-project.org) with a plug-in function for logistic regression. The resulting analysis was 
adjusted for gender, age, and six top principle components of ancestry. All variants with a 
significance of P < 1x10
-4
 (determined in PLINK) in the Dallas cohort were tested in the 
Schroeder cohort.  
 
4.3 RESULTS 
4.3.1 MRGPRX4 screening reveals novel activators 
To identify novel chemical matter for MRGPRX4, I initially screened 5,695 unique 
compounds at 10 µM concentration for agonist activity against three members of the MRGPRX 
family (MRGPRX1, 2, and 4) using the PRESTO-Tango β-arrestin screening platform as 
described previously (Kroeze et al., 2015; Lansu and Karpiak et al., 2017). Focusing on 
compounds with greater than 2-fold activation at MRGPRX4 that did not activate either 
MRGPRX1 or MRGPRX2 (n=35), I found three primary compounds of interest including the 
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FDA-approved anti-diabetic compound nateglinide (as reported previously in Kroeze et al., 
2015). Additionally, the angiotensin 2 receptor (AT2R) antagonist PD123319 and the 
neurotensin1/2 receptor (NTSR1, NTSR2) antagonist SR-142948 activated MRGPRX4 by 6-fold 
and 9-fold over basal levels, respectively (Fig 4.1a). The chemical structures of these compounds 
varied substantially in size and chemotype, with carboxylic acid substituents as the most obvious 
shared substituent among these three compounds (Fig 4.1b). 
I confirmed the activity of the three compounds using 12-point concentration response 
curves in the PRESTO-Tango assay (Fig 4.1c). This revealed apparent potency (EC50) values of 
8.8 µM for nateglinide, 33.4 µM for PD123319, and 1.7 µM for SR-142948 (Fig 4.1c, Table 4.1). 
Figure 4.1: Small molecule screening reveals novel MRGPRX4 activators. A) Scatter plot showing the 
activity of ~8,000 compounds (5900 unique) at MRGPRX4 in the PRESTO-Tango assay. Arrows indicate 
locations of agonists nateglinide (red, appears in multiple libraries), PD123319 (blue, appears in multiple 
libraries) or SR-142948 (Black arrow). The Y axis is log2 of the fold change. B) Structures for compounds 
identified with arrows in A. C) 12-point concentration-response curves for nateglinide, PD, and SR in 




The PRESTO-Tango concentration-response curves also revealed that PD123319 and SR-
142948 have partial agonist activity in comparison to the apparent full agonist nateglinide (Fig 
4.1c). MRGPRX4 was previously reported to couple to Gαq (Kroeze et al., 2015). Thus, to 
validate the activity of the discovered compounds in an orthogonal assay, I tested each small 
molecule in 12-point concentration-response curves in the FLIPR intracellular calcium assay 
(Fig 4.1d) using a tetracycline-inducible MRGPRX4 HEK-T cell line (for details, see methods). 
The EC50 values for these compounds in the FLIPR assay were comparable to those determined 
by PRESTO-Tango: 10.3 µM for nateglinide, 33.2 µM for PD123319, and 3.7 µM for SR-
142948 (Fig 4.1d, Table 4.1).  
Figure 4.2: Activation of MRGPRX4 by glinide drugs. A, B) 12-point concentration response 
curves for the glinide drugs nateglinide, mitiglinide, and repaglinide in PRESTO-Tango or FLIPR, 
respectively. Data shown are the average of multiple experiments (n = 3 for nateglinide and 
mitiglinide in Tango and FLIPR; n = 2 for repaglinide in Tango; n = 1 for repaglinide in FLIPR). 
Error bars are in s.e.m.  
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4.3.2 Glinides activate MRGPRX4 
Nateglinide is an FDA-approved anti-diabetic drug. Several other glinide compounds 
with similar chemical structure are also FDA-approved. To determine whether MRGPRX4 could 
be activated by other, structurally and clinically related glinides, I tested the activity of 
repaglinide (Prandin ®) and mitiglinide (Glufast ®) in PRESTO-Tango and FLIPR intracellular 
calcium assays and found that both compounds readily activated MRGPRX4 in both assays. 
Repaglinide had reduced efficacy, but similar potency, when compared with nateglinide in 
PRESTO-Tango (Fig 4.2a, Table 4.1). In the intracellular calcium assay, nateglinide and 
mitiglinide had comparable efficacy and potency, whereas repaglinide had elevated efficacy in 
this assay (Fig 4.2.b, Table 4.1). In total, these assays support this chemotype as activating at 
MRGPRX4 and demonstrate that further major modifications are well-tolerated and retain 
activity.  
 
4.3.3 In silico model of MRGPRX4 predicts binding pocket residues 
Using a similar approach as I employed for MRGPRX2 (Lansu et al., 2017), Joel Karpiak 
(UCSF) generated an in silico homology model of MRGPRX4 using the Modeller program 
(Eswar, 2007) based this receptor’s structure on the structure of the human KOR receptor in 
complex with the antagonist JDTic (Wu et al., 2012). He chose KOR based on a search for 
receptors with known structure that had the highest homology with MRGPRX4 (in this case, 
26%). The initial model was expanded using 300+ further structures using the elastic network 
modeling program ENM. Each of these models were further expanded with Modeller to generate 
over 1,000 MRGPRX4 models. Using the PLOP program (Jacobson et al., 2002), he then 
iteratively docked the actives from the 5,695 small molecule screen against each of the 1,000+ 
models, using the inactive screening compounds as decoys, to predict an orthosteric binding site. 
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He looked for models that best enriched nateglinide over the decoy molecules. The resulting 
model is shown in Figure 4.3 and shows two arginines R86 and R95 that appear to anchor the 
carboxylic acid of nateglinide.  
 
4.3.4 R86 and R95 residues mediate agonist activity  
To assess potential binding pocket residues responsible for nateglinide activity in the 
MRGPRX4 binding pocket, I mutated the R86 and R95 that were predicted to interact with the 
carboxylic substituents of nateglinide. I generated R86M and R95M mutations and tested them 
against nateglinide, SR-142948, PD123319, and repaglinide in the PRESTO-Tango assay (Fig 
4.4) and found that the R86M mutation substantially reduced nateglinide’s efficacy from 85.1 
fold activation at the wild type (WT) to 18.1 fold (Fig 4.4a). In contrast, the R95M mutation had 
almost no effect on nateglinide’s efficacy, but slightly reduced the potency of nateglinide (Fig 
Figure 4.3: In silico model of MRGPRX4. (Left) Flow chart showing the generation of the in silico model of 
MRGPRX4, based on the KOR inactive JDTic structure (Wu et al., 2012). (Right) Close-up of the predicted 
binding MRGPRX4 pocket shown docked with nateglinide (orange). R86, R95, and various TMs and 




Surprisingly, the much larger MRGPRX4 agonist SR-142948 also showed a decrease in 
efficacy from 34.3-fold at the WT to only 9.9-fold activation at the R86M mutation (Fig 4.4b). 
Further, both the R86M and R95M mutations reduced SR-142948’s potency to 5.0 µM and 31.4 
µM, respectively, when compared to the WT EC50 value of 1.8 µM (Fig 4.4b). This finding 
suggests that perhaps the carboxylic acid contained in the structures of nateglinide and SR-
142948 may be interacting with similar residues despite their difference in size.  
Interestingly, the R86M mutation improved the potency of PD123319 from an EC50 of 38 
Figure 4.4: Mutagenesis experiments with MRGPRX4 in PRESTO-Tango. A-D) 12 point 
concentration-response curves in PRESTO-Tango for MRGPRX4 WT, R86M, or R95M, separated by 
ligand (nateglinide, SR, PD, and repaglinide, respectively). Data are normalized to fold over basal signal.  
Average of n = 2 in triplicate, error bars are in s.e.m. Structures of compounds are shown above each graph.  
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µM at the wild type to 515 nM, albeit with substantially reduced fold activation (Fig 4.4c). In 
contrast, the R95M mutation did not affect PD123319’s potency, but increased the Emax only at 
30 µM (Fig 4.4c). These differences seem to suggest PD123319 may engage different residues 
than nateglinide or SR-142948, as the mutated arginines in these experiments had little effect on 
PD123319’s activity at MRGPRX4. 
Repaglinide, another glinide compound with antidiabetic activity in humans, had notable 
changes in activity at the MRGPRX4 R86M and R95M mutations. Repaglinide is a partial 
agonist at the WT receptor (EC50 = 5.1 µM; Emax = 31.6 fold) and like nateglinide and SR-
142948, the R86M mutation drastically reduces efficacy of this compound (Fig 4.4d). 
Surprisingly, the R95M mutation improves repaglinide’s efficacy up to 170-fold activation of 
MRGPRX4, with an EC50 improved to 1.7 µM (Fig 4.4d). Thus, it appears that R86 is important 
for activation of MRGPRX4 by nateglinide, SR-142948, and repaglinide, with R95 being 
important for the interaction of some, but not all, agonists tested here.  
 
4.3.5 (D)-phenylalanine nateglinide analogs are active at MRGPRX4  
Nateglinide is a D-phenylalanine derivative with high bioavailability and good 
pharmacokinetic parameters (McLeod, 2004; Shinkai et al., 1988). Due to these optimal drug-
like properties and nateglinide’s MRGPRX4 activity, I sought to generate analogs that would 
retain MRGPRX4 agonism while losing potassium channel antagonism. I based the initial 
analogs on the nateglinide medicinal chemistry literature (Shinkai et al., 1989), focusing on those 
nateglinide analogs that lacked hypoglycemic activity. The first non-hypoglycemic  compound 
that I synthesized was cycloheptanecarbonyl-D-phenylalanine, or (D)-KL1, which was active at 
MRGPRX4 in PRESTO-Tango and the FLIPR intracellular calcium assay with EC50 values of 
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17.2 µM and 8.5 µM, respectively (Fig 4.5a,b, Table 4.1). To assess the importance of the 
stereochemistry of the phenylalanine component of the analogs, I synthesized 
cycloheptanecarbonyl-L-phenylalanine ((L)-KL1) and tested it for activity at MRGPRX4. (L)-
KL1 was inactive in the PRESTO-Tango and FLIPR intracellular calcium assays (Fig 4.5a,b, 
Table 4.1). A second L-isomer analog with a different R group, (R/S)-1,2,3,4-
tetrahydronapthalene-2-carbonyl-L-phenylalanine ((L)-KL2) was also inactive at MRGPRX4 in 
PRESTO-Tango and intracellular calcium assays (Fig 4.5c,d, Table 4.1). These data suggest that 
the D isomer of phenylalanine is important for the activity of these nateglinide analogs.  
To explore the chemical space and find molecules with improved MRGPRX4 potency, I 
generated a series of analogs with a D-phenylalanine base and varying R groups (Fig 4.5c-e,  
Table 4.1: Glinide and nateglinide analog functional data at MRGPRX4. Table showing compound names 
with pEC50 values for Tango and FLIPR (each are average of n = 3 in triplicate wells except repaglinide and 
mitiglinide n=2 in Tango, and for repaglinide n=1 in FLIPR). NA = Not applicable (due to inactivity). Emax 
values are provided as a percentage of nateglinide activity. Note that KL2a or 2b are also called F2 or F3 to 
refer to the fraction number from purification on the chromatatron (see methods). We assumed these to be 
distinct isomers based on their molecular weight and differential fractionation.  
Analog Name TANGO pEC50




FLIPR Emax (% 
Nateglinide)
Nateglinide -5.23 99.26 -5.33 99.31
Mitiglinide -4.53 129.5 -4.96 92.59
Repaglinide -5.32 45.7 -4.95 143.9
(D)-KL1 -4.765 95.69 -5.07 94.14
(L)-KL1 NA 5.77 NA 9.2
(D)-KL2a [or F2] -4.465 120.7 -4.922 102.4
(D)-KL2b [or F3] -4.467 110.3 -4.939 101
(D)-KL3 -4.5 46.5 -4.542 114
(D)-KL5 -3.873 50.84 -4.157 144
(L)-KL2 NA 4.121 NA 3.236
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Figure 4.5: (D)-phenylalanine nateglinide analogs are agonists of MRGPRX4. A-D) 12 point 
concentration-response curves in PRESTO-Tango for nateglinide analogs, with structures shown in 




Table 4.1).  (R) and (S)-1,2,3,4-tetrahydronapthalene-2-carbonyl-D-phenylalanine ((D)- Table 
4.1).  (R) and (S)-1,2,3,4-tetrahydronapthalene-2-carbonyl-D-phenylalanine ((D)-KL2-F2 and 
(D)-KL2-F3) were both MRGPRX4 agonists in PRESTO-Tango and FLIPR assays with similar 
potencies for the (R)- and (S)-tetrahydronaphthoic moiety (Tango EC50 = 34.2 µM; FLIPR EC50 
= 12.0 µM) (Fig 4.5c,d, Table 4.1). This finding suggests that the stereochemistry of the 
tetrahydronaphthalene was not vital for activity of this compound (Fig 4.5c,d). Adding larger or 
more polar substituents to the R position, as with 4-phenylcyclohexane-1-carbonyl-D-
phenylalanine ((D)-KL3) and (4-hydroxycyclohexane-1-carbonyl)-D-phenylalanine ((D)-KL5)  
reduced potency and efficacy at MRGPRX4 in PRESTO-Tango (Fig 5.5c). Similarly, (D)-KL3 
and (D)-KL5 had reduced potency compared to nateglinide in FLIPR, but retained full agonism 
(Fig 4.5d, Table 4.1). In a similar trend as nateglinide (Fig 4.4a), all of the generated nateglinide 
analog agonists displayed reduced affinity and/or potency when tested against the R86M and 
R95M mutations (data not shown). 
 
4.3.6 (L)-phenylalanine nateglinide analogs do not antagonize MRGPRX4 
 To test whether the (L)-phenylalanine nateglinide analogs (L)-KL1 and (L)-KL2 could 
function as MRGPRX4 antagonists, I performed a Schild competition experiment in PRESTO-
Tango (Fig 4.6a, b) and FLIPR (Fig 4.6c, d). Using the test agonist nateglinide, neither (L)-KL1 
or (L)-KL2 competitively or non-competitively reduced agonist activity (Fig 4.6a-d). These data 
suggest (L)-KL1 and (L)-KL2 are not antagonists and do not interact with the receptor up to 




4.3.7 An MRGPRX4 variant confers menthol cigarette preference in African Americans 
 Menthol is an additive in cigarettes that increases addiction liability and makes quitting 
more difficult (Anderson, 2011; Ferris Wayne and Connolly, 2004). Furthermore, there is an 
unequal distribution of menthol smoking among demographics, and elevated preference for 
smoking mentholated cigarettes in young adults and African Americans (Caraballo and Asman, 
2011; Giovino et al., 2004; Substance Abuse and Mental Health Services Administration and 
Figure 4.6: (L)-phenylalanine analogs do not antagonize MRGPRX4. A-D) 12 point concentration-response 
curves of nateglinide in PRESTO-Tango (A,B) or FLIPR intracellular calcium (C,D) against MRGPRX4 WT in 
the presence of increasing concentrations of either (L)-KL1 or (L)-KL2. Data shown as either relative 




Figure 4.7: MRGPRX4 rs7102322 is associated with menthol smoking in African American 
Participants. A) Table showing the minor allele frequency (MAF) and association with mentholated 
smoking in the four groups genotyped. Data in this table gathered and generated by Dr. Drayna and 
colleagues at NIH. B) Image generated from the MRGPRX4 homology model (generated by Joel Karpiak) 
depicting the predicted location of N245S residue in the receptor, including labels of receptor TMs and ELs. 
Office of Applied Studies, 2009; Tobacco Products Scientific Advisory Committee, 2011). To 
determine whether there is a genetic basis for this disparity between demographic groups, 
collaborators at the NIH performed a genome-wide association study in two cohorts of smokers 
(for further details, see Methods). One variant, rs7102322 in the gene MRGPRX4 increased the 
odds of smoking mentholated cigarettes by 5-8 fold among smokers and met the criteria for 
genome wide signficance (P<=1.6x10
-3
). The rs7102332 variant results in a coding change 
N245S and was observed exclusively in African American participants with a frequency of 5-8% 
in the two cohorts (for cohort details, see methods) (Fig 4.7a). This rs7102332 SNP was in 




 To determine where this variant occurs in MRGPRX4, I turned to the homology model 
generated by our collaborators and found N245 is predicted to be in extracellular loop 3 (EL3) 
(Fig 4.7b). This asparagine was not predicted to be a glycosylation site for MRGPRX4 by the 
NetNGluc1.0 prediction software (http://www.cbs.dtu.dk/services/NetNGlyc/). Thus, we 
hypothesized that this variant could have effects on signaling.  
 
4.3.8 MRGPRX4 N245S mutation attenuates agonist activity  
 To determine the functional and signaling effects of the N245S variant (in concert with 
the T3T nonsynonymous variant), I generated N245S+T3T mutations in the FLAG-tagged 
MRGPRX4-Tango construct and made tetracycline-inducible stable cell lines expressing a 
FLAG-tagged N245S+T43T variant. I first tested whether WT and N245S+T43T variants had 
differential membrane expression for the Tango constructs and stable cell line and found no 
substantial difference in receptor expression as measured by whole cell ELISA (Fig 4.8a,b).  
 Then, to determine if there were differences in signaling capacity or ligand activation 
between WT and the N245S+T43T variant, I tested each receptor for agonism with the 
previously published agonist nateglinide (Kroeze et al., 2015) in the PRESTO-Tango β-arrestin 
recruitment assay. I found that nateglinide had equal potency at the WT and N245S+T43T 
receptors, but there was a 66% reduction in maximal β-arrestin recruitment at the N245S+T43T 
in comparison to WT (p<0.001, Fig 4.8c, Table 4.2). Then, I tested the effect of this mutant on 
nateglinide-induced PI hydrolysis, a measurement of Gαq signaling. Similar to the results from 
the Tango assay, I found little difference in potency between variant and WT but found maximal 
PI hydrolysis was reduced by 44% in cells expressing the N245S+T43T variant compared to WT 
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Figure 4.8: MRGPRX4 N245S variant has dampened signaling when compared to WT. A) Receptor 
expression as calculated by whole cell ELISA in HTLA cells transfected with N245S+T43T or WT receptor 
with mock transfected shown as negative control (n=2, 64 wells per experiment; y axis is fold expression 
normalized to WT). B) Receptor expression as calculated by whole cell ELISA in tetracycline inducible WT or 
N245S+T43T cells with non-tetracycline-induced cells shown as negative control (n=2, 64 wells per 
experiment; y axis depicts fold expression normalized to WT). C) Average concentration response curves for 
nateglinide in PRESTO-Tango arrestin assay with WT and N245S+T43T receptors, (n=4, in quadruplicate; y 
axis is in fold response over basal 588 signaling). D) Average concentration response curves for nateglinide in 
PI hydrolysis assay with WT and N245S+T43T tet-inducible cell lines, (n=3, in duplicate; y axis is in fold 
response over basal signaling). * indicates P 
(P<0.001, Fig. 4.8d, Table 4.2). 
4.3.9 (-)-Menthol suppresses MRGPRX4 agonism 
To determine if (-)-menthol, the additive in cigarettes, could modulate MRGPRX4 WT or 
the N245S+T43T variant, I tested (-)-menthol as an agonist in concentration response curves up 
to 1 mM in the PRESTO-Tango assay but found no activation of WT or variant (Figure 4.10a,b). 
Then, I tested whether (-)-menthol could modulate MRGPRX4 WT or N245S + T43T receptors 
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by incubating concentration response curves of agonist nateglinide in the presence of increasing 
concentrations of (-)-menthol in PRESTO-Tango and PI hydrolysis assays (Figure 4.9). I found 
that 100 and 300 µM (-)-menthol significantly reduced the Emax of nateglinide on the WT 
Figure 4.9: (-)-Menthol reduces MRGPRX4 WT and N245S+T43T arrestin signaling. A,B) Average 
concentration response curves for nateglinide in MRGPRX4-WT-Tango (A) or MRGPRX4-N245S+T43T-Tango 
(B) following 100 µM or 300 µM (-)-menthol addition, (n=3, in triplicate, y axis is % nateglinide). C,D) Average 
concentration response curves for nateglinide-induced PI hydrolysis in MRGPRX4-WT (C) or MRGPRX4- 
N245S+T43T (D) tetracycline inducible cells following 100 µM or 300 µM (-)-menthol addition, (n=3, in 
duplicate, y axis is % nateglinide). E) Plot showing the effect of agonist treatments (x 600 axis) nateglinide (gray 
circles), nateglinide + 100 µM (-)-menthol (gray squares) and nateglinide + 300 µM (-)-menthol (gray triangles) 
between WT and N245S+T43T variant shown as ΔΔLog(Emax/EC50) values (y axis). Y vales > 0 indicate 
increased effect for agonist at WT and values < 0 indicate increased effect for agonist at N+T variant. Bars depict 
95% confidence intervals. F) Average concentration response curves for fold change activation with nateglinide 
in MRGPRX4-WT-Tango or MRGPRX4- N245S+T43T-Tango following 300 µM or 300 µM (-)-menthol 
addition, (n=3, in quadruplicate). For all: NS = not significant, * p 
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(P<0.001) and N245S+T43T (P<0.001) in the PRESTO-Tango assay (Fig. 4.9a,b) but not in the 
PI hydrolysis assay (Fig. 4.9c,d).   
To determine if (-)-menthol’s could modulate the variant and wild type receptors 
differently, I calculated ΔΔlog(Emax/EC50) (Kenakin et al., 2012) using nateglinide as the 
reference agonist +/- 100 or 300 µM (-)-menthol and found that (-)-menthol there was no 
significant difference between menthol’s negative modulatory effect on WT versus 
N245S+T43T variant (Fig 4.9e). When I compared the fold change activation of β-arrestin 
recruitment, this revealed that 300 µM (-)-menthol significantly reduces nateglinide-induced fold 
Figure 4.10: Positive Controls for MRGPRX4 Menthol Experiments. A,B) Average concentration response 
curves for Nateglinide or (-)-menthol in agonist mode for MRGPRX4-WT-Tango or MRGPRX4- N245S+T43T-
Tango (n=2, in triplicate, y axis is % nateglinide). C) Average concentration response curves for D2 receptor 
agonist quinpirole in D2-Tango 100 µM or 300 µM (-)-menthol addition, (n=3, in triplicate, y axis is % 
Quinpirole). D) Average concentration response curves for Nateglinide-induced PI hydrolysis in MRGPRX4-
WT tetracycline inducible cells without tetracycline addition (ie, no receptor expression) following 100 µM or 
300 µM (-)-menthol addition, (n=3, in triplicate, y axis is relative luminescent counts (RLU). 
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activation when compared to WT (P<0.001, Fig 4.9f), similar to the differences in fold change 
for non-menthol conditions (Fig 4.8c). The unrelated D2 dopamine receptor was not modulated 
by (-)-menthol in the PRESTO-Tango assay (Fig. 4.10c). Similarly, (-)-menthol and nateglinide 
had no effect on PI hydrolysis in cells where tetracycline was not added (i.e., with no 
MRGPRX4 receptor expression). 
 
4.4 CONCLUSIONS 
 This work identifies three major findings for the oGPCR MRGPRX4. First, I discovered 
several low micromolar potency small molecule agonists for this receptor, including the 
NTSR1/2 antagonist SR-142948, the AT2R antagonist PD123319, and two FDA-approved 
glinide drugs mitiglinide and repaglinide. Furthermore, I generated seven nateglinide analogs to 
ascertain basic SAR of this scaffold and found that two of these compounds ((D)-KL1 and (L)-
KL1) may be suitable as MRGPRX4 probes (pending assays for selectivity). Using the chemical 
matter identified here, I demonstrated that residues R86 and R95 are important for MRGPRX4 
agonist activity. Lastly, I identified (-)-menthol as an allosteric modulator of MRGPRX4 at WT 
and a coding variant associated with menthol cigarette preference. This work uncovers novel 
chemical matter for this understudied receptor that may suggest putative MRGPRX4 function 
and lays groundwork for the generation of improved MRGPRX4-selective compounds.  
Table 4.2: Statistics for WT versus variant values in functional assays. Curve fits were compared between 
constructs for Figure 2C and 2D to determine significant differences in fold change and potency. P values were 
calculated via F-test comparing statistical difference between either EC50 or Emax values between WT and 
variant. Yellow highlights significant P values. 
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MRGPRX4 is agonized by three FDA-approved glinide drugs (nateglinide, repaglinide, 
and mitiglinide) and this finding could provide insight to this receptor’s putative functions in 
vivo. Glinides canonically antagonize potassium channels located in pancreatic β cells (McLeod, 
2004). Type 2 diabetic patients take glinides with every meal to induce insulin secretion and 
proper glucose regulation (Rosenstock et al., 2004). Pharmacokinetic data for oral dosing of 
nateglinide indicate maximum plasma concentrations reach between 3 and 20 micromolar, well-
within the appropriate range of activating MRGPRX4 in humans (McLeod, 2004).  
MRGPRX4 is expressed in sensory neurons of the DRG and TG (Dong et al., 2001; 
Lembo et al., 2002), which jointly innervate the skin and peripheral tissues, the forehead, eyes, 
cheeks, teeth and jaws (Haas et al., 2011; Zheng et al., 2014). Additionally, one study suggests 
MRG receptors are also expressed in vagal sensory afferents, some of which innervate the lungs 
(Lee et al., 2008). Vagal neuron expression would be especially interesting in light of the 
associated MRGPRX4 N245S variants associated with smoking African Americans. Further, 
MRGPRX4’s expression and the high in vivo concentration of nateglinide suggest MRGPRX4 
could mediate some of the off-target effects of this class of drugs, which include upper 
respiratory infection, sinusitis, constipation, itch/rash, and headache (Rosenstock et al., 2004; 
Twaites et al., 2007). As we have not determined these effects experimentally, further studies 
will need to be performed to test these hypotheses directly.  
The in silico homology model and mutagenesis experiments suggest R86 and R95 
mediate the agonist activity of glinides and other D-phenylalanine derivatives at MRGPRX4. 
Interestingly, these mutations in EL1 residues suggest that like KOR, MRGPRX4 may utilize an 
extended TM2/EL1 binding pocket (Wu et al., 2012). R86M and R95M reduced efficacy and/or 
potency of these molecules at MRGPRX4 despite variations in the R group (as shown in Fig 5.5e) 
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or substantial structural differences between the glinides, SR-142948, and PD123319 (Fig 5.3). 
Our data suggest these two arginines, especially R86, are likely essential for the interaction of 
the shared carboxylic acid component of these structures with the receptor. Future studies to 
develop novel ligands for MRGPRX4 may want to consider engaging these residues.  
The SAR determined here for MRGPRX4 demonstrate a limitation on the size of the R 
group attached to the D-phenylalanine and a preference for dextrorotary amino acid derivatives. 
These observations are similar to the agonist preferences of the related receptor MRGPRX2, 
which prefers dextrorotary opioid molecules to the levorotary isomers (Lansu et al., 2017). This 
suggests there may be some shared structural features in the binding pockets of this family of 
receptors, however, we also note that the determined chemical matter for MRGPRX4 and 
MRGPRX2 (see (Lansu et al., 2017) or Chapter 2) are distinct and non-overlapping. This is in 
line with previous reports that suggest this family of receptors experienced positive selection and 
divergence within the binding pocket residues (Choi and Lahn, 2003).  
Two of the generated MRGPRX4 agonists, (D)-KL1 and (L)-KL1, will likely have 
minimal potassium channel antagonism based on the medicinal chemistry studies performed by 
Shinkai and colleagues (Shinkai et al., 1989) although future studies will need to be performed to 
test this directly. The active ((D)-KL1) and inactive ((L)-KL1 molecules provide initial tool 
compounds to assess MRGPRX4 activity until better analogs of these compounds can be 
synthesized.  
I demonstrate here that (-)-menthol negatively modulates MRGPRX4 at 100 and 300 µM 
concentration. Although this concentration is high, it has been shown that cigarettes can contain 
up to 19 mg (-)-menthol per cigarette, depending on the brand (Ai et al., 2016). It remains to be 
demonstrated what the actual concentrations of menthol in the face and lungs are for chronic and 
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acute mentholated smoking, although the high menthol concentration in cigarettes may poise the 
saliva to reach high µM concentrations capable of interacting with MRGPRX4. 
This work expanded the known chemical matter for the oGPCR MRGPRX4 from 1 to 9 
agonists and two inactive control compounds. The identified agonists have varying efficacies in 
β-arrestin and Gαq, including the partial agonists SR-142948 and PD123319, and at least three 
full agonists nateglinide, mitiglinide, and (D)-KL1. Furthermore, I defined putative SAR for the 
D-phenylalanine derivatives and identified two important binding pocket residues for their 
activity. Despite their micromolar potency, these compounds will be valuable tools for assessing 
MRGPRX4 function in vitro and in vivo. The molecules, homology model, and mutagenesis 
experiments generated in this study also provide a roadmap for future MRGPRX4 probe or drug 
development. Lastly, while the physiological role of MRGPRX4 remains to be determined 
experimentally, the glinide agonists identified here and their adverse effects may shed light on 










CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 




Our world is encoded by chemical information. GPCRs are primary translators of 
chemical stimuli into biological instructions for cellular and physiological phenomena. Thus, 
much of how we perceive and experience the world is mediated via GPCRs, including sight, 
smell, touch, pain, and various motivational or euphoric states. Despite the great complexity of 
these systems, humans have learned to modulate GPCR action and our experience of the world 
for thousands of years with drugs. As we continue to learn about the molecular and physiological 
details of GPCR action, we will undoubtedly improve our understanding of these systems and 
our ability to modulate them.  
The research contained in this dissertation focuses on the primate-exclusive MRGPRX 
family of orphan GPCRs expressed in sensory neurons and immune cells, two sensitive and 
diverse systems fine-tuned for detection and protection of the organism. In total, I generated 
novel chemical probes for the pharmacologically dark receptors MRGPRX2 and MRGPRX4 
using the PRESTO-Tango β-arrestin screening platform in combination with in silico homology 
models and genome-wide association studies. Then I demonstrated that endogenous opioid 
peptides and exogenous opiates activate MRGPRX2, and that this receptor mediates 
degranulation when agonized by the selective probes and opioids in a human mast cell line. 
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Lastly, I identified (-)-menthol as a negative allosteric modulator of MRGPRX4 and 
characterized a functional variant associated with menthol cigarette preference in African 
Americans. As mentioned during the introduction, the generation of selective oGPCR ligands 
catalyzes the discovery of receptor function. The experiments contained in Chapters 2-5 and the 
chemical probes I discovered provide some insight into putative functional roles of the 
MRGPRX receptors in vivo and will be discussed below. 
MRGPRX receptors are likely important for transducing sensory information and have 
several similarities to other important genes in the sensory system including the olfactory and 
vomeronasal receptors. For example, all of these genes occur in gene family clusters on similar 
chromosomes, and appear to have undergone species-specific expansion, duplication, and 
positive selection events (Choi and Lahn, 2003; Zylka et al., 2003). The evolution of sensory-
expressed receptors to meet species-specific needs has the advantage of optimizing sensory 
capabilities for specific environments to provide survival or fitness benefits (Liman, 2012). But 
what potential advantages could MRGPRX receptors provide primates? While this question 
cannot be answered today, one can hypothesize potential roles for these receptors in primates 
based on the expression pattern and pharmacological characteristics of the MRGPRX receptors.  
 
5.2 FUNCTIONAL IMPLICATIONS FROM MRGPRX2 STUDIES 
MRGPRX receptor expression in small diameter, nociceptive neurons of the DRG and 
TG innervate cutaneous layers of the skin (Bader et al., 2014). Cutaneous sensory afferents are 
vital detectors of potentially injurious chemical, thermal, and mechanical stimuli (Smith and 
Lewin, 2009). As I showed in Chapter 3, MRGPRX2 is activated by many plant-derived 
alkaloids such as sinomenine, morphine, codeine, and berberine (data not shown); suggesting 
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MRGPRX receptors may detect many natural product-based scaffolds. If true, these receptors 
may function to detect the presence of various plants in primate environments. Depending on the 
neuronal subpopulation of MRGPRX expression, this could either alert the body to 
helpful/pleasurable plant alkaloids, as has been shown with MrgB receptor stimulation in rodents 
(Vrontou et al., 2013), or unpleasant itch sensations similar to the MrgA receptors (Liu et al., 
2009).  
MRGPRX2 receptors could alternately be involved in detecting microbes present on the 
skin. Almost all MRGPRX2 agonists contained amines or basic amino acids, which are known to 
be pro-inflammatory and indicative of bacterial or viral infection products (Hassan et al., 2012). 
Similarly, it is possible that the evolution of primate skin led to changes in the cutaneous 
microbiome (Council et al., 2016) that necessitated positive selection of the MRGs to detect 
alternate types of bacteria or pathogens. In this way, MRGPRX would be fine-tuned to prevent 
inflammation and disease while maintaining healthy bacterial balance.  
There are at least four proposed endogenous peptides for MRGPRX2, including 
Cortistatin-14(Robas et al., 2003), PAMP(9-20)(Kamohara et al., 2005), Substance P(Tatemoto 
et al., 2006), and Dynorphin A (1-13)(Lansu et al., 2017). Substance P, Dynorphin A, and 
MRGPRX2 are all expressed in various sensory afferent subtypes, along with canonical 
Substance P receptors NK1/2, and the canonical Dynorphin receptor KOR (Ryall, 1989). Thus, 
MRGPRX2 could function as a simple feedback trigger on the sensory neurons where it is 
expressed. For example, as dynorphin levels rise, which can occur in pathologic pain and itch 
states (Podvin et al., 2016), peptide selectivity for KOR would shift to include MRGPRX2. The 
resulting shift from inhibitory Gαi to excitatory Gαq signaling would providing important 
feedback onto this system and could either increase or attenuate neuronal signaling depending on 
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the synaptic location of MRGPRX2. Future studies that demonstrate MRGPRX2 synaptic 
expression and co-occurance with other sensory receptor subtypes would be useful to determine 
how MRGPRX receptors function in these neuronal circuits.   
The complexity of peptide and receptor expression in the sensory afferents makes 
MRGPRX2’s peptide promiscuity especially interesting, suggesting that this receptor could 
integrate multiple signals by functioning as a coincidence detector. Coincidence detection in 
neuroscience is the integration of multiple input events occurring temporally close together but 
in different spatial locations (Bi and Poo, 2001). In this way, the same signals (e.g. peptides and 
small molecules) can encode a much larger set of functional outcomes depending on the 
temporal order and/or spatial location in which they occur (Spitzer, 2004).  
The sensory system is a prime example of the utilization of coincidence detection 
because it is constructed to encode multiple senses in a variety of ways, allowing for a large 
number of complex outputs stemming from a limited stimulus set. In contrast to gustatory 
detection, where tastants are perceived in a switch-like manner leading to either aversion or 
attraction (Julius, 2013), pain, temperature, and itch encode graded responses by activating 
multiple distinct proteins (TRP channels, GPCRs, etc) on distinct neuronal subtypes to produce a 
variety of intensities and qualities of the experience. The number of sensory neurons that are 
known to encode purely itch is minimal (Baraniuk, 2012) and the fact that MRG receptors are 
expressed in both overlapping and non-overlapping sensory neuron subsets is exemplary of this 
type of coding. When considering how the MRGPRX receptors fit into this picture, it is 
important to recall that they appear to be adapted to unique ligand sets for each gene and species, 
leading to receptor and species-specific sensory modalities. 
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To support this idea, work by other labs demonstrated mMRGRPA3 agonism produces 
itch that is dependent on transient receptor potential (TRP) channel expression (Liu et al., 2009), 
demonstrating that the sensory output downstream of MRG receptors depends on the expression 
of other sensory proteins within those neurons. Note that TRP ion channels regulate neuronal 
excitability and can be activated by their own array of chemical, temperature, and mechanical 
stimuli (Le Pichon and Chesler, 2014). It is likely that MRGPRX receptors also modulate 
downstream TRP channels in the sensory afferents where they are expressed and that the 
convergence of signals on MRGPRX and TRP channels will encode a specific itch or pain 
response.  
 
5.3 FUNCTIONAL IMPLICATIONS FROM MRGPRX4 STUDIES 
Thus far, there are still no proposed endogenous ligands for MRGPRX4, making it 
difficult to hypothesize about specific in vivo implications. However, in chapter 4 I characterized 
a coding variant N245S in MRGPRX4 that confers preference for mentholated cigarettes in 
African Americans and identified (-)-menthol as a negative allosteric modulator of MRGPRX4. 
Canonically, (-)-menthol produces cooling sensations by activating TRPM8 (Bautista et al., 2007) 
and TRPA1 (Karashima et al., 2009)channels. Activated Gαq-coupled GPCRs hydrolyze PIP2, a 
negative regulator of TRP channels, and promote TRP channel activation or increased sensitivity 
to ligands (Julius, 2013). As mentioned above, MRGPRX receptor signaling upstream of TRP 
channels may lead to the coding of specific sensory outputs and MRGPRX4 is poised to be 
activated by menthol-containing cigarettes since TG sensory neurons innervate the head and 
mouth (Zheng et al., 2014). Previous studies have shown, however, that TRPM8 and TRPA1 are 
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not expressed in the non-peptidergic C fibers where MRG receptors are found (Le Pichon and 
Chesler, 2014), making direct TRPM8/A1/MRGPRX4 interaction less likely.  
Nevertheless, it is tempting to speculate that the cooling sensations elicited by (-)-
menthol may be a product of the ratio of TRP channel activation and MRGPRX4 signal 
dampening in some fashion, which is dependent on (-)-menthol concentration. Furthermore, the 
genetic association study suggests that a reduction of MRGPRX4 signaling promotes increased 
menthol preference, potentially in the form of decreased aversion or increased enjoyment. 
Whether or not the central nervous system is engaged following MRGPRX4 modulation by 
menthol remains unanswered. Future studies to assess which neurons express MRGPRX4 would 
better illuminate the neuronal circuitry involved and begin to tease out the function of this unique 
receptor.  
 Alternately, at least one study suggests MRG receptors can be expressed in vagal 
afferent neurons(Lee et al., 2008). The vagal nerve innervates a variety of internal organs and 
acts in concert with the sympathetic nervous system to sense internal states. One of the major 
sites of vagal innervation is the lungs, where the sensory afferents regulate breathing. Thus, it 
would be interesting to see if MRGPRX4 receptors are found in primate vagal pulmonary 
afferents where it could mediate breathing or the sensation of menthol and other MRGPRX4-
interacting ligands.   
Established GPCRs in the sensory and immune systems, including opioid, serotonin, and 
purinergic receptors, have extremely effective modulatory capacity and potently induce 
inflammation, analgesia and/or itch upon ligand-stimulation. In contrast, orphan receptors of the 
sensory and immune systems have largely unknown functions. While this is primarily due to the 
lack of chemical matter to interrogate these receptors, it is also likely that oGPCRs in these 
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systems are responsible for fine-tuning of these responses. One example of this is the oGPCR 
GPR65, which is expressed in a small subset of vagal afferents to the intestines and detects 
nutrients and gut motility (Williams et al., 2016). As we continue to uncover functions of 
oGPCRs using chemical and genetic tools, it is likely that we will improve our ability to make 
more subtle modifications of physiological systems. Continued studies of MRGPRX function in 
the sensory and immune systems will elucidate the intricacies of these receptors’ functions and 
uncover the complexities of sensory encoding in primates.  
 
5.4 IMPLICATIONS FROM IN SILICO HOMOLOGY MODELS 
This work generated in silico homology models of MRGPRX2 and MRGPRX4, for 
which there are no solved crystal structures. Both homology models were based on the structure 
of the KOR in complex with antagonist JDTic (Wu et al., 2012). MRGPRX2 and MRGPRX4 
share no more than 26% sequence identity with KOR. Despite these drastic sequence differences, 
MRGPRX2 and KOR share ligands, most notably the cyclazocines and prodynorphin derived 
peptides. In contrast, MRGPRX4 is not activated by any opiates tested. Even more surprisingly, 
and MRGPRX2 have 63% sequence identity to one another and yet do not share ligands. These 
homology models provide critical insights to the putative binding sites of these oGPCRs and 
prompt several intriguing interpretations.  
 MRGPRX2 and MRGPRX4 sequences contain all of the highly conserved Class A 
residues (N1.50, D2.50, R3.50, W4.50, P6.50, P7.50, sodium binding site residues) except for 
the highly conserved proline in TM5 (P5.50) (See Table 6.1 below). P5.50 is a component of the 
P-I-F activation motif in the opioid receptors and appears to be an important component of 
receptor activation and TM shape (Vardy et al., 2013). In MRGPRX2, this residue is a 
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methionine and in MRGPRX4, a valine (Table 6.1). Likewise, MRGPRX2 and MRGPRX4 have 
leucines rather than isoleucines in position 3.40 of the P-I-F motif (Table 6.1), suggesting both of 
these receptors may not utilize this motif as an essential component for activation. Future studies 
that determine the structures of both MRGPRX2 and MRGPRX4 could assess whether these 
receptors have a compensatory P-I-F motif formed from alternate residues not observed in these 
models or if it is unnecessary for MRGX activation.  
 Further comparison of the MRGPRX homology models with the opioid receptor 
structures demonstrates that most of the residues in the canonical opioid receptor orthosteric 
binding site differ in both MRGPRX2 and MRGPRX4 (Table 6.1). Importantly, as discussed in 
Chapter 2, the D3.32 that is forms a salt bridge with the amine of opioid ligands and the opioid 
receptors is a methionine (M3.32) in MRGPRX2. Instead, MRGPRX2’s binding pocket appears 
to be in a reverse orientation, with D5.36 forming an ionic interaction between receptor and 
amine, leading to a completely different opioid ligand orientation in this receptor. This appears to 
explain how KOR and MRGPRX2 can be activated by the same ligands despite low amino acid 
similarity. Trace amine receptors (TAARs) also have a non-classical salt bridge between ligand 
and receptor mediated by an aspartate in TM5 (D5.42), and it has been suggested that this non-
traditional amine recognition site occurs in receptors as a result of rapid evolutionary events 
where amine recognition was lost and then regained (Li et al., 2015). Furthermore, the evolution 
of detecting reverse-oriented amine ligands in binding pockets of TAAR and MRGPRX 
receptors allow organisms to detect divergent stimuli and may lead to novel ways of detecting 
complex arrays of chemicals (Li et al., 2015)..   
MRGPRX4 also has a Met in position 3.32 and D5.36 (Table 6.1); however, the docking 




Table 6.1: Amino acids among opioid receptor structures and MRGPRX models. As before, opioid receptors are 
shown with the following: light gray background - residues within 4 Å of ligands indicated with a "+" or "-" if present; 
Dark blue font indicates identical residues at all four receptors; light blue font indicates identical residues in MOP, DOP, 
and KOP, but unique to NOP; red font labels divergent residues in all receptors; orange font indicates unique residues to 
either MOP, DOP, or KOP; dark gray background - conserved residues involved in receptor function; blue background -  
associated with sodium binding. Motifs are labeled. (Modified from Filizola and Devi, 2013.) For MRGPRXRs, actual 
residue is listed and are shown with the following: dark orange background - different from opioid receptors but 
consistent among XRs; dark green – unique to MRGPRX4; light orange – different from opioid but similar residue; light 
green – different from X2 but similar to opioid residue.  
Interacting residues MOP DOP KOP NOP X2 X4 MOTIF
N/N/N/N 1.50 + + + + N N
D/D/D/D 2.50 + + + + D D
A/A/V/V 2.53 - - + - F F
T/T/T/T 2.56 - - + - F F
Q/Q/Q/Q 2.60 - - + + N R
N/K/V/D 2.63 - - + + V L
V/V/V/V 3.28 - - + + F L
I/L/L/I 3.29 - - + + T V
D/D/D/D 3.32 + + + + M M
Y/Y/Y/Y 3.33 + + + + T T
N/N/N/N 3.35 + + + + A P
M/M/M/M 3.36 + + + + Y Y
F/F/F/F 3.37 - - - + L F
S/S/S/S 3.39 + + + + G G
I/I/I/T 3.40 + + + - L L PIF
R/R/R/R 3.50 + + + + R R DRY
W/W/W/W 4.50 + + + + W W
E/D/D/G 5.35 + - - - Q E
K/K/K/A 5.39 + + + - F F
V/V/V/I 5.42 + + + + A V
A/A/A/S 5.46 - - - + I I
P/P/P/P 5.50 + + + + M V PIF
F/F/F/F 6.44 + + + + F F PIF
W/W/W/W 6.48 + + + + G G CWxP
P/P/P/P 6.50 + + + + P P CWxP
I/I/I/V 6.51 + + + + F F
H/H/H/Q 6.52 + + + + G G
V/V/I/V 6.55 + + + + W G
K/W/E/Q 6.58 + + - - I I
W/L/Y/L 7.35 + + + - H Y
I/I/I/T 7.39 + + + + V M
G/G/G/G 7.42 - - + - S S
Y/Y/Y/Y 7.43 + + + + S S
P/P/P/P 7.50 + + + + P P NPxxY
W/W/W124/W (EL1) - - + - - -
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appears to capitalize on the extended binding pocket near TM2 and EL1. R86 and R95 were 
predicted from the homology model to interact with the carboxylic acids of nateglinide and other 
MRGPRX4 ligands. Mutations of these two arginines reduced MRGPRX4 activation by glinides,   
(D)-phenylalanine analogs, SR-142948, and PD123319.  
Most of the residues near the top of TM2 and into EL1 differ between MRGPRX2 and 
MRGPR4 (Table 6.1). Further distinctions between MRGPRX2 and MRGPRX4 residues occur 
near the top of TM7 (Table 6.1). In the opioid receptors, many of these residues in TM2, TM7, 
and EL1 were important for determining ligand specificity among the opioid receptors and thus it 
is no surprise that alterations in these residues between MRGPRX2 and MRGPRX4 may confer 
MRGPRX-subtype specificity of ligands. Future studies that seek to generate MRGPRX 
subtype-specific ligands should aim to engage one or more of these residues and/or the residues 
in TMs 4 and 5 discussed earlier.  
The homology models of these receptors expose further evidence of their diverse 
pharmacologic profiles and demonstrate the importance of subtle alterations in binding pocket 
residue to ligand specificity and functional divergence across species. Of course, to fully 
determine the extent of the atomic level differences in MRGPRX receptors, it will be necessary 
to solve the crystal structures of these receptors. Hopefully, advances in ligand development for 
MRGPRX receptors or in X-ray crystallography techniques will enable the determination of 
these structures soon.  
 
5.5 FINAL COMMENTS 
The research contained within this dissertation provides multiple novel small molecule 
probes for MRGPRX oGPCRs, greatly expanding the repertoire of small molecules for these 
receptors and providing the scientific community with valuable tools to elucidate their functions. 
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This work is a model of how novel chemical probes can be used to determine biochemical and 
functional properties of GPCRs. As mentioned, however, GPCR signaling is multi-faceted. As 
the library of selective chemical matter for GPCRs grows, it will be interesting to determine the 
varieties of GPCR ligand recognition and activation mechanisms, as well as test the contributions 
of multiple receptors to phenotypic outputs. For the MRGPRX receptors, it is likely that these 
GPCRs will become increasingly important for an assortment of sensations, behaviors, and 







Compound pEC50 SEM Emax SEM n pEC50 SEM Emax SEM n
1 (-)-Bremazocine NC NC 2.38 0.87 3 NC NC 15.74 7.08 4
2 (-)-Cis-Normetazocine NC NC 24.58 7.55 3 4.30 0.21 40.44 10.47 3
3 (-)-Codeine 5.00 0.02 69.50 5.58 3 5.17 0.11 88.11 8.14 3
4 (-)-Cyclazocine NC NC 1.32 1.05 3 NC NC 8.69 2.21 3
5 (-)-Metazocine 4.82 0.09 68.17 3.60 3 4.72 0.26 43.27 5.42 3
6 (-)-Morphine 5.18 0.12 84.23 4.81 3 5.21 0.05 57.41 7.48 6
7 (-)-N-allyl-Nortmetazocine NC NC 1.34 0.88 3 NC NC 5.92 5.41 4
8 (-)-Naloxone NC NC 1.07 0.70 3 NC NC 9.39 1.46 3
9 (-)-Pentazocine NC NC 1.90 1.16 3 NC NC 12.32 1.48 3
10 (-)-Phenazocine NC NC 7.04 1.27 3 NC NC 54.95 5.69 4
11 (+)-Alpha-propoxyphene 4.50 0.08 55.83 3.46 3 4.82 0.23 65.09 2.52 3
12 (+)-Bremazocine NC NC 0.67 0.40 3 NC NC 5.28 5.14 4
13 (+)-Cis-N-Normetazocine 4.87 0.09 69.49 5.69 3 4.84 0.14 54.72 6.64 8
14 (+)-Codeine 4.86 0.07 59.05 7.14 3 5.26 0.18 88.45 5.52 3
15 (+)-Cyclazocine NC NC 1.80 0.56 3 NC NC 8.54 5.98 5
16 (+)-Dezocine NC NC 3.46 1.08 3 NC NC 49.48 12.52 3
17 (+)-Metazocine 5.03 0.07 81.85 0.09 3 5.14 0.18 53.15 8.59 7
18 (+)-Morphine 5.30 0.11 88.39 5.84 3 5.47 0.12 67.20 7.14 6
19 (+)-N-allyl-N-Normetazocine NC NC 1.03 0.55 3 NC NC 18.14 6.62 3
20 (+)-Naloxone NC NC 0.91 0.13 3 NC NC 9.08 2.49 3
21 (+)Pentazocine NC NC 0.92 0.38 3 NC NC 20.79 11.08 3
22 (+)-Phenazocine NC NC 13.90 2.41 3 NC NC 54.26 0.68 3
23 (+)-TAN-67 6.54 0.04 100.44 5.16 3 6.37 0.28 82.18 16.63 3
24 (+/-) Methadone NC NC 7.24 0.97 3 4.36 0.13 67.43 11.48 3
25 4FBNTI NC NC 5.05 3.22 3 5.25 0.27 39.29 13.48 3
26 6-Acetyl-Codeine 4.60 0.05 53.07 5.06 3 4.72 0.13 77.21 4.18 3
27 6-Acetyl-Morphine 4.68 0.03 52.87 4.10 3 4.92 0.15 80.47 9.54 3
28 ADL-5859 NT NT NT NT 0 5.29 0 64.78 NC 1
29 Alpha-neoendorphin 5.37 0.14 84.69 3.90 2 NC NC 54.12 19.01 2
30 BAM-12 NC NC 27.48 11.07 3 NC NC 11.82 5.89 3
31 BAM-22 NC NC 14.22 0.00 1 NC NC 2.53 NC 1
32 BAM8-22 5.05 0.22 72.13 7.02 2 4.95 0.73 55.73 11.77 3
33 Beta-endorphin NC NC 42.92 0.00 1 NC NC 23.46 NC 1
34 Beta-neoendorphin NC NC 51.86 22.11 3 NC NC 35.62 15.54 3
35 BUFFER NC NC 0.37 0.99 3 NC NC 4.94 0.21 3
36 Buprenorpine NC NC 0.17 0.74 3 NC NC 9.81 2.04 3
37 BW373U86 NC NC 2.03 0.25 3 NC NC 18.51 11.31 3
38 CM2-183 NC NC 63.52 16.57 3 NC NC 9.09 1.77 3
39 Codeine-6G NC NC 12.10 2.34 3 4.36 0.35 65.79 5.96 3
40 Cortistatin-14 6.38 0.13 112.69 12.09 4 6.84 0.35 33.16 6.54 3
41 Dermorphin NC NC 1.29 0.44 3 NC NC 16.97 6.11 3






Table 1: Table of all tested opioids at MRGPRX2 shown in TANGO and FLIPR. 
Compounds are numbered with name listed in Column 2. Emax is given as a percentage of (+/-)-
TAN-67 activity, a full agonist. Abbreviations: NC = Not calculable in Prism because curve did 
not saturate at concentrations up to 100 µM, NT = Not tested. 
 
43 Dextromethorphan 5.23 0.17 88.03 1.68 4 5.49 0.12 62.34 6.26 7
44 Dextrorphan 5.41 0.19 86.89 1.13 3 5.38 0.05 64.55 9.15 6
45 Dihydrocodinone 4.96 0.05 70.17 6.31 3 4.73 0.14 49.72 7.54 3
46 Diprenorphine NC NC 0.22 1.33 3 NC NC 12.45 1.05 3
47 Dynorphin A (1-13) 5.98 0.09 91.85 3.96 2 4.52 0.06 67.07 3.16 3
48 Dynorphin A (1-17) 5.64 0.09 88.84 3.82 5 4.68 0.49 53.64 16.34 3
49 Dynorphin A (13-17) NC NC 1.44 0.10 2 NC NC 11.43 4.95 2
50 Dynorphin A (1-6) NC NC 2.34 0.67 2 NC NC 16.84 2.11 2
51 Dynorphin A (1-7) NC NC 0.98 0.59 2 NC NC 25.19 6.46 2
52 Dynorphin A (1-8) NC NC 22.66 11.28 3 NC NC 16.35 11.60 3
53 Dynorphin A (1-9) 4.81 0.22 64.62 11.87 3 NC NC 20.91 7.89 3
54 Dynorphin A (2-8) NC NC 4.62 0.77 3 NC NC 21.31 9.92 3
55 Dynorphin A (6-17) NC NC 34.26 16.79 2 NC NC 15.72 3.70 2
56 Dynorphin B (1-13) 5.19 0.19 83.67 3.50 4 4.48 0.10 41.69 15.26 3
57 Endomorphin-1 NC NC 6.75 3.01 3 NC NC 35.20 13.13 3
58 Endomorphin-2 NC NC 3.29 1.00 3 NC NC 29.89 6.78 3
59 Etorphine NC NC 0.37 0.83 3 NC NC 11.51 8.82 3
60 Fedotozine NC NC 0.51 0.77 3 NC NC 24.73 2.44 3
61 Fentanyl NC NC 0.37 0.81 3 NC NC 10.79 5.31 3
62 IBNTXA NC NC 4.65 1.13 3 NC NC 16.23 10.98 3
63 JDTic NC NC 2.12 0.10 3 NC NC 106.67 22.23 3
64 KNT-127 NC NC -0.44 2.32 4 4.73 0.71 35.42 7.94 4
65 Leu-Enkephalin NC NC 1.67 0.06 3 NC NC 26.04 11.07 3
66 Levallorphan NC NC 4.50 1.88 4 NC NC 22.02 13.81 3
67 Levorphanol 4.90 0.14 62.30 7.77 5 4.65 0.06 56.78 8.31 6
68 Meperidine NC NC 14.06 5.26 4 NC NC 27.95 7.79 3
69 Met-enkephalin NC NC 1.86 0.25 3 NC NC 21.04 6.18 3
70 Morphine-3G NC NC 0.60 0.28 3 4.56 0.03 33.15 7.50 3
71 Morphine-6G NC NC 12.84 2.48 3 4.72 0.22 72.54 8.73 3
72 Nalfurafine NC NC 0.50 0.27 3 NC NC 20.32 4.50 3
73 Nalorphine NC NC 1.12 0.10 3 NC NC 10.93 2.51 3
74 Naltrexone NC NC 1.65 0.39 3 NC NC 10.57 1.51 3
75 Norcodeine NC NC 4.23 1.25 3 4.79 0.21 54.72 5.36 3
76 RB64 NC NC 0.43 0.85 3 NC NC 44.15 9.68 3
77 RTI-4356-2 NC NC 17.07 7.69 4 5.19 0.16 63.33 12.55 6
78 RTI-4612-105 NC NC 33.79 7.86 4 4.66 0.33 46.34 2.19 3
79 RTI-4612-118 NC NC 14.96 4.51 4 4.83 0.10 52.71 12.89 3
80 RTI-4612-158 NC NC 5.02 1.77 4 4.67 0.04 21.02 2.24 3
81 RTI-4612-96 5.17 0.10 83.81 4.27 4 5.09 0.06 56.77 8.78 3
82 RTI-4612-97 5.19 0.21 84.05 3.98 3 5.04 0.10 52.11 5.91 3
83 Salvinorin A NC NC 2.18 0.72 3 NC NC 10.32 3.85 3
84 Sinomenine 5.40 0.18 92.08 3.29 3 5.27 0.09 61.35 10.03 4
85 Substance P 5.97 0.16 106.00 5.47 8 5.29 0.11 49.05 2.49 5
86 TAN-67 (racemic) 6.19 0.06 100.00 0.00 16 5.74 0.09 100.00 0.00 20
87 Thebaine 4.12 0.05 35.13 4.37 3 4.95 0.22 90.84 5.23 3





Table 2: Small Molecule Screening Information 
Supplementary Table 3.  Small molecule screening data 
 
Category Parameter Description 
Assay Type of assay PRESTO-TANGO cell-based β-arrestin recruitment 
assay 
 
 Target GPCR activation as measured by transcription of a 
luciferase reporter 
 
 Primary measurement Detection of luminescence 
 Key reagents  Luciferin (Bright-Glo) 
 Assay protocol Kroeze, et al., Nat Struct Mol Bio. 22(5):362-9 (2015) 
 
 Additional comments  
Library  Library size 9 separate libraries were used containing 5,695 
unique compounds (9,128 compounds in total) 
 
 Library composition Small molecules, FDA-approved drugs 
 Source Libraries used: NIH Clinical Collection NCC-1 and 
NCC-2, NIMH X-901, Tocris Tocriscreen Plus, 
Prestwick Chemical Library, Sigma Aldrich 
LOPAC®1280, Selleck BioActive Compound Library, 
Microsource SPECTRUM collection, and the Roth 
Lab Collection (in-house). 
 Additional comments  
Screen Format 384 well clear bottom plates coated with poly lysine, 
drugs were added in quadruplicate wells 
 
 Concentration(s) tested 10 µM  
 
 Plate controls Buffer-only control in four columns (64 wells) per 
plate.  
 
 Reagent/ compound dispensing system Compounds were dispensed manually using a 
repeating multichannel pipettor (Thermo Scientific 
Finnpipette) 
 
 Detection instrument and software The Perkin Elmer MicroBeta TriLux 1450 LSC & 
Luminescence Counter was used in combination 
with the Microbeta Workstation software to detect 
and export raw data in the form of Excel 
spreadsheets.  
 
 Assay validation/QC Z’ score = 0.71 +/- 0.20 (average Z’ score for 15 
plates +/- standard deviation) 
 
 Correction factors NA 
 Normalization NA 
 Additional comments  
Post-HTS analysis Hit criteria Compounds with 2-fold or greater activation above 
the plate median were considered hits and were 
selected for further analysis. Known false positives 
(from previous assays or from cross-checking in 
PubChem) were excluded. 
 
 Hit rate Raw hit rate = 1.86% 
Hit rate with duplicate compounds and known false 
positives excluded = 0.86% 
 
 Additional assay(s) An orthogonal fluorescence dye-based intracellular 
calcium release assay was used as a secondary 
assay for hit confirmation and dose response curves. 
 
 Confirmation of hit purity and structure Compounds were re-purchased commercially from a 
variety of vendors for validation assays.  Key probe 
candidates were confirmed by mass spectrometry 
and resynthesized.  










Figure 1: Off target activity for (R)-ZINC-3573 and (S)-ZINC-3573 at GCPRs and Kinases. 
Top: All 21 receptors with greater than two-fold activity from original GPCRome screening (see 
Supplemental Figure 8) were tested with both (R)- and (S)-ZINC-3573 in PRESTO-Tango 
concentration response curves with gene names listed above each curve. Where possible, positive 
control compounds were used or DMSO (vehicle) for reference. N=1 in triplicate for each 
receptor, error bars show SEM for average value of triplicate wells. Bottom: results of Kinome 
screen for 10 µM of ZINC-9232 yielded only three potential kinases (listed). Follow-up kinase 












































Plasmid map for MRGPRX1-Tango construct. Includes schematic at top, vector is 
PCDNA3.1. Note the presence of a stop codon following the TEV protease cut site and tTA 
(listed here as “TEV CUT SITE). MRGPRX1 coding sequence (CDS) is swapped out for other 
codon optimized MRGPRX sequences in other constructs, as expected. Sequences for all 
























Plasmid map for pcDNA5/FRT/TO for FLP-IN Constructs. . Vector (provided by 
Invitrogen) with annotated cut sites and location of MRGPRX gene insertion. MRGPRX 
receptors were swapped out into this location to generate each of the tet-inducible stable cell 
lines. Sequences for all receptors and mutants will be provided below.  For all inducible stable 
cell lines, the codon-optimized CDS for each receptor from the Tango construct was inserted, 
































































































































































































12. ENTIRE MRGPRX2-TANGO SEQUENCE WITH N TERMINAL HA, FLAG, 
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